<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/168898#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:PathwayStep rdf:ID="PathwayStep809">
 <bp:stepProcess rdf:resource="#BiochemicalReaction670" />
 <bp:stepProcess rdf:resource="#Catalysis326" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep808">
 <bp:stepProcess rdf:resource="#BiochemicalReaction669" />
 <bp:stepProcess rdf:resource="#Catalysis325" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep807">
 <bp:stepProcess rdf:resource="#BiochemicalReaction668" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep806">
 <bp:stepProcess rdf:resource="#BiochemicalReaction667" />
 <bp:stepProcess rdf:resource="#Catalysis324" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence658">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep805">
 <bp:stepProcess rdf:resource="#BiochemicalReaction666" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence659">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep804">
 <bp:stepProcess rdf:resource="#BiochemicalReaction665" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence656">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep803">
 <bp:stepProcess rdf:resource="#BiochemicalReaction664" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence657">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep802">
 <bp:stepProcess rdf:resource="#BiochemicalReaction663" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep801">
 <bp:stepProcess rdf:resource="#Catalysis323" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction662" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep800">
 <bp:stepProcess rdf:resource="#BiochemicalReaction661" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence650">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence651">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence654">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence655">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence652">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence653">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence669">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence667">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence668">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence661">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence662">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence660">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence665">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence666">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence663">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence664">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep829">
 <bp:stepProcess rdf:resource="#BiochemicalReaction687" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep828">
 <bp:stepProcess rdf:resource="#BiochemicalReaction686" />
 <bp:stepProcess rdf:resource="#Catalysis337" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence636">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep827">
 <bp:stepProcess rdf:resource="#BiochemicalReaction685" />
 <bp:stepProcess rdf:resource="#Catalysis336" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence637">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep826">
 <bp:stepProcess rdf:resource="#Catalysis335" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction684" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence634">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep825">
 <bp:stepProcess rdf:resource="#BiochemicalReaction683" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence635">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep824">
 <bp:stepProcess rdf:resource="#Pathway143" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep823">
 <bp:stepProcess rdf:resource="#Catalysis334" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction682" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep822">
 <bp:stepProcess rdf:resource="#Catalysis333" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction681" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence638">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep821">
 <bp:stepProcess rdf:resource="#BiochemicalReaction680" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence639">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep820">
 <bp:stepProcess rdf:resource="#Pathway142" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence632">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence633">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence630">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence631">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep819">
 <bp:stepProcess rdf:resource="#Pathway141" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep818">
 <bp:stepProcess rdf:resource="#Catalysis332" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction679" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep817">
 <bp:stepProcess rdf:resource="#Catalysis331" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction678" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence647">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep816">
 <bp:stepProcess rdf:resource="#BiochemicalReaction677" />
 <bp:stepProcess rdf:resource="#Catalysis330" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence648">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep815">
 <bp:stepProcess rdf:resource="#BiochemicalReaction676" />
 <bp:stepProcess rdf:resource="#Catalysis329" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence645">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep814">
 <bp:stepProcess rdf:resource="#BiochemicalReaction675" />
 <bp:stepProcess rdf:resource="#Catalysis328" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence646">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep813">
 <bp:stepProcess rdf:resource="#BiochemicalReaction674" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep812">
 <bp:stepProcess rdf:resource="#BiochemicalReaction673" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep811">
 <bp:stepProcess rdf:resource="#BiochemicalReaction672" />
 <bp:stepProcess rdf:resource="#Catalysis327" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence649">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep810">
 <bp:stepProcess rdf:resource="#BiochemicalReaction671" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence640">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence643">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence644">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence641">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence642">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence614">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence615">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence612">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence613">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence618">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence619">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence616">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence617">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction730">
 <bp:evidence rdf:resource="#Evidence881" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">oxLDL:CD36 binds TLR4:TLR6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction732">
 <bp:evidence rdf:resource="#Evidence883" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G or G analog binds C-ter TLR7 dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction731">
 <bp:evidence rdf:resource="#Evidence882" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SFTPA/SFTPD binds TLR4:LY96</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence610">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction734">
 <bp:evidence rdf:resource="#Evidence885" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S100A1 binds TLR4:LY96</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence611">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction733">
 <bp:evidence rdf:resource="#Evidence884" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HMGB1 binds TLR4:LY96</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction736">
 <bp:evidence rdf:resource="#Evidence887" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">oxPL binds LBP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction735">
 <bp:evidence rdf:resource="#Evidence886" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleaved fibrinogen products bind TLR4:LY96</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction738">
 <bp:evidence rdf:resource="#Evidence889" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HMGB1 release from cells</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction737">
 <bp:evidence rdf:resource="#Evidence888" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">oxPL binds CD14</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction739">
 <bp:evidence rdf:resource="#Evidence890" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SFTPA/SFTPD binds TLR2:TLR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence625">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence626">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence623">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence624">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence629">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence627">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence628">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction721">
 <bp:evidence rdf:resource="#Evidence871" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction720">
 <bp:evidence rdf:resource="#Evidence869" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to p-IRAK2  </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence621">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction723">
 <bp:evidence rdf:resource="#Evidence873" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence622">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction722">
 <bp:evidence rdf:resource="#Evidence872" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction725">
 <bp:evidence rdf:resource="#Evidence875" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence620">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction724">
 <bp:evidence rdf:resource="#Evidence874" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction727">
 <bp:evidence rdf:resource="#Evidence878" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HMGB1 binds LPS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction726">
 <bp:evidence rdf:resource="#Evidence876" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR1/2 ligand binds to CD14</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction729">
 <bp:evidence rdf:resource="#Evidence880" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HMGB1 binds LTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction728">
 <bp:evidence rdf:resource="#Evidence879" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S100A8:S100A9 binds TLR4:LY96</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction710">
 <bp:evidence rdf:resource="#Evidence859" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction712">
 <bp:evidence rdf:resource="#Evidence861" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction711">
 <bp:evidence rdf:resource="#Evidence860" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction714">
 <bp:evidence rdf:resource="#Evidence863" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of p-IRAK2:TRAF6 from the activated TLR:oligo-Myd88:TIRAP:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction713">
 <bp:evidence rdf:resource="#Evidence862" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR2/4:TIRAP interacts with BTK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction716">
 <bp:evidence rdf:resource="#Evidence865" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1:TRAF6 from the activated TLR:oligo-Myd88:TIRAP:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction715">
 <bp:evidence rdf:resource="#Evidence864" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction718">
 <bp:evidence rdf:resource="#Evidence867" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction717">
 <bp:evidence rdf:resource="#Evidence866" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR:TIRAP:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction719">
 <bp:evidence rdf:resource="#Evidence868" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 forms a complex with TIRAP:activated TLR2/4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence609">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence603">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence604">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence601">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence602">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence607">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence608">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence605">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence606">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction701">
 <bp:evidence rdf:resource="#Evidence849" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence600">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction700">
 <bp:evidence rdf:resource="#Evidence848" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction703">
 <bp:evidence rdf:resource="#Evidence851" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction702">
 <bp:evidence rdf:resource="#Evidence850" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction705">
 <bp:evidence rdf:resource="#Evidence854" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction704">
 <bp:evidence rdf:resource="#Evidence852" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction707">
 <bp:evidence rdf:resource="#Evidence856" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction706">
 <bp:evidence rdf:resource="#Evidence855" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction709">
 <bp:evidence rdf:resource="#Evidence858" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction708">
 <bp:evidence rdf:resource="#Evidence857" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction381">
 <bp:evidence rdf:resource="#Evidence463" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction380">
 <bp:evidence rdf:resource="#Evidence462" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction383">
 <bp:evidence rdf:resource="#Evidence466" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction382">
 <bp:evidence rdf:resource="#Evidence464" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1/or IRAK2:TRAF6-oligomer from the p-IRAK4 :oligo-Myd88:activated TLR7/8 or 9 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction385">
 <bp:evidence rdf:resource="#Evidence469" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction384">
 <bp:evidence rdf:resource="#Evidence467" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction387">
 <bp:evidence rdf:resource="#Evidence471" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction386">
 <bp:evidence rdf:resource="#Evidence470" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction378">
 <bp:evidence rdf:resource="#Evidence460" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction377">
 <bp:evidence rdf:resource="#Evidence459" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction379">
 <bp:evidence rdf:resource="#Evidence461" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction370">
 <bp:evidence rdf:resource="#Evidence451" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction372">
 <bp:evidence rdf:resource="#Evidence453" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction371">
 <bp:evidence rdf:resource="#Evidence452" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction374">
 <bp:evidence rdf:resource="#Evidence456" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction373">
 <bp:evidence rdf:resource="#Evidence454" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction376">
 <bp:evidence rdf:resource="#Evidence458" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction375">
 <bp:evidence rdf:resource="#Evidence457" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction367">
 <bp:evidence rdf:resource="#Evidence448" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction366">
 <bp:evidence rdf:resource="#Evidence446" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction369">
 <bp:evidence rdf:resource="#Evidence450" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction368">
 <bp:evidence rdf:resource="#Evidence449" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction361">
 <bp:evidence rdf:resource="#Evidence439" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction360">
 <bp:evidence rdf:resource="#Evidence438" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction363">
 <bp:evidence rdf:resource="#Evidence442" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction362">
 <bp:evidence rdf:resource="#Evidence441" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction365">
 <bp:evidence rdf:resource="#Evidence444" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction364">
 <bp:evidence rdf:resource="#Evidence443" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction356">
 <bp:evidence rdf:resource="#Evidence432" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction355">
 <bp:evidence rdf:resource="#Evidence431" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction358">
 <bp:evidence rdf:resource="#Evidence436" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction357">
 <bp:evidence rdf:resource="#Evidence435" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction359">
 <bp:evidence rdf:resource="#Evidence437" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction350">
 <bp:evidence rdf:resource="#Evidence425" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction352">
 <bp:evidence rdf:resource="#Evidence428" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction351">
 <bp:evidence rdf:resource="#Evidence426" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction354">
 <bp:evidence rdf:resource="#Evidence430" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction353">
 <bp:evidence rdf:resource="#Evidence429" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction345">
 <bp:evidence rdf:resource="#Evidence417" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1/or p-IRAK2:p-IRAK4:MyD88:activated TLR7/8 or 9  </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction344">
 <bp:evidence rdf:resource="#Evidence416" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 interacts with the activated TLR receptor 7, 8 or 9 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction347">
 <bp:evidence rdf:resource="#Evidence419" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation steps within the complex pIRAK4:MyD88:activated TLR7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction346">
 <bp:evidence rdf:resource="#Evidence418" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to the activated TLR7/8 or 9 receptor:MyD88 complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction349">
 <bp:evidence rdf:resource="#Evidence424" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction348">
 <bp:evidence rdf:resource="#Evidence420" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation in the complex with MyD88:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
 <bp:stepProcess rdf:resource="#Catalysis38" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis218">
 <bp:controlled rdf:resource="#BiochemicalReaction455" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis219">
 <bp:controlled rdf:resource="#BiochemicalReaction456" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
 <bp:stepProcess rdf:resource="#Catalysis39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#Catalysis37" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction341">
 <bp:evidence rdf:resource="#Evidence413" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of p-IRF7:p-IRF7 to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis214">
 <bp:controlled rdf:resource="#BiochemicalReaction451" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction340">
 <bp:evidence rdf:resource="#Evidence412" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 interacts with IRF7 upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis215">
 <bp:controlled rdf:resource="#BiochemicalReaction452" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction343">
 <bp:evidence rdf:resource="#Evidence415" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 ubiquitinqtes IRF7 within the activated TLR7/8 or 9 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis216">
 <bp:controlled rdf:resource="#BiochemicalReaction453" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction342">
 <bp:evidence rdf:resource="#Evidence414" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of p-IRF7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis217">
 <bp:controlled rdf:resource="#BiochemicalReaction454" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction334">
 <bp:evidence rdf:resource="#Evidence405" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to MyD88: activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis221">
 <bp:controlled rdf:resource="#BiochemicalReaction458" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction333">
 <bp:evidence rdf:resource="#Evidence403" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR7 dimer binds TLR7, TLR8 ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis222">
 <bp:controlled rdf:resource="#BiochemicalReaction459" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction336">
 <bp:evidence rdf:resource="#Evidence407" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR 7/8 or 9 : MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis223">
 <bp:controlled rdf:resource="#BiochemicalReaction460" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#Catalysis40" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction335">
 <bp:evidence rdf:resource="#Evidence406" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to MyD88:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis224">
 <bp:controlled rdf:resource="#BiochemicalReaction462" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction338">
 <bp:evidence rdf:resource="#Evidence409" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomer:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction337">
 <bp:evidence rdf:resource="#Evidence408" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1/or IRAK2 binds to the activated IRAK4 :MyD88:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction339">
 <bp:evidence rdf:resource="#Evidence411" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation and release of IRF7 upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis220">
 <bp:controlled rdf:resource="#BiochemicalReaction457" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis229">
 <bp:controlled rdf:resource="#BiochemicalReaction476" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#Pathway20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
 <bp:stepProcess rdf:resource="#Catalysis41" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction330">
 <bp:evidence rdf:resource="#Evidence400" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR7 dimer binds HCQ</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis225">
 <bp:controlled rdf:resource="#BiochemicalReaction463" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
 <bp:stepProcess rdf:resource="#Catalysis42" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis226">
 <bp:controlled rdf:resource="#BiochemicalReaction464" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction332">
 <bp:evidence rdf:resource="#Evidence402" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR7 dimer binds imiquimod</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis227">
 <bp:controlled rdf:resource="#BiochemicalReaction466" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction331">
 <bp:evidence rdf:resource="#Evidence401" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR8 dimer binds TLR7, TLR8 ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis228">
 <bp:controlled rdf:resource="#BiochemicalReaction473" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction323">
 <bp:evidence rdf:resource="#Evidence391" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral dsRNA binds the Toll-Like Receptor 3 (TLR3)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis232">
 <bp:controlled rdf:resource="#BiochemicalReaction485" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction322">
 <bp:evidence rdf:resource="#Evidence390" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral dsRNA:TLR3:TRIF complex recruits RIP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis233">
 <bp:controlled rdf:resource="#BiochemicalReaction486" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction325">
 <bp:evidence rdf:resource="#Evidence395" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of p-S446-IRF5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep399">
 <bp:stepProcess rdf:resource="#BiochemicalReaction330" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis234">
 <bp:controlled rdf:resource="#BiochemicalReaction489" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction324">
 <bp:evidence rdf:resource="#Evidence394" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TASL is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep398">
 <bp:stepProcess rdf:resource="#BiochemicalReaction329" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis235">
 <bp:controlled rdf:resource="#BiochemicalReaction491" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction327">
 <bp:evidence rdf:resource="#Evidence397" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated IKBKB phosphorylates IRF5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep397">
 <bp:stepProcess rdf:resource="#BiochemicalReaction328" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction326">
 <bp:evidence rdf:resource="#Evidence396" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TASL recruits IRF5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep396">
 <bp:stepProcess rdf:resource="#Catalysis156" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction327" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep395">
 <bp:stepProcess rdf:resource="#BiochemicalReaction326" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction329">
 <bp:evidence rdf:resource="#Evidence399" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-S446-IRF5 dimer translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis230">
 <bp:controlled rdf:resource="#BiochemicalReaction478" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep394">
 <bp:stepProcess rdf:resource="#BiochemicalReaction325" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction328">
 <bp:evidence rdf:resource="#Evidence398" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC15A4 binds TASL</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis231">
 <bp:controlled rdf:resource="#BiochemicalReaction483" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep393">
 <bp:stepProcess rdf:resource="#BiochemicalReaction324" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep392">
 <bp:stepProcess rdf:resource="#Pathway70" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep391">
 <bp:stepProcess rdf:resource="#Pathway69" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep390">
 <bp:stepProcess rdf:resource="#BiochemicalReaction323" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#Catalysis27" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#Catalysis24" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#Catalysis25" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#Catalysis26" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
 <bp:stepProcess rdf:resource="#Catalysis22" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction321">
 <bp:evidence rdf:resource="#Evidence389" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKG subunit of IKK complex binds K63pUb- RIP1 within the TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
 <bp:stepProcess rdf:resource="#Catalysis23" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction320">
 <bp:evidence rdf:resource="#Evidence388" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">K63-linked ubiquitination of RIP1 bound to the activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction312">
 <bp:evidence rdf:resource="#Evidence378" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR3-induced ripoptosome assembly</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction311">
 <bp:evidence rdf:resource="#Evidence377" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Caspase-8 processing within TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis200">
 <bp:controlled rdf:resource="#BiochemicalReaction425" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction314">
 <bp:evidence rdf:resource="#Evidence381" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of recruited TAK1 within the activated TLR3 complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis201">
 <bp:controlled rdf:resource="#BiochemicalReaction430" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#Catalysis28" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction313">
 <bp:evidence rdf:resource="#Evidence379" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RIP3 binds TICAM1 within TLR3 complex to mediate necroptosis </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis202">
 <bp:controlled rdf:resource="#BiochemicalReaction434" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction316">
 <bp:evidence rdf:resource="#Evidence383" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral dsRNA:TLR3:TICAM1 complex recruits TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction315">
 <bp:evidence rdf:resource="#Evidence382" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains upon TLR3 stimulation </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction318">
 <bp:evidence rdf:resource="#Evidence385" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiqitination of TRAF6 bound to viral dsRNS:TLR3:TICAM1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction317">
 <bp:evidence rdf:resource="#Evidence384" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR3:TRIF:K63pUb-TRAF6 recruits TAK1complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction319">
 <bp:evidence rdf:resource="#Evidence386" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated TAK1 dissociates from the TLR3 receptor complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#Catalysis35" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
 <bp:stepProcess rdf:resource="#Catalysis33" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis207">
 <bp:controlled rdf:resource="#BiochemicalReaction441" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis208">
 <bp:controlled rdf:resource="#BiochemicalReaction442" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis209">
 <bp:controlled rdf:resource="#BiochemicalReaction445" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#Catalysis34" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#Catalysis29" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis203">
 <bp:controlled rdf:resource="#BiochemicalReaction435" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
 <bp:stepProcess rdf:resource="#Catalysis30" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis204">
 <bp:controlled rdf:resource="#BiochemicalReaction437" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
 <bp:stepProcess rdf:resource="#Catalysis31" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction310">
 <bp:evidence rdf:resource="#Evidence375" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF3 binds to TRIF:activated TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis205">
 <bp:controlled rdf:resource="#BiochemicalReaction438" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
 <bp:stepProcess rdf:resource="#Catalysis32" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis206">
 <bp:controlled rdf:resource="#BiochemicalReaction440" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction301">
 <bp:evidence rdf:resource="#Evidence365" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 binds K63-pUb-TANK:K63-pUb-TRAF3:TRIF:activated TLR3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis210">
 <bp:controlled rdf:resource="#BiochemicalReaction446" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction300">
 <bp:evidence rdf:resource="#Evidence364" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRF3/IRF7 recruitment to p-TBK1/p-IKK epsilon bound to the activated TLR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis211">
 <bp:controlled rdf:resource="#BiochemicalReaction447" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#Catalysis36" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction303">
 <bp:evidence rdf:resource="#Evidence367" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TANK binds K63-poly-Ub-TRAF3:TICAM1:activated TLR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis212">
 <bp:controlled rdf:resource="#BiochemicalReaction449" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction302">
 <bp:evidence rdf:resource="#Evidence366" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TANK is ubiquitinated within TANK:K63polyUb-TRAF3:TICAM1:TLR3:viral dsRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis213">
 <bp:controlled rdf:resource="#BiochemicalReaction450" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction305">
 <bp:evidence rdf:resource="#Evidence370" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 is ubiquitinated within TBK1:K63polyUb-TANK:K63polyUb-TRAF3:TRIF:activated TLR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction304">
 <bp:evidence rdf:resource="#Evidence368" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of phosphorylated IRF3/IRF7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction307">
 <bp:evidence rdf:resource="#Evidence372" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKK&#949; (IKBKE) is ubiquitinated within the activated TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction306">
 <bp:evidence rdf:resource="#Evidence371" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OPTN binds TBK1 within the activated TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction309">
 <bp:evidence rdf:resource="#Evidence374" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKK&#949; (IKBKE) is phosphorylated within the activated TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction308">
 <bp:evidence rdf:resource="#Evidence373" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerized phospho-IRF3/IRF7 is transported to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis258">
 <bp:controlled rdf:resource="#BiochemicalReaction539" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis259">
 <bp:controlled rdf:resource="#BiochemicalReaction540" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep369">
 <bp:stepProcess rdf:resource="#BiochemicalReaction305" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep368">
 <bp:stepProcess rdf:resource="#Pathway65" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis265">
 <bp:controlled rdf:resource="#BiochemicalReaction546" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep367">
 <bp:stepProcess rdf:resource="#BiochemicalReaction304" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis266">
 <bp:controlled rdf:resource="#BiochemicalReaction547" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep366">
 <bp:stepProcess rdf:resource="#BiochemicalReaction303" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis267">
 <bp:controlled rdf:resource="#BiochemicalReaction548" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep365">
 <bp:stepProcess rdf:resource="#BiochemicalReaction302" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis268">
 <bp:controlled rdf:resource="#BiochemicalReaction549" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep364">
 <bp:stepProcess rdf:resource="#BiochemicalReaction301" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis261">
 <bp:controlled rdf:resource="#BiochemicalReaction542" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep363">
 <bp:stepProcess rdf:resource="#BiochemicalReaction300" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis262">
 <bp:controlled rdf:resource="#BiochemicalReaction543" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep362">
 <bp:stepProcess rdf:resource="#Catalysis151" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction299" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis263">
 <bp:controlled rdf:resource="#BiochemicalReaction544" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep361">
 <bp:stepProcess rdf:resource="#BiochemicalReaction298" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis264">
 <bp:controlled rdf:resource="#BiochemicalReaction545" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep360">
 <bp:stepProcess rdf:resource="#BiochemicalReaction297" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis260">
 <bp:controlled rdf:resource="#BiochemicalReaction541" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis269">
 <bp:controlled rdf:resource="#BiochemicalReaction551" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep359">
 <bp:stepProcess rdf:resource="#Catalysis150" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction296" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep358">
 <bp:stepProcess rdf:resource="#Pathway64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep357">
 <bp:stepProcess rdf:resource="#BiochemicalReaction295" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis276">
 <bp:controlled rdf:resource="#BiochemicalReaction565" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep356">
 <bp:stepProcess rdf:resource="#BiochemicalReaction294" />
 <bp:stepProcess rdf:resource="#Catalysis149" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis277">
 <bp:controlled rdf:resource="#BiochemicalReaction566" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep355">
 <bp:stepProcess rdf:resource="#BiochemicalReaction293" />
 <bp:stepProcess rdf:resource="#Catalysis148" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis278">
 <bp:controlled rdf:resource="#BiochemicalReaction573" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep354">
 <bp:stepProcess rdf:resource="#BiochemicalReaction292" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis279">
 <bp:controlled rdf:resource="#BiochemicalReaction574" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep353">
 <bp:stepProcess rdf:resource="#Catalysis147" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction291" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis272">
 <bp:controlled rdf:resource="#BiochemicalReaction555" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep352">
 <bp:stepProcess rdf:resource="#BiochemicalReaction290" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis273">
 <bp:controlled rdf:resource="#BiochemicalReaction559" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep351">
 <bp:stepProcess rdf:resource="#BiochemicalReaction289" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis274">
 <bp:controlled rdf:resource="#BiochemicalReaction561" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep350">
 <bp:stepProcess rdf:resource="#BiochemicalReaction288" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis275">
 <bp:controlled rdf:resource="#BiochemicalReaction564" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis270">
 <bp:controlled rdf:resource="#BiochemicalReaction552" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis271">
 <bp:controlled rdf:resource="#BiochemicalReaction553" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis236">
 <bp:controlled rdf:resource="#BiochemicalReaction492" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis237">
 <bp:controlled rdf:resource="#BiochemicalReaction493" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis238">
 <bp:controlled rdf:resource="#BiochemicalReaction499" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis239">
 <bp:controlled rdf:resource="#BiochemicalReaction500" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence199">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis243">
 <bp:controlled rdf:resource="#BiochemicalReaction511" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep389">
 <bp:stepProcess rdf:resource="#BiochemicalReaction322" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis244">
 <bp:controlled rdf:resource="#BiochemicalReaction516" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence197">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep388">
 <bp:stepProcess rdf:resource="#BiochemicalReaction321" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis245">
 <bp:controlled rdf:resource="#BiochemicalReaction518" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence198">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep387">
 <bp:stepProcess rdf:resource="#Catalysis155" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction320" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis246">
 <bp:controlled rdf:resource="#BiochemicalReaction519" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep386">
 <bp:stepProcess rdf:resource="#Pathway68" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep385">
 <bp:stepProcess rdf:resource="#BiochemicalReaction319" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis240">
 <bp:controlled rdf:resource="#BiochemicalReaction502" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep384">
 <bp:stepProcess rdf:resource="#BiochemicalReaction318" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis241">
 <bp:controlled rdf:resource="#BiochemicalReaction506" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep383">
 <bp:stepProcess rdf:resource="#BiochemicalReaction317" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis242">
 <bp:controlled rdf:resource="#BiochemicalReaction509" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence191">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep382">
 <bp:stepProcess rdf:resource="#BiochemicalReaction316" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence192">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep381">
 <bp:stepProcess rdf:resource="#BiochemicalReaction315" />
 <bp:stepProcess rdf:resource="#Catalysis154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep380">
 <bp:stepProcess rdf:resource="#BiochemicalReaction314" />
 <bp:stepProcess rdf:resource="#Catalysis153" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence190">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence195">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence196">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence193">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence194">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis247">
 <bp:controlled rdf:resource="#BiochemicalReaction521" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis248">
 <bp:controlled rdf:resource="#BiochemicalReaction523" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis249">
 <bp:controlled rdf:resource="#BiochemicalReaction526" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep379">
 <bp:stepProcess rdf:resource="#Pathway67" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis254">
 <bp:controlled rdf:resource="#BiochemicalReaction534" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep378">
 <bp:stepProcess rdf:resource="#BiochemicalReaction313" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis255">
 <bp:controlled rdf:resource="#BiochemicalReaction535" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep377">
 <bp:stepProcess rdf:resource="#BiochemicalReaction312" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis256">
 <bp:controlled rdf:resource="#BiochemicalReaction536" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep376">
 <bp:stepProcess rdf:resource="#BiochemicalReaction311" />
 <bp:stepProcess rdf:resource="#Catalysis152" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis257">
 <bp:controlled rdf:resource="#BiochemicalReaction538" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep375">
 <bp:stepProcess rdf:resource="#Pathway66" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis250">
 <bp:controlled rdf:resource="#BiochemicalReaction527" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep374">
 <bp:stepProcess rdf:resource="#BiochemicalReaction310" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis251">
 <bp:controlled rdf:resource="#BiochemicalReaction529" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep373">
 <bp:stepProcess rdf:resource="#BiochemicalReaction309" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis252">
 <bp:controlled rdf:resource="#BiochemicalReaction530" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep372">
 <bp:stepProcess rdf:resource="#BiochemicalReaction308" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis253">
 <bp:controlled rdf:resource="#BiochemicalReaction531" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep371">
 <bp:stepProcess rdf:resource="#BiochemicalReaction307" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep370">
 <bp:stepProcess rdf:resource="#BiochemicalReaction306" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep329">
 <bp:stepProcess rdf:resource="#BiochemicalReaction269" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep328">
 <bp:stepProcess rdf:resource="#Pathway61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep327">
 <bp:stepProcess rdf:resource="#BiochemicalReaction268" />
 <bp:stepProcess rdf:resource="#Catalysis139" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep326">
 <bp:stepProcess rdf:resource="#BiochemicalReaction267" />
 <bp:stepProcess rdf:resource="#Catalysis138" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep325">
 <bp:stepProcess rdf:resource="#Catalysis137" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction266" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence177">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep324">
 <bp:stepProcess rdf:resource="#Catalysis136" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction265" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway82">
 <bp:pathwayOrder rdf:resource="#PathwayStep456" />
 <bp:pathwayOrder rdf:resource="#PathwayStep455" />
 <bp:pathwayOrder rdf:resource="#PathwayStep462" />
 <bp:pathwayOrder rdf:resource="#PathwayStep461" />
 <bp:pathwayOrder rdf:resource="#PathwayStep460" />
 <bp:pathwayOrder rdf:resource="#PathwayStep459" />
 <bp:pathwayOrder rdf:resource="#PathwayStep458" />
 <bp:pathwayOrder rdf:resource="#PathwayStep457" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction378" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction377" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction379" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction381" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction380" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction374" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction376" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction375" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence455" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence178">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep323">
 <bp:stepProcess rdf:resource="#Catalysis135" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction264" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway83">
 <bp:pathwayOrder rdf:resource="#PathwayStep467" />
 <bp:pathwayOrder rdf:resource="#PathwayStep466" />
 <bp:pathwayOrder rdf:resource="#PathwayStep465" />
 <bp:pathwayOrder rdf:resource="#PathwayStep482" />
 <bp:pathwayOrder rdf:resource="#PathwayStep481" />
 <bp:pathwayOrder rdf:resource="#PathwayStep480" />
 <bp:pathwayOrder rdf:resource="#PathwayStep479" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction399" />
 <bp:pathwayComponent rdf:resource="#Pathway84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction383" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction396" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction384" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction398" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction397" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence465" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence175">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep322">
 <bp:stepProcess rdf:resource="#Catalysis134" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction263" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway84">
 <bp:pathwayOrder rdf:resource="#PathwayStep478" />
 <bp:pathwayOrder rdf:resource="#PathwayStep477" />
 <bp:pathwayOrder rdf:resource="#PathwayStep476" />
 <bp:pathwayOrder rdf:resource="#PathwayStep475" />
 <bp:pathwayOrder rdf:resource="#PathwayStep474" />
 <bp:pathwayOrder rdf:resource="#PathwayStep473" />
 <bp:pathwayOrder rdf:resource="#PathwayStep472" />
 <bp:pathwayOrder rdf:resource="#PathwayStep471" />
 <bp:pathwayOrder rdf:resource="#PathwayStep470" />
 <bp:pathwayOrder rdf:resource="#PathwayStep469" />
 <bp:pathwayOrder rdf:resource="#PathwayStep468" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction389" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction388" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction390" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction392" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction391" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction394" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction393" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction385" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction395" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction387" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction386" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence468" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence176">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep321">
 <bp:stepProcess rdf:resource="#Catalysis133" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction262" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway85">
 <bp:pathwayOrder rdf:resource="#PathwayStep488" />
 <bp:pathwayOrder rdf:resource="#PathwayStep487" />
 <bp:pathwayOrder rdf:resource="#PathwayStep486" />
 <bp:pathwayOrder rdf:resource="#PathwayStep485" />
 <bp:pathwayOrder rdf:resource="#PathwayStep484" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction400" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction402" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction401" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction404" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction403" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence484" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep320">
 <bp:stepProcess rdf:resource="#Pathway60" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence179">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway80">
 <bp:pathwayOrder rdf:resource="#PathwayStep445" />
 <bp:pathwayOrder rdf:resource="#PathwayStep453" />
 <bp:pathwayOrder rdf:resource="#PathwayStep452" />
 <bp:pathwayOrder rdf:resource="#PathwayStep451" />
 <bp:pathwayOrder rdf:resource="#PathwayStep450" />
 <bp:pathwayOrder rdf:resource="#PathwayStep449" />
 <bp:pathwayOrder rdf:resource="#PathwayStep446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction366" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction369" />
 <bp:pathwayComponent rdf:resource="#Pathway81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction370" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction372" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction371" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction373" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence445" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway81">
 <bp:pathwayOrder rdf:resource="#PathwayStep448" />
 <bp:pathwayOrder rdf:resource="#PathwayStep447" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction368" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence447" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence170">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence173">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway86">
 <bp:pathwayOrder rdf:resource="#PathwayStep493" />
 <bp:pathwayOrder rdf:resource="#PathwayStep492" />
 <bp:pathwayOrder rdf:resource="#PathwayStep491" />
 <bp:pathwayOrder rdf:resource="#PathwayStep490" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction406" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction405" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction408" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction407" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence490" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence174">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway87">
 <bp:pathwayOrder rdf:resource="#PathwayStep497" />
 <bp:pathwayOrder rdf:resource="#PathwayStep496" />
 <bp:pathwayOrder rdf:resource="#PathwayStep508" />
 <bp:pathwayOrder rdf:resource="#PathwayStep507" />
 <bp:pathwayOrder rdf:resource="#PathwayStep506" />
 <bp:pathwayOrder rdf:resource="#PathwayStep505" />
 <bp:pathwayOrder rdf:resource="#PathwayStep504" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction410" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction417" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction419" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction418" />
 <bp:pathwayComponent rdf:resource="#Pathway88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction420" />
 <bp:pathwayComponent rdf:resource="#Pathway89" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence496" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 9 (TLR9) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CpG DNA is an unusual Pathogen-Associated Molecular Pattern (PAMP). Cytosine methylation exists in mammalian but not bacterial cells, and most (but not all) CpG in the mammalian genome is methylated. Therefore, unmethylated CpG DNA may signal the presence of microbial infection. Evidence of CpG recognition by TLR9 was demonstrated both in human and  mouse, and this type of signaling requires its internalization into late endosomal/lysosomal compartments. TLR9 has been reported to be able to discern different types of CpG motifs, and therefore that it presumably recognizes CpG DNA directly. It appears that over evolutionary periods, TLR9 molecules expressed by different species have diverged. This has led to differences in the precise sequence motif (CpG dinucleotide plus flanking regions) that optimally stimulate the innate immune system of different animals.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence171">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway88">
 <bp:pathwayOrder rdf:resource="#PathwayStep500" />
 <bp:pathwayOrder rdf:resource="#PathwayStep499" />
 <bp:pathwayOrder rdf:resource="#PathwayStep498" />
 <bp:pathwayOrder rdf:resource="#PathwayStep503" />
 <bp:pathwayOrder rdf:resource="#PathwayStep502" />
 <bp:pathwayOrder rdf:resource="#PathwayStep501" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction411" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction413" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction412" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction415" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction414" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction416" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence498" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC15A4:TASL-dependent IRF5 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This Reactome module describes the Toll-like receptor 7 (TLR7), TLR8, or TLR9 &#8211; induced activation of interferon regulatory factor 5 (IRF5) via the SLC15A4:TASL axis.  Solute carrier family 15, member 4 (SLC15A4, also known as PHT1) is a proton-coupled L-histidine/oligopeptide transporter. In addition to its function as a transporter, SLC15A4 regulates TLR7-9 signaling pathways in late endosomes/lysosomes (Heinz LX. et al., 2020; Kobayashi T et al., 2021). SLC15A4 acts as a signaling scaffold, recruiting the protein TLR adaptor interacting with SLC15A4 on the lysosome (TASL) to the cytosolic surface of endolysosomes (Heinz LX. et al., 2020; Custodio TF et al., 2023; Chen X et al., 2023). Upon activation of endosomal TLR signaling, TASL undergoes phosphorylation and recruits IRF5 to its pLxIS motif (Heinz LX. et al., 2020). The SLC15A4:TASL complex facilitates IRF5 phosphorylation by IKBKB (IKK&#946;) and subsequent IRF5 homodimerization downstream of TLR7-TLR9 (Heinz LX. et al., 2020; Zhang H et al., 2023; Chen X et al., 2023; Boeszoermeny A et al., 2023). Once activated, IRF5 translocates to the nucleus to induce the transcription of genes encoding type I interferons (IFNs) and pro-inflammatory cytokines. Hyperactivation of the SLC15A4:TASL:IRF5 pathway, often caused by the detection of endogenous nucleic acids, leads to increased production of type I IFNs and is associated with pathogenesis of inflammatory diseases such as systemic lupus erythematosus (SLE) (Odhams CA et al., 2019; Heinz LX. et al., 2020; Kobayashi T et al., 2021). .</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence172">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway89">
 <bp:pathwayOrder rdf:resource="#PathwayStep511" />
 <bp:pathwayOrder rdf:resource="#PathwayStep522" />
 <bp:pathwayOrder rdf:resource="#PathwayStep510" />
 <bp:pathwayOrder rdf:resource="#PathwayStep521" />
 <bp:pathwayOrder rdf:resource="#PathwayStep520" />
 <bp:pathwayOrder rdf:resource="#PathwayStep509" />
 <bp:pathwayOrder rdf:resource="#PathwayStep514" />
 <bp:pathwayOrder rdf:resource="#PathwayStep525" />
 <bp:pathwayOrder rdf:resource="#PathwayStep513" />
 <bp:pathwayOrder rdf:resource="#PathwayStep524" />
 <bp:pathwayOrder rdf:resource="#PathwayStep512" />
 <bp:pathwayOrder rdf:resource="#PathwayStep523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction422" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction433" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction421" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction432" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction424" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction435" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction423" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction434" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction425" />
 <bp:pathwayComponent rdf:resource="#Pathway90" />
 <bp:pathwayComponent rdf:resource="#Pathway91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction431" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence509" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 dependent cascade initiated on endosome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Upon binding of their ligands, TLR7/8 and TLR9 recruit a cytoplasmic adaptor MyD88 and IRAKs, downstream of which the signaling pathways are divided to induce either inflammatory cytokines or type I IFNs.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction291">
 <bp:evidence rdf:resource="#Evidence354" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction290">
 <bp:evidence rdf:resource="#Evidence353" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction293">
 <bp:evidence rdf:resource="#Evidence356" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction292">
 <bp:evidence rdf:resource="#Evidence355" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep319">
 <bp:stepProcess rdf:resource="#Catalysis132" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction261" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction295">
 <bp:evidence rdf:resource="#Evidence358" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARM binds viral dsRNA:TLR3:TICAM1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep318">
 <bp:stepProcess rdf:resource="#Pathway59" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction294">
 <bp:evidence rdf:resource="#Evidence357" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep317">
 <bp:stepProcess rdf:resource="#Catalysis131" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction260" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction297">
 <bp:evidence rdf:resource="#Evidence361" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKK&#949; (IKBKE) binds K63-pUb-TANK:K63-pUb-TRAF3:TRIF:activated TLR3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep316">
 <bp:stepProcess rdf:resource="#BiochemicalReaction259" />
 <bp:stepProcess rdf:resource="#Catalysis130" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction296">
 <bp:evidence rdf:resource="#Evidence360" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto-ubiquitination of TRAF3 within activated TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep315">
 <bp:stepProcess rdf:resource="#BiochemicalReaction258" />
 <bp:stepProcess rdf:resource="#Catalysis129" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction299">
 <bp:evidence rdf:resource="#Evidence363" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRF-3/IRF7 and their release from the activated TLR3 complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep799">
 <bp:stepProcess rdf:resource="#Catalysis322" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction660" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep314">
 <bp:stepProcess rdf:resource="#BiochemicalReaction257" />
 <bp:stepProcess rdf:resource="#Catalysis128" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction298">
 <bp:evidence rdf:resource="#Evidence362" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 is phosphorylated within the activated TLR3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep798">
 <bp:stepProcess rdf:resource="#BiochemicalReaction659" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence188">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep313">
 <bp:stepProcess rdf:resource="#Pathway58" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway93">
 <bp:pathwayOrder rdf:resource="#PathwayStep530" />
 <bp:pathwayOrder rdf:resource="#PathwayStep529" />
 <bp:pathwayOrder rdf:resource="#PathwayStep528" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction437" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction436" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction438" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence528" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep797">
 <bp:stepProcess rdf:resource="#BiochemicalReaction658" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence189">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep312">
 <bp:stepProcess rdf:resource="#BiochemicalReaction256" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction289">
 <bp:evidence rdf:resource="#Evidence352" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway94">
 <bp:pathwayOrder rdf:resource="#PathwayStep533" />
 <bp:pathwayOrder rdf:resource="#PathwayStep532" />
 <bp:pathwayOrder rdf:resource="#PathwayStep536" />
 <bp:pathwayOrder rdf:resource="#PathwayStep535" />
 <bp:pathwayOrder rdf:resource="#PathwayStep534" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction443" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction439" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction442" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction441" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence532" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep796">
 <bp:stepProcess rdf:resource="#Catalysis321" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction657" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence186">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep311">
 <bp:stepProcess rdf:resource="#Catalysis127" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction255" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway95">
 <bp:pathwayOrder rdf:resource="#PathwayStep544" />
 <bp:pathwayOrder rdf:resource="#PathwayStep538" />
 <bp:pathwayOrder rdf:resource="#PathwayStep549" />
 <bp:pathwayComponent rdf:resource="#Pathway96" />
 <bp:pathwayComponent rdf:resource="#Pathway97" />
 <bp:pathwayComponent rdf:resource="#Pathway98" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence538" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep795">
 <bp:stepProcess rdf:resource="#BiochemicalReaction656" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence187">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep310">
 <bp:stepProcess rdf:resource="#Catalysis126" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction254" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway96">
 <bp:pathwayOrder rdf:resource="#PathwayStep543" />
 <bp:pathwayOrder rdf:resource="#PathwayStep542" />
 <bp:pathwayOrder rdf:resource="#PathwayStep541" />
 <bp:pathwayOrder rdf:resource="#PathwayStep540" />
 <bp:pathwayOrder rdf:resource="#PathwayStep539" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction444" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction445" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction448" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction447" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence539" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep794">
 <bp:stepProcess rdf:resource="#Pathway140" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep793">
 <bp:stepProcess rdf:resource="#BiochemicalReaction655" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway90">
 <bp:pathwayOrder rdf:resource="#PathwayStep519" />
 <bp:pathwayOrder rdf:resource="#PathwayStep518" />
 <bp:pathwayOrder rdf:resource="#PathwayStep517" />
 <bp:pathwayOrder rdf:resource="#PathwayStep516" />
 <bp:pathwayOrder rdf:resource="#PathwayStep515" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction426" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction428" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction427" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction429" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction430" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence515" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In plasmacytoid dendritic cell induction of type I IFNs critically depends on IFN regulatory factor 7 in TLR7 and 9 signaling (Honda et al 2005). IRF-7, but not IRF3, interacts with MyD88, TRAF6, and IRAKs and translocates to the nucleus upon phosphorylation (Kawai et al 2004; Uematsu et al 2005).  TLR7/8 signaling was shown to induce IRF5 activation along with IRF7 [Schoenemeyer et al 2005], while IRF8 [Tsujimura H et al 2004] and IRF1 were reported to be implicated in TLR9 signaling.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep792">
 <bp:stepProcess rdf:resource="#BiochemicalReaction654" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway91">
 <bp:pathwayOrder rdf:resource="#PathwayStep588" />
 <bp:pathwayOrder rdf:resource="#PathwayStep599" />
 <bp:pathwayOrder rdf:resource="#PathwayStep594" />
 <bp:pathwayOrder rdf:resource="#PathwayStep526" />
 <bp:pathwayOrder rdf:resource="#PathwayStep569" />
 <bp:pathwayOrder rdf:resource="#PathwayStep568" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction469" />
 <bp:pathwayComponent rdf:resource="#Pathway92" />
 <bp:pathwayComponent rdf:resource="#Pathway101" />
 <bp:pathwayComponent rdf:resource="#Pathway103" />
 <bp:pathwayComponent rdf:resource="#Pathway104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction496" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence526" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 mediates NFkB activation via canonical phosphorylation of IKK complex by TAK1. TRAF6 and TAK1 also regulate MAPK cascades leading to the activation of AP-1.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep791">
 <bp:stepProcess rdf:resource="#Pathway139" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway92">
 <bp:pathwayOrder rdf:resource="#PathwayStep531" />
 <bp:pathwayOrder rdf:resource="#PathwayStep527" />
 <bp:pathwayOrder rdf:resource="#PathwayStep537" />
 <bp:pathwayOrder rdf:resource="#PathwayStep559" />
 <bp:pathwayComponent rdf:resource="#Pathway93" />
 <bp:pathwayComponent rdf:resource="#Pathway94" />
 <bp:pathwayComponent rdf:resource="#Pathway95" />
 <bp:pathwayComponent rdf:resource="#Pathway100" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence527" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep790">
 <bp:stepProcess rdf:resource="#BiochemicalReaction653" />
 <bp:stepProcess rdf:resource="#Catalysis320" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence180">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence181">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence184">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway97">
 <bp:pathwayOrder rdf:resource="#PathwayStep548" />
 <bp:pathwayOrder rdf:resource="#PathwayStep547" />
 <bp:pathwayOrder rdf:resource="#PathwayStep546" />
 <bp:pathwayOrder rdf:resource="#PathwayStep545" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction449" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction451" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction450" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction452" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence545" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence185">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway98">
 <bp:pathwayOrder rdf:resource="#PathwayStep555" />
 <bp:pathwayOrder rdf:resource="#PathwayStep554" />
 <bp:pathwayOrder rdf:resource="#PathwayStep551" />
 <bp:pathwayOrder rdf:resource="#PathwayStep550" />
 <bp:pathwayOrder rdf:resource="#PathwayStep558" />
 <bp:pathwayOrder rdf:resource="#PathwayStep557" />
 <bp:pathwayOrder rdf:resource="#PathwayStep556" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction457" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction456" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction459" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction458" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction460" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction453" />
 <bp:pathwayComponent rdf:resource="#Pathway99" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence550" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence182">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway99">
 <bp:pathwayOrder rdf:resource="#PathwayStep553" />
 <bp:pathwayOrder rdf:resource="#PathwayStep552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction455" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction454" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence552" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence183">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction280">
 <bp:evidence rdf:resource="#Evidence343" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction282">
 <bp:evidence rdf:resource="#Evidence345" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction281">
 <bp:evidence rdf:resource="#Evidence344" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction284">
 <bp:evidence rdf:resource="#Evidence347" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction283">
 <bp:evidence rdf:resource="#Evidence346" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction286">
 <bp:evidence rdf:resource="#Evidence349" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction285">
 <bp:evidence rdf:resource="#Evidence348" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep349">
 <bp:stepProcess rdf:resource="#BiochemicalReaction287" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep348">
 <bp:stepProcess rdf:resource="#Catalysis146" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction286" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction288">
 <bp:evidence rdf:resource="#Evidence351" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep347">
 <bp:stepProcess rdf:resource="#BiochemicalReaction285" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction287">
 <bp:evidence rdf:resource="#Evidence350" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence155">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway60">
 <bp:pathwayOrder rdf:resource="#PathwayStep322" />
 <bp:pathwayOrder rdf:resource="#PathwayStep321" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction262" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction263" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence321" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction279">
 <bp:evidence rdf:resource="#Evidence341" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep346">
 <bp:stepProcess rdf:resource="#Catalysis145" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction284" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis287">
 <bp:controlled rdf:resource="#BiochemicalReaction596" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence156">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway61">
 <bp:pathwayOrder rdf:resource="#PathwayStep335" />
 <bp:pathwayOrder rdf:resource="#PathwayStep334" />
 <bp:pathwayOrder rdf:resource="#PathwayStep333" />
 <bp:pathwayOrder rdf:resource="#PathwayStep332" />
 <bp:pathwayOrder rdf:resource="#PathwayStep331" />
 <bp:pathwayOrder rdf:resource="#PathwayStep330" />
 <bp:pathwayOrder rdf:resource="#PathwayStep329" />
 <bp:pathwayOrder rdf:resource="#PathwayStep336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction269" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction271" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction270" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction273" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction272" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction275" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction274" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction276" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence329" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction278">
 <bp:evidence rdf:resource="#Evidence340" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep345">
 <bp:stepProcess rdf:resource="#BiochemicalReaction283" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis288">
 <bp:controlled rdf:resource="#BiochemicalReaction597" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence153">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway62">
 <bp:pathwayOrder rdf:resource="#PathwayStep356" />
 <bp:pathwayOrder rdf:resource="#PathwayStep355" />
 <bp:pathwayOrder rdf:resource="#PathwayStep354" />
 <bp:pathwayOrder rdf:resource="#PathwayStep353" />
 <bp:pathwayOrder rdf:resource="#PathwayStep341" />
 <bp:pathwayOrder rdf:resource="#PathwayStep340" />
 <bp:pathwayOrder rdf:resource="#PathwayStep339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction279" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction278" />
 <bp:pathwayComponent rdf:resource="#Pathway63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction291" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction293" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction292" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction294" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence339" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep344">
 <bp:stepProcess rdf:resource="#BiochemicalReaction282" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis289">
 <bp:controlled rdf:resource="#BiochemicalReaction598" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence154">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway63">
 <bp:pathwayOrder rdf:resource="#PathwayStep346" />
 <bp:pathwayOrder rdf:resource="#PathwayStep345" />
 <bp:pathwayOrder rdf:resource="#PathwayStep344" />
 <bp:pathwayOrder rdf:resource="#PathwayStep343" />
 <bp:pathwayOrder rdf:resource="#PathwayStep342" />
 <bp:pathwayOrder rdf:resource="#PathwayStep352" />
 <bp:pathwayOrder rdf:resource="#PathwayStep351" />
 <bp:pathwayOrder rdf:resource="#PathwayStep350" />
 <bp:pathwayOrder rdf:resource="#PathwayStep349" />
 <bp:pathwayOrder rdf:resource="#PathwayStep348" />
 <bp:pathwayOrder rdf:resource="#PathwayStep347" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction289" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction280" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction290" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction282" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction281" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction284" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction283" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction286" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction285" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction288" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction287" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence342" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep343">
 <bp:stepProcess rdf:resource="#Catalysis144" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction281" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence159">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep342">
 <bp:stepProcess rdf:resource="#BiochemicalReaction280" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis283">
 <bp:controlled rdf:resource="#BiochemicalReaction588" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep341">
 <bp:stepProcess rdf:resource="#Pathway63" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis284">
 <bp:controlled rdf:resource="#BiochemicalReaction590" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence157">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep340">
 <bp:stepProcess rdf:resource="#BiochemicalReaction279" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis285">
 <bp:controlled rdf:resource="#BiochemicalReaction591" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence158">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis286">
 <bp:controlled rdf:resource="#BiochemicalReaction593" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway68">
 <bp:pathwayOrder rdf:resource="#PathwayStep389" />
 <bp:pathwayOrder rdf:resource="#PathwayStep388" />
 <bp:pathwayOrder rdf:resource="#PathwayStep387" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction322" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction321" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction320" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence387" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TICAM1, RIP1-mediated IKK complex recruitment</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Receptor-interacting protein 1 (RIP1) mediates the activation of interferon-alpha/beta via intermediate activation of IKK/TBK1 or NFkB pathways.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway69">
 <bp:pathwayOrder rdf:resource="#PathwayStep401" />
 <bp:pathwayOrder rdf:resource="#PathwayStep400" />
 <bp:pathwayOrder rdf:resource="#PathwayStep399" />
 <bp:pathwayOrder rdf:resource="#PathwayStep392" />
 <bp:pathwayOrder rdf:resource="#PathwayStep403" />
 <bp:pathwayOrder rdf:resource="#PathwayStep402" />
 <bp:pathwayComponent rdf:resource="#Pathway71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction333" />
 <bp:pathwayComponent rdf:resource="#Pathway70" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction330" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction332" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction331" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence392" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 7/8 (TLR7/8) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA can serve as a danger signal, both in its double-stranded form as well as single-stranded RNA (ssRNA). Toll like receptor 7 (TLR7) and TLR8 are endosomal receptors that sense ssRNA oligonucleotides containing guanosine (G)- and uridine (U)-rich sequences from RNA viruses (Jurk M et al. 2002; Heil F et al. 2004; Diebold SS et al. 2004; Li Y et al. 2013; reviewed in Lester SN    Li K 2014). TLR7 is primarily expressed in plasmacytoid dendritic cells (pDCs) and, to some extent, in B cells, monocytes and macrophages, whereas TLR8 is mostly expressed in monocytes, macrophages and myeloid DCs. Upon engagement of ssRNAs in endosomes, TLR7/8 initiate the myeloid differentiation factor 88 (MyD88)-dependent pathway, culminating in synthesis of type I and type III IFNs and proinflammatory mediators via activation of IFN regulatory factors (IRF7, IRF5) and NF-kappaB, respectively, depending on the cell type (Takaoka A et al., 2005; Heinz LX et al., 2020; reviewed in Lester SN    Li K 2014). TLR7 and TLR8 are able to detect GU-rich ssRNA sequences from the viral genomes of influenza, human immunodeficiency virus-1 (HIV-1), vesicular stomatitis virus (VSV), coxsackie B virus, coronavirus and flaviviruses (hepatitis C virus, HCV and West Nile virus, WNV; reviewed in Lester SN    Li K 2014). Specifically, GU-rich ssRNA oligonucleotides derived from HIV-1, for example, stimulate dendritic cells (DC) and macrophages to secrete interferon-alpha and proinflammatory, as well as regulatory, cytokines (Heil F et al. 2004). This has been found to be mediated by TLR7, as well as TLR8. Similarly, severe acute respiratory syndrome-associated coronavirus type 1 (SARS-CoV-1) GU-rich ssRNAs had powerful immunostimulatory activities in mononuclear phagocytes to induce considerable level of pro-inflammatory cytokine TNF-a, IL-6 and IL-12 release via the TLR7 and TLR8 (Li Y et al. 2013). Further, mice deficient in either Tlr7 or the TLR adaptor protein Myd88 demonstrated reduced responses to in vivo infection with VSV (Lund JM et al. 2004),  mouse-adapted SARS-CoV-1 (Sheahan et al. 2008; Totura et al., 2015). Upon Middle East respiratory syndrome-related coronavirus (MERS-CoV) infection, lack of MyD88 signaling resulted in delayed viral clearance and increased lung pathology in mice (Zhao et al. 2014). Consistently, another study showed that Tlr7-/- mice have reduced IFN expression compared with wild-type mice (Channappanavar et al. 2019). In addition, loss of function TLR7 variants identified in the patients with SARS-CoV-2 (COVID-19) resulted in defective upregulation of type I IFN&#8211;related genes in the TLR7 pathway (Figure 3) in response to the TLR7 agonist imiquimod as compared with controls (Van der Made CI et al. 2020). Separate studies showed that synthetic imidazoquinoline compounds (e.g. imiquimod and R-848, low-molecular-weight immune response modifiers that can induce the synthesis of interferon-alpha) also exert their effects in a MyD88-dependent fashion through TLR7 or TLR8 (Hemmi H et al. 2002; Jurk M et al. 2002; Diebold SS et al. 2004). Some viruses utilize multiple strategies to evade antiviral innate immune signaling, as is seen with influenza or SARS coronaviruses. TLR7-mediated innate immunity, for example, was associated with the negative regulation through removing Lys63-linked polyubiquitin chains of TRAF3/TRAF6 by papin-like protease (PLpro) catalytic domain of nsp3 from SARS-CoV-1 (Li SW et al. 2016). Thus, TLR7 and TLR8 play a critical role in sensing of viral ssRNA in the endosome.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis280">
 <bp:controlled rdf:resource="#BiochemicalReaction578" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis281">
 <bp:controlled rdf:resource="#BiochemicalReaction581" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis282">
 <bp:controlled rdf:resource="#BiochemicalReaction583" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence151">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway64">
 <bp:pathwayOrder rdf:resource="#PathwayStep359" />
 <bp:pathwayOrder rdf:resource="#PathwayStep368" />
 <bp:pathwayOrder rdf:resource="#PathwayStep367" />
 <bp:pathwayOrder rdf:resource="#PathwayStep366" />
 <bp:pathwayOrder rdf:resource="#PathwayStep365" />
 <bp:pathwayOrder rdf:resource="#PathwayStep364" />
 <bp:pathwayOrder rdf:resource="#PathwayStep363" />
 <bp:pathwayOrder rdf:resource="#PathwayStep374" />
 <bp:pathwayOrder rdf:resource="#PathwayStep362" />
 <bp:pathwayOrder rdf:resource="#PathwayStep373" />
 <bp:pathwayOrder rdf:resource="#PathwayStep361" />
 <bp:pathwayOrder rdf:resource="#PathwayStep372" />
 <bp:pathwayOrder rdf:resource="#PathwayStep360" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction297" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction296" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction299" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction310" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction298" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction301" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction300" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction303" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction302" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction304" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction309" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction308" />
 <bp:pathwayComponent rdf:resource="#Pathway65" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence359" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TICAM1-dependent activation of IRF3/IRF7</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cell stimulation with viral double-stranded (ds) RNA and bacterial lipopolysaccharide (LPS) activate Toll-like receptors 3 (TLR3) and TLR4, respectively, triggering the activation the activation of two IKK-related serine/threonine kinases, TANK-binding kinase 1 (TBK1) and I&#954;B kinase &#949; (IKK&#949;, IKBKE) which directly phosphorylate interferon regulatory factor 3 (IRF3) and IRF7 promoting their dimerization and translocation into the nucleus. Although both kinases show structural and functional similarities, it seems that TBK1 and IKBKE differ in their regulation of downstream signaling events of TLR3/TLR4.  IRF3 activation and interferon &#946; (IFN&#946;) production by poly(I:C), a synthetic analog of dsRNA, are decreased in TBK1-deficient mouse fibroblasts, whereas normal activation was observed in the IKBKE-deficient fibroblasts. However, in double-deficient mouse fibroblasts, the activation of IRF3 is completely abolished, suggesting a partially redundant functions of TBK1 and IKK&#949; (IKBKE) (Hemmi H et al., 2004).  The poly(I:C)-induced phosphorylation of TBK1 and IRF3 was abolished in TRIF (TICAM1)-knockout human keratinocyte HACAT cells (Bakshi S et al., 2017). TICAM1 is utilized as an adaptor protein by TLR3 and TLR4 (Yamamoto M et al., 2003).  TLR3 recruits and activates PI3 kinase (PI3K), which activates the downstream kinase, Akt, leading to full phosphorylation and activation of IRF3 (Sarkar SN et al., 2004). When PI3K is not recruited to TLR3 or its activity is blocked, IRF3 is only partially phosphorylated and fails to bind the promoter of the target gene (Sarkar SN et al., 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence152">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway65">
 <bp:pathwayOrder rdf:resource="#PathwayStep371" />
 <bp:pathwayOrder rdf:resource="#PathwayStep370" />
 <bp:pathwayOrder rdf:resource="#PathwayStep369" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction305" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction307" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction306" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence369" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of TBK1, IKK&#949;-mediated activation of IRF3, IRF7 upon TLR3 ligation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Production of type I IFN genes in response to Toll-like receptor 3 (TLR3) and TLR4 ligands is mediated by TANK-binding kinase 1 (TBK1) or I-kappa-B kinase epsilon (IKK&#949;, IKBKE), which phosphorylate IFN regulatory factor 3 (IRF3) and IRF7. The activity of TBK1 and/or IRF3, IRF7 is regulated by multiple mechanisms including post-translational modifications, protein-protein interactions, and protein degradation (Zhao W et al., 2013; Runde AP et al., 2022).  This Reactome module describes regulation of TBK1, IKK&#949; activity by K63-linked ubiquitination of TBK1 and IKK&#949;, and TBK1 interaction with OPTN.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway66">
 <bp:pathwayOrder rdf:resource="#PathwayStep378" />
 <bp:pathwayOrder rdf:resource="#PathwayStep377" />
 <bp:pathwayOrder rdf:resource="#PathwayStep376" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction312" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction311" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction313" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence376" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR3-mediated TICAM1-dependent programmed cell death</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR3 and TLR4 trigger TRIF(TICAM1)-dependent programmed cell death in various human and mouse cells (Kalai M et al. 2002; Han KJ et al. 2004; Kaiser WJ and Offermann MK 2005; Estornes Y et al. 2012; He S et al. 2011). Apoptosis is a prevalent form of programmed cell death and is mediated by the activation of a set of caspases. In addition to apoptosis, TLR3/TLR4 activation induces RIP3-dependent necroptosis. These two programmed cell-death pathways may suppress each other. When the caspase activity is impaired or inhibited, certain cell types switch the apoptotic death program to necroptosis in response to various stimuli (TNF, Fas, viral infection and other stress stimuli) (Kalai M et al. 2002; Weber A et al. 2010; Feoktistova M et al. 2011, Tenev et al 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence150">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway67">
 <bp:pathwayOrder rdf:resource="#PathwayStep385" />
 <bp:pathwayOrder rdf:resource="#PathwayStep384" />
 <bp:pathwayOrder rdf:resource="#PathwayStep383" />
 <bp:pathwayOrder rdf:resource="#PathwayStep382" />
 <bp:pathwayOrder rdf:resource="#PathwayStep381" />
 <bp:pathwayOrder rdf:resource="#PathwayStep380" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction314" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction316" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction315" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction318" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction317" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction319" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence380" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TICAM1,TRAF6-dependent induction of TAK1 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In human, together with ubiquitin-conjugating E2-type enzymes UBC13 and UEV1A (also known as UBE2V1), TRAF6 catalyses Lys63-linked ubiquitination. It is believed that auto polyubiquitination  and oligomerization of TRAF6 is followed by binding the ubiquitin receptors of TAB2 or TAB3 (TAK1 binding protein 2 and 3), which stimulates phosphorylation and activation of TGF beta-activated kinase 1(TAK1). TAK1 phosphorylates IKK alpha and IKK beta, which in turn phosphorylate NF-kB inhibitors - IkB  and eventually results in IkB degradation and NF-kB translocation to the nucleus. Also TAK1 mediates JNK and p38 MAP kinases activation by phosphorylating MKK4/7 and MKK3/6 respectivly resulting in the activation of many transcription factors.  The role of TRAF6 is somewhat controversial and probably cell type specific. TRAF6 autoubiquitination was found to be dispensable for TRAF6 function to activate TAK1 pathway. These findings are consistent with the new mechanism of TRAF6-mediated NF-kB activation that was suggested by Xia et al. (2009). TRAF6 generates unanchored Lys63-linked polyubiquitin chains that bind to the regulatory subunits of TAK1 (TAB2 or TAB3) and IKK(NEMO), leading to the activation of the kinases.  Xia et al. (2009) demonstrated in vitro that unlike polyubiquitin chains covalently attached to TRAF6 or IRAK, TAB2 and NEMO-associated ubiquitin chains were found to be unanchored and susceptible to N-terminal ubiquitin cleavage. Only K63-linked polyubiquitin chains, but not monomeric ubiquitin, activated TAK1 in a dose-dependent manner. Optimal activation of the IKK complex was achieved using ubiquitin polymers containing both K48 and K63 linkages. Furthermore, the authors proposed that the TAK1 complexes might be brougt in close proximity by binding several TAB2/3 to a single polyubiquitin chain to facilitate TAK1 kinase trans-phosphorylation. Alternativly, the possibility that polyUb binding promotes allosteric activation of TAK1 complex should  be considered (Walsh et al 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction271">
 <bp:evidence rdf:resource="#Evidence332" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction270">
 <bp:evidence rdf:resource="#Evidence331" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction273">
 <bp:evidence rdf:resource="#Evidence334" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction272">
 <bp:evidence rdf:resource="#Evidence333" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction275">
 <bp:evidence rdf:resource="#Evidence336" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep339">
 <bp:stepProcess rdf:resource="#BiochemicalReaction278" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction274">
 <bp:evidence rdf:resource="#Evidence335" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep338">
 <bp:stepProcess rdf:resource="#Pathway62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep337">
 <bp:stepProcess rdf:resource="#BiochemicalReaction277" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction277">
 <bp:evidence rdf:resource="#Evidence338" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral dsRNA:TLR3 recruits TRIF (TICAM1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep336">
 <bp:stepProcess rdf:resource="#BiochemicalReaction276" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction276">
 <bp:evidence rdf:resource="#Evidence337" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence166">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction268">
 <bp:evidence rdf:resource="#Evidence328" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep335">
 <bp:stepProcess rdf:resource="#BiochemicalReaction275" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway71">
 <bp:pathwayOrder rdf:resource="#PathwayStep420" />
 <bp:pathwayOrder rdf:resource="#PathwayStep409" />
 <bp:pathwayOrder rdf:resource="#PathwayStep408" />
 <bp:pathwayOrder rdf:resource="#PathwayStep419" />
 <bp:pathwayOrder rdf:resource="#PathwayStep407" />
 <bp:pathwayOrder rdf:resource="#PathwayStep418" />
 <bp:pathwayOrder rdf:resource="#PathwayStep406" />
 <bp:pathwayOrder rdf:resource="#PathwayStep417" />
 <bp:pathwayOrder rdf:resource="#PathwayStep405" />
 <bp:pathwayOrder rdf:resource="#PathwayStep416" />
 <bp:pathwayOrder rdf:resource="#PathwayStep404" />
 <bp:pathwayOrder rdf:resource="#PathwayStep415" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction334" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction345" />
 <bp:pathwayComponent rdf:resource="#Pathway72" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction344" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction347" />
 <bp:pathwayComponent rdf:resource="#Pathway73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction346" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction338" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction337" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction348" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence404" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 dependent cascade initiated on endosome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Upon binding of their ligands, TLR7/8 and TLR9 recruit a cytoplasmic adaptor MyD88 and IRAKs, downstream of which the signaling pathways are divided to induce either inflammatory cytokines or type I IFNs.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis298">
 <bp:controlled rdf:resource="#BiochemicalReaction611" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence167">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction267">
 <bp:evidence rdf:resource="#Evidence327" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep334">
 <bp:stepProcess rdf:resource="#Catalysis143" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction274" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway72">
 <bp:pathwayOrder rdf:resource="#PathwayStep412" />
 <bp:pathwayOrder rdf:resource="#PathwayStep411" />
 <bp:pathwayOrder rdf:resource="#PathwayStep410" />
 <bp:pathwayOrder rdf:resource="#PathwayStep414" />
 <bp:pathwayOrder rdf:resource="#PathwayStep413" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction341" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction340" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction343" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction342" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence410" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In plasmacytoid dendritic cell induction of type I IFNs critically depends on IFN regulatory factor 7 in TLR7 and 9 signaling (Honda et al 2005). IRF-7, but not IRF3, interacts with MyD88, TRAF6, and IRAKs and translocates to the nucleus upon phosphorylation (Kawai et al 2004; Uematsu et al 2005).  TLR7/8 signaling was shown to induce IRF5 activation along with IRF7 [Schoenemeyer et al 2005], while IRF8 [Tsujimura H et al 2004] and IRF1 were reported to be implicated in TLR9 signaling.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis299">
 <bp:controlled rdf:resource="#BiochemicalReaction612" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence164">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep333">
 <bp:stepProcess rdf:resource="#BiochemicalReaction273" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway73">
 <bp:pathwayOrder rdf:resource="#PathwayStep489" />
 <bp:pathwayOrder rdf:resource="#PathwayStep421" />
 <bp:pathwayOrder rdf:resource="#PathwayStep464" />
 <bp:pathwayOrder rdf:resource="#PathwayStep463" />
 <bp:pathwayOrder rdf:resource="#PathwayStep483" />
 <bp:pathwayOrder rdf:resource="#PathwayStep494" />
 <bp:pathwayComponent rdf:resource="#Pathway83" />
 <bp:pathwayComponent rdf:resource="#Pathway74" />
 <bp:pathwayComponent rdf:resource="#Pathway85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction382" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction409" />
 <bp:pathwayComponent rdf:resource="#Pathway86" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence421" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 mediates NFkB activation via canonical phosphorylation of IKK complex by TAK1. TRAF6 and TAK1 also regulate MAPK cascades leading to the activation of AP-1.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence165">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction269">
 <bp:evidence rdf:resource="#Evidence330" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep332">
 <bp:stepProcess rdf:resource="#Catalysis142" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction272" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway74">
 <bp:pathwayOrder rdf:resource="#PathwayStep422" />
 <bp:pathwayOrder rdf:resource="#PathwayStep432" />
 <bp:pathwayOrder rdf:resource="#PathwayStep454" />
 <bp:pathwayOrder rdf:resource="#PathwayStep426" />
 <bp:pathwayComponent rdf:resource="#Pathway82" />
 <bp:pathwayComponent rdf:resource="#Pathway75" />
 <bp:pathwayComponent rdf:resource="#Pathway76" />
 <bp:pathwayComponent rdf:resource="#Pathway77" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence422" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep331">
 <bp:stepProcess rdf:resource="#Catalysis141" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction271" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis294">
 <bp:controlled rdf:resource="#BiochemicalReaction605" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep330">
 <bp:stepProcess rdf:resource="#Catalysis140" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction270" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis295">
 <bp:controlled rdf:resource="#BiochemicalReaction606" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence168">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis296">
 <bp:controlled rdf:resource="#BiochemicalReaction607" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence169">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway70">
 <bp:pathwayOrder rdf:resource="#PathwayStep398" />
 <bp:pathwayOrder rdf:resource="#PathwayStep397" />
 <bp:pathwayOrder rdf:resource="#PathwayStep396" />
 <bp:pathwayOrder rdf:resource="#PathwayStep395" />
 <bp:pathwayOrder rdf:resource="#PathwayStep394" />
 <bp:pathwayOrder rdf:resource="#PathwayStep393" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction325" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction324" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction327" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction326" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction329" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction328" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence393" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC15A4:TASL-dependent IRF5 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This Reactome module describes the Toll-like receptor 7 (TLR7), TLR8, or TLR9 &#8211; induced activation of interferon regulatory factor 5 (IRF5) via the SLC15A4:TASL axis.  Solute carrier family 15, member 4 (SLC15A4, also known as PHT1) is a proton-coupled L-histidine/oligopeptide transporter. In addition to its function as a transporter, SLC15A4 regulates TLR7-9 signaling pathways in late endosomes/lysosomes (Heinz LX. et al., 2020; Kobayashi T et al., 2021). SLC15A4 acts as a signaling scaffold, recruiting the protein TLR adaptor interacting with SLC15A4 on the lysosome (TASL) to the cytosolic surface of endolysosomes (Heinz LX. et al., 2020; Custodio TF et al., 2023; Chen X et al., 2023). Upon activation of endosomal TLR signaling, TASL undergoes phosphorylation and recruits IRF5 to its pLxIS motif (Heinz LX. et al., 2020). The SLC15A4:TASL complex facilitates IRF5 phosphorylation by IKBKB (IKK&#946;) and subsequent IRF5 homodimerization downstream of TLR7-TLR9 (Heinz LX. et al., 2020; Zhang H et al., 2023; Chen X et al., 2023; Boeszoermeny A et al., 2023). Once activated, IRF5 translocates to the nucleus to induce the transcription of genes encoding type I interferons (IFNs) and pro-inflammatory cytokines. Hyperactivation of the SLC15A4:TASL:IRF5 pathway, often caused by the detection of endogenous nucleic acids, leads to increased production of type I IFNs and is associated with pathogenesis of inflammatory diseases such as systemic lupus erythematosus (SLE) (Odhams CA et al., 2019; Heinz LX. et al., 2020; Kobayashi T et al., 2021). .</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis297">
 <bp:controlled rdf:resource="#BiochemicalReaction610" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway79">
 <bp:pathwayOrder rdf:resource="#PathwayStep443" />
 <bp:pathwayOrder rdf:resource="#PathwayStep442" />
 <bp:pathwayOrder rdf:resource="#PathwayStep441" />
 <bp:pathwayOrder rdf:resource="#PathwayStep440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction362" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction365" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction364" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence440" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis290">
 <bp:controlled rdf:resource="#BiochemicalReaction599" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis291">
 <bp:controlled rdf:resource="#BiochemicalReaction600" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis292">
 <bp:controlled rdf:resource="#BiochemicalReaction602" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis293">
 <bp:controlled rdf:resource="#BiochemicalReaction603" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence162">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway75">
 <bp:pathwayOrder rdf:resource="#PathwayStep423" />
 <bp:pathwayOrder rdf:resource="#PathwayStep425" />
 <bp:pathwayOrder rdf:resource="#PathwayStep424" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction349" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction350" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction351" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence423" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence163">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway76">
 <bp:pathwayOrder rdf:resource="#PathwayStep431" />
 <bp:pathwayOrder rdf:resource="#PathwayStep430" />
 <bp:pathwayOrder rdf:resource="#PathwayStep429" />
 <bp:pathwayOrder rdf:resource="#PathwayStep428" />
 <bp:pathwayOrder rdf:resource="#PathwayStep427" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction356" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction355" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction352" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction354" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction353" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence427" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence160">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway77">
 <bp:pathwayOrder rdf:resource="#PathwayStep433" />
 <bp:pathwayOrder rdf:resource="#PathwayStep444" />
 <bp:pathwayOrder rdf:resource="#PathwayStep439" />
 <bp:pathwayComponent rdf:resource="#Pathway80" />
 <bp:pathwayComponent rdf:resource="#Pathway79" />
 <bp:pathwayComponent rdf:resource="#Pathway78" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence433" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence161">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway78">
 <bp:pathwayOrder rdf:resource="#PathwayStep434" />
 <bp:pathwayOrder rdf:resource="#PathwayStep438" />
 <bp:pathwayOrder rdf:resource="#PathwayStep437" />
 <bp:pathwayOrder rdf:resource="#PathwayStep436" />
 <bp:pathwayOrder rdf:resource="#PathwayStep435" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction358" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction357" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction359" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction361" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction360" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence434" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway39">
 <bp:pathwayOrder rdf:resource="#PathwayStep203" />
 <bp:pathwayOrder rdf:resource="#PathwayStep202" />
 <bp:pathwayOrder rdf:resource="#PathwayStep201" />
 <bp:pathwayOrder rdf:resource="#PathwayStep204" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction163" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction165" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction166" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence201" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence139">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep769">
 <bp:stepProcess rdf:resource="#BiochemicalReaction636" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep768">
 <bp:stepProcess rdf:resource="#BiochemicalReaction635" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep767">
 <bp:stepProcess rdf:resource="#BiochemicalReaction634" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep766">
 <bp:stepProcess rdf:resource="#BiochemicalReaction633" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep765">
 <bp:stepProcess rdf:resource="#BiochemicalReaction632" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence133">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep764">
 <bp:stepProcess rdf:resource="#BiochemicalReaction631" />
 <bp:stepProcess rdf:resource="#Catalysis315" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence134">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep763">
 <bp:stepProcess rdf:resource="#BiochemicalReaction630" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence131">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway40">
 <bp:pathwayOrder rdf:resource="#PathwayStep223" />
 <bp:pathwayOrder rdf:resource="#PathwayStep222" />
 <bp:pathwayOrder rdf:resource="#PathwayStep221" />
 <bp:pathwayOrder rdf:resource="#PathwayStep220" />
 <bp:pathwayOrder rdf:resource="#PathwayStep208" />
 <bp:pathwayOrder rdf:resource="#PathwayStep207" />
 <bp:pathwayOrder rdf:resource="#PathwayStep206" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction168" />
 <bp:pathwayComponent rdf:resource="#Pathway41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction181" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction180" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction182" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction167" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence206" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep762">
 <bp:stepProcess rdf:resource="#BiochemicalReaction629" />
 <bp:stepProcess rdf:resource="#Catalysis314" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence132">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway41">
 <bp:pathwayOrder rdf:resource="#PathwayStep214" />
 <bp:pathwayOrder rdf:resource="#PathwayStep213" />
 <bp:pathwayOrder rdf:resource="#PathwayStep212" />
 <bp:pathwayOrder rdf:resource="#PathwayStep211" />
 <bp:pathwayOrder rdf:resource="#PathwayStep210" />
 <bp:pathwayOrder rdf:resource="#PathwayStep209" />
 <bp:pathwayOrder rdf:resource="#PathwayStep219" />
 <bp:pathwayOrder rdf:resource="#PathwayStep218" />
 <bp:pathwayOrder rdf:resource="#PathwayStep217" />
 <bp:pathwayOrder rdf:resource="#PathwayStep216" />
 <bp:pathwayOrder rdf:resource="#PathwayStep215" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction169" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction179" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction170" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction172" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction171" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction174" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction173" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction176" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction175" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction178" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction177" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence209" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep761">
 <bp:stepProcess rdf:resource="#BiochemicalReaction628" />
 <bp:stepProcess rdf:resource="#Catalysis313" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence137">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep760">
 <bp:stepProcess rdf:resource="#Catalysis312" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction627" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence138">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence135">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence136">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway46">
 <bp:pathwayOrder rdf:resource="#PathwayStep247" />
 <bp:pathwayOrder rdf:resource="#PathwayStep246" />
 <bp:pathwayOrder rdf:resource="#PathwayStep250" />
 <bp:pathwayOrder rdf:resource="#PathwayStep249" />
 <bp:pathwayOrder rdf:resource="#PathwayStep248" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction202" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction201" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction204" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction203" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction205" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence246" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway47">
 <bp:pathwayOrder rdf:resource="#PathwayStep255" />
 <bp:pathwayOrder rdf:resource="#PathwayStep254" />
 <bp:pathwayOrder rdf:resource="#PathwayStep253" />
 <bp:pathwayOrder rdf:resource="#PathwayStep252" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction206" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction208" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction209" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence252" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway48">
 <bp:pathwayOrder rdf:resource="#PathwayStep258" />
 <bp:pathwayOrder rdf:resource="#PathwayStep257" />
 <bp:pathwayOrder rdf:resource="#PathwayStep265" />
 <bp:pathwayOrder rdf:resource="#PathwayStep264" />
 <bp:pathwayOrder rdf:resource="#PathwayStep263" />
 <bp:pathwayOrder rdf:resource="#PathwayStep262" />
 <bp:pathwayOrder rdf:resource="#PathwayStep261" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction213" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction215" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction214" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction217" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction216" />
 <bp:pathwayComponent rdf:resource="#Pathway49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction210" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence257" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway49">
 <bp:pathwayOrder rdf:resource="#PathwayStep260" />
 <bp:pathwayOrder rdf:resource="#PathwayStep259" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction212" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction211" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence259" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway42">
 <bp:pathwayOrder rdf:resource="#PathwayStep234" />
 <bp:pathwayOrder rdf:resource="#PathwayStep244" />
 <bp:pathwayOrder rdf:resource="#PathwayStep266" />
 <bp:pathwayOrder rdf:resource="#PathwayStep238" />
 <bp:pathwayComponent rdf:resource="#Pathway50" />
 <bp:pathwayComponent rdf:resource="#Pathway43" />
 <bp:pathwayComponent rdf:resource="#Pathway44" />
 <bp:pathwayComponent rdf:resource="#Pathway45" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence234" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence130">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway43">
 <bp:pathwayOrder rdf:resource="#PathwayStep236" />
 <bp:pathwayOrder rdf:resource="#PathwayStep235" />
 <bp:pathwayOrder rdf:resource="#PathwayStep237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction194" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction193" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction195" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence235" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway44">
 <bp:pathwayOrder rdf:resource="#PathwayStep243" />
 <bp:pathwayOrder rdf:resource="#PathwayStep242" />
 <bp:pathwayOrder rdf:resource="#PathwayStep241" />
 <bp:pathwayOrder rdf:resource="#PathwayStep240" />
 <bp:pathwayOrder rdf:resource="#PathwayStep239" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction196" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction198" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction197" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction200" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction199" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence239" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway45">
 <bp:pathwayOrder rdf:resource="#PathwayStep245" />
 <bp:pathwayOrder rdf:resource="#PathwayStep256" />
 <bp:pathwayOrder rdf:resource="#PathwayStep251" />
 <bp:pathwayComponent rdf:resource="#Pathway46" />
 <bp:pathwayComponent rdf:resource="#Pathway47" />
 <bp:pathwayComponent rdf:resource="#Pathway48" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence245" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep759">
 <bp:stepProcess rdf:resource="#BiochemicalReaction626" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep758">
 <bp:stepProcess rdf:resource="#Pathway134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep757">
 <bp:stepProcess rdf:resource="#Catalysis311" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction625" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep756">
 <bp:stepProcess rdf:resource="#Catalysis310" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction624" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep755">
 <bp:stepProcess rdf:resource="#BiochemicalReaction623" />
 <bp:stepProcess rdf:resource="#Catalysis309" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep754">
 <bp:stepProcess rdf:resource="#BiochemicalReaction622" />
 <bp:stepProcess rdf:resource="#Catalysis308" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence144">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep753">
 <bp:stepProcess rdf:resource="#BiochemicalReaction621" />
 <bp:stepProcess rdf:resource="#Catalysis307" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence145">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway50">
 <bp:pathwayOrder rdf:resource="#PathwayStep269" />
 <bp:pathwayOrder rdf:resource="#PathwayStep268" />
 <bp:pathwayOrder rdf:resource="#PathwayStep267" />
 <bp:pathwayOrder rdf:resource="#PathwayStep274" />
 <bp:pathwayOrder rdf:resource="#PathwayStep273" />
 <bp:pathwayOrder rdf:resource="#PathwayStep272" />
 <bp:pathwayOrder rdf:resource="#PathwayStep271" />
 <bp:pathwayOrder rdf:resource="#PathwayStep270" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction223" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction225" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction219" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction218" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction220" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction222" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction221" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence267" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep752">
 <bp:stepProcess rdf:resource="#BiochemicalReaction620" />
 <bp:stepProcess rdf:resource="#Catalysis306" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence142">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway51">
 <bp:pathwayOrder rdf:resource="#PathwayStep288" />
 <bp:pathwayOrder rdf:resource="#PathwayStep287" />
 <bp:pathwayOrder rdf:resource="#PathwayStep286" />
 <bp:pathwayOrder rdf:resource="#PathwayStep285" />
 <bp:pathwayOrder rdf:resource="#PathwayStep284" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction235" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction234" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction236" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction238" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence284" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep751">
 <bp:stepProcess rdf:resource="#BiochemicalReaction619" />
 <bp:stepProcess rdf:resource="#Catalysis305" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence143">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway52">
 <bp:pathwayOrder rdf:resource="#PathwayStep357" />
 <bp:pathwayOrder rdf:resource="#PathwayStep379" />
 <bp:pathwayOrder rdf:resource="#PathwayStep375" />
 <bp:pathwayOrder rdf:resource="#PathwayStep386" />
 <bp:pathwayOrder rdf:resource="#PathwayStep295" />
 <bp:pathwayOrder rdf:resource="#PathwayStep390" />
 <bp:pathwayOrder rdf:resource="#PathwayStep338" />
 <bp:pathwayOrder rdf:resource="#PathwayStep337" />
 <bp:pathwayOrder rdf:resource="#PathwayStep358" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction323" />
 <bp:pathwayComponent rdf:resource="#Pathway62" />
 <bp:pathwayComponent rdf:resource="#Pathway68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction295" />
 <bp:pathwayComponent rdf:resource="#Pathway53" />
 <bp:pathwayComponent rdf:resource="#Pathway64" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction277" />
 <bp:pathwayComponent rdf:resource="#Pathway66" />
 <bp:pathwayComponent rdf:resource="#Pathway67" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence295" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 3 (TLR3) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll-like receptor 3 (TLR3) as was shown for mammals is expressed in various tissues and cells, including myeloid dendritic cells, macrophages, respiratory and intestinal epithelium, neurons and microglial cells to induce antiviral and inflammatory responses of the innate immunity in combating viral infections. TLR3 recognizes dsRNA in the endosome and that triggers the receptor dimerization. TLR3 recruits the adaptor TRIF (TICAM1), leading to the activation of NF-kappa-B and the production of type I interferons (IFNs). dsRNA-stimulated phosphorylation of two specific TLR3 tyrosine residues (Tyr759 and Tyr858) is essential for initiating TLR3 signaling pathways.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep750">
 <bp:stepProcess rdf:resource="#Pathway133" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence148">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence149">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence146">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence147">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway57">
 <bp:pathwayOrder rdf:resource="#PathwayStep312" />
 <bp:pathwayOrder rdf:resource="#PathwayStep311" />
 <bp:pathwayOrder rdf:resource="#PathwayStep310" />
 <bp:pathwayOrder rdf:resource="#PathwayStep309" />
 <bp:pathwayOrder rdf:resource="#PathwayStep308" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction256" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction253" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction252" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction255" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction254" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence308" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway58">
 <bp:pathwayOrder rdf:resource="#PathwayStep317" />
 <bp:pathwayOrder rdf:resource="#PathwayStep316" />
 <bp:pathwayOrder rdf:resource="#PathwayStep315" />
 <bp:pathwayOrder rdf:resource="#PathwayStep314" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction257" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction259" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction258" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction260" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence314" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway59">
 <bp:pathwayOrder rdf:resource="#PathwayStep324" />
 <bp:pathwayOrder rdf:resource="#PathwayStep323" />
 <bp:pathwayOrder rdf:resource="#PathwayStep320" />
 <bp:pathwayOrder rdf:resource="#PathwayStep319" />
 <bp:pathwayOrder rdf:resource="#PathwayStep327" />
 <bp:pathwayOrder rdf:resource="#PathwayStep326" />
 <bp:pathwayOrder rdf:resource="#PathwayStep325" />
 <bp:pathwayComponent rdf:resource="#Pathway60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction268" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction267" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction261" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction264" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction266" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction265" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence319" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence140">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway53">
 <bp:pathwayOrder rdf:resource="#PathwayStep300" />
 <bp:pathwayOrder rdf:resource="#PathwayStep296" />
 <bp:pathwayOrder rdf:resource="#PathwayStep306" />
 <bp:pathwayOrder rdf:resource="#PathwayStep328" />
 <bp:pathwayComponent rdf:resource="#Pathway61" />
 <bp:pathwayComponent rdf:resource="#Pathway54" />
 <bp:pathwayComponent rdf:resource="#Pathway55" />
 <bp:pathwayComponent rdf:resource="#Pathway56" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence296" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence141">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway54">
 <bp:pathwayOrder rdf:resource="#PathwayStep299" />
 <bp:pathwayOrder rdf:resource="#PathwayStep298" />
 <bp:pathwayOrder rdf:resource="#PathwayStep297" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction246" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction245" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction244" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence297" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway55">
 <bp:pathwayOrder rdf:resource="#PathwayStep302" />
 <bp:pathwayOrder rdf:resource="#PathwayStep301" />
 <bp:pathwayOrder rdf:resource="#PathwayStep305" />
 <bp:pathwayOrder rdf:resource="#PathwayStep304" />
 <bp:pathwayOrder rdf:resource="#PathwayStep303" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction248" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction247" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction249" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction251" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction250" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence301" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway56">
 <bp:pathwayOrder rdf:resource="#PathwayStep313" />
 <bp:pathwayOrder rdf:resource="#PathwayStep307" />
 <bp:pathwayOrder rdf:resource="#PathwayStep318" />
 <bp:pathwayComponent rdf:resource="#Pathway57" />
 <bp:pathwayComponent rdf:resource="#Pathway58" />
 <bp:pathwayComponent rdf:resource="#Pathway59" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence307" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep289" />
 <bp:pathwayOrder rdf:resource="#PathwayStep198" />
 <bp:pathwayOrder rdf:resource="#PathwayStep197" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayOrder rdf:resource="#PathwayStep194" />
 <bp:pathwayOrder rdf:resource="#PathwayStep293" />
 <bp:pathwayOrder rdf:resource="#PathwayStep292" />
 <bp:pathwayOrder rdf:resource="#PathwayStep291" />
 <bp:pathwayOrder rdf:resource="#PathwayStep290" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction239" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction161" />
 <bp:pathwayComponent rdf:resource="#Pathway37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction240" />
 <bp:pathwayComponent rdf:resource="#Pathway38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction242" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction241" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction243" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 4 (TLR4) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR4 is unique among the TLR family in its ability to recruit four adapters to activate two distinct signaling pathways. One pathway is activated by the pair of the adapters  Mal or TIRAP (Toll/interleukin-1-receptor (TIR)-domain-containing adapter protein) and MyD88, which leads to the NFkB activation and the induction of pro-inflammatory cytokines. The second pathway is activated by the adapters TRIF (TIR-domain-containing adapter protein inducing interferon-beta) and TRAM (TRIF-related adapter molecule). The combined use of TRIF and TRAM adapters is specific for TLR4 signaling pathway and leads to the induction of type I interferons  and delayed activation of NFkB. The previous model of TLR4 signaling pathway described the simultaneous activation of these two signaling pathways at the plasma membrane, however the later studies suggested that upon activation TLR4 first induces TIRAP-MyD88 signaling at the plasma membrane and is then endocytosed and activates TRAM-TRIF signaling from the early endosome [Kagan JC et al 2008; Tanimura N et al 2008; Zanoni I et al 2011].
Toll-like Receptor 4 is a microbe associated molecular pattern receptor well known for it&apos;s sensitivity to bacterial lipopolysaccharides (LPS). LPS is assembled within diverse Gram-negative bacteria, many of which are human or plant pathogens. It is a component of the outer membrane of Gram-negative bacteria and consists of lipid A, a core polysaccharide and an O-polysaccharide of variable length (often more than 50 monosaccharide units). LPS is a potent activator of the innate immune response in humans, causing reactions including fever, headache, nausea, diarrhoea, changes in leukocyte and platelet counts, disseminated intravascular coagulation, multiorgan failure, shock and death. All these reactions are induced by cytokines and other endogenous mediators which are produced after interaction of LPS with the humoral and cellular targets of the host. In macrophages and dendritic cells, LPS-mediated activation of TLR4 triggers the biosynthesis of diverse mediators of inflammation, such as TNF-alpha and IL6, and activates the production of co-stimulatory molecules required for the adaptive immune response. In mononuclear and endothelial cells, LPS also stimulates tissue factor production. These events are desirable for clearing local infections, but when these various mediators and clotting factors are overproduced, they can damage small blood vessels and precipitate shock accompanied by disseminated intravascular coagulation and multiple organ failure.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep193" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:pathwayComponent rdf:resource="#Pathway20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88-independent TLR4 cascade </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The MyD88-independent signaling pathway is shared by TLR3 and TLR4 cascades. TIR-domain-containing adapter-inducing interferon-beta (TRIF or TICAM1) is a key adapter molecule in transducing signals from TLR3 and TLR4 in a MyD88-independent manner (Yamamoto M et al. 2003a). TRIF is recruited to the ligand-stimulated TLR3 or 4 complex via its TIR domain. TLR3 directly binds TRIF (Oshiumi H et al 2003). In contrast, the TLR4-mediated signaling pathway requires two adapter molecules, TRAM (TRIF-related adapter molecule or TICAM2) and TRIF. TRAM(TICAM2) is thought to bridge the activated TLR4 complex and TRIF (Yamamoto M et al. 2003b, Tanimura N et al. 2008, Kagan LC et al. 2008). TRIF recruitment to the TLR complex stimulates distinct pathways leading to the production of type I interferons (IFNs) and pro-inflammatory cytokines and to the induction of programmed cell death.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence119">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep309">
 <bp:stepProcess rdf:resource="#Catalysis125" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction253" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence117">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep308">
 <bp:stepProcess rdf:resource="#BiochemicalReaction252" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence118">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep307">
 <bp:stepProcess rdf:resource="#Pathway57" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep306">
 <bp:stepProcess rdf:resource="#Pathway56" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep305">
 <bp:stepProcess rdf:resource="#BiochemicalReaction251" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep789">
 <bp:stepProcess rdf:resource="#BiochemicalReaction652" />
 <bp:stepProcess rdf:resource="#Catalysis319" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep304">
 <bp:stepProcess rdf:resource="#Catalysis124" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction250" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep788">
 <bp:stepProcess rdf:resource="#BiochemicalReaction651" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep303">
 <bp:stepProcess rdf:resource="#Catalysis123" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction249" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep787">
 <bp:stepProcess rdf:resource="#BiochemicalReaction650" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence111">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep302">
 <bp:stepProcess rdf:resource="#Catalysis122" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction248" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence595">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep786">
 <bp:stepProcess rdf:resource="#Pathway138" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence112">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep301">
 <bp:stepProcess rdf:resource="#BiochemicalReaction247" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence596">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep785">
 <bp:stepProcess rdf:resource="#BiochemicalReaction649" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep300">
 <bp:stepProcess rdf:resource="#Pathway55" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence593">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep784">
 <bp:stepProcess rdf:resource="#Pathway137" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence594">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep783">
 <bp:stepProcess rdf:resource="#BiochemicalReaction648" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence599">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep782">
 <bp:stepProcess rdf:resource="#Pathway136" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence116">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep781">
 <bp:stepProcess rdf:resource="#BiochemicalReaction647" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence597">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep780">
 <bp:stepProcess rdf:resource="#BiochemicalReaction646" />
 <bp:stepProcess rdf:resource="#Catalysis318" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence598">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway24">
 <bp:pathwayOrder rdf:resource="#PathwayStep112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep123" />
 <bp:pathwayOrder rdf:resource="#PathwayStep118" />
 <bp:pathwayComponent rdf:resource="#Pathway25" />
 <bp:pathwayComponent rdf:resource="#Pathway26" />
 <bp:pathwayComponent rdf:resource="#Pathway27" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway25">
 <bp:pathwayOrder rdf:resource="#PathwayStep115" />
 <bp:pathwayOrder rdf:resource="#PathwayStep114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep117" />
 <bp:pathwayOrder rdf:resource="#PathwayStep116" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway26">
 <bp:pathwayOrder rdf:resource="#PathwayStep122" />
 <bp:pathwayOrder rdf:resource="#PathwayStep121" />
 <bp:pathwayOrder rdf:resource="#PathwayStep120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction94" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction97" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction96" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway27">
 <bp:pathwayOrder rdf:resource="#PathwayStep125" />
 <bp:pathwayOrder rdf:resource="#PathwayStep124" />
 <bp:pathwayOrder rdf:resource="#PathwayStep132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep131" />
 <bp:pathwayOrder rdf:resource="#PathwayStep130" />
 <bp:pathwayOrder rdf:resource="#PathwayStep129" />
 <bp:pathwayOrder rdf:resource="#PathwayStep128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction103" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction104" />
 <bp:pathwayComponent rdf:resource="#Pathway28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction101" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction98" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway20">
 <bp:pathwayOrder rdf:resource="#PathwayStep189" />
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayOrder rdf:resource="#PathwayStep165" />
 <bp:pathwayOrder rdf:resource="#PathwayStep142" />
 <bp:pathwayOrder rdf:resource="#PathwayStep161" />
 <bp:pathwayOrder rdf:resource="#PathwayStep182" />
 <bp:pathwayComponent rdf:resource="#Pathway30" />
 <bp:pathwayComponent rdf:resource="#Pathway35" />
 <bp:pathwayComponent rdf:resource="#Pathway36" />
 <bp:pathwayComponent rdf:resource="#Pathway21" />
 <bp:pathwayComponent rdf:resource="#Pathway32" />
 <bp:pathwayComponent rdf:resource="#Pathway33" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRIF (TICAM1)-mediated TLR4 signaling </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRIF (TICAM1) was shown to induce IRF3/7 and NF-kappa-B activation as well as apoptosis through distinct intracellular signaling pathways (Yamamoto M et al., 2003; Fitzgerald KA et al., 2003; Han KJ et al., 2004; Kaiser WJ    Offermann MK 2005).  TRIF consists of an N-terminal domain (NTD) (1-153), an intermediate disordered proline-rich region, a TIR domain, and a C-terminal region (Mahita J    Sowdhamin R 2017). The disordered proline-rich region between NTD domain and the TIR domain of TICAM1 contains binding sites for TRAF (TNF receptor associated factor) family proteins, which, in turn, recruit protein kinases to promote activation of IRF3 and/or NF-kappa-B (Sato S et al., 2003; Fitzgerald KA et al., 2003). The C-terminal region of TICAM1 (TRIF) can recruit receptor-interacting serine/threonine-protein kinase 1 (RIPK1), and this event is followed by the activation of the IKK complex or the induction of programmed cell death (Han KJ et al., 2004; Kaiser WJ    Offermann MK 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence591">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway21">
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep111" />
 <bp:pathwayOrder rdf:resource="#PathwayStep133" />
 <bp:pathwayOrder rdf:resource="#PathwayStep105" />
 <bp:pathwayComponent rdf:resource="#Pathway29" />
 <bp:pathwayComponent rdf:resource="#Pathway24" />
 <bp:pathwayComponent rdf:resource="#Pathway22" />
 <bp:pathwayComponent rdf:resource="#Pathway23" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence592">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway22">
 <bp:pathwayOrder rdf:resource="#PathwayStep104" />
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway23">
 <bp:pathwayOrder rdf:resource="#PathwayStep110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep109" />
 <bp:pathwayOrder rdf:resource="#PathwayStep108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep107" />
 <bp:pathwayOrder rdf:resource="#PathwayStep106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence590">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway28">
 <bp:pathwayOrder rdf:resource="#PathwayStep126" />
 <bp:pathwayOrder rdf:resource="#PathwayStep127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction99" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction100" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway29">
 <bp:pathwayOrder rdf:resource="#PathwayStep137" />
 <bp:pathwayOrder rdf:resource="#PathwayStep136" />
 <bp:pathwayOrder rdf:resource="#PathwayStep135" />
 <bp:pathwayOrder rdf:resource="#PathwayStep134" />
 <bp:pathwayOrder rdf:resource="#PathwayStep141" />
 <bp:pathwayOrder rdf:resource="#PathwayStep140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep139" />
 <bp:pathwayOrder rdf:resource="#PathwayStep138" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction113" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction108" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction111" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence129">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep779">
 <bp:stepProcess rdf:resource="#BiochemicalReaction645" />
 <bp:stepProcess rdf:resource="#Catalysis317" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep778">
 <bp:stepProcess rdf:resource="#BiochemicalReaction644" />
 <bp:stepProcess rdf:resource="#Catalysis316" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep777">
 <bp:stepProcess rdf:resource="#BiochemicalReaction643" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep776">
 <bp:stepProcess rdf:resource="#BiochemicalReaction642" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence122">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep775">
 <bp:stepProcess rdf:resource="#Pathway135" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence123">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep774">
 <bp:stepProcess rdf:resource="#BiochemicalReaction641" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence120">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep773">
 <bp:stepProcess rdf:resource="#BiochemicalReaction640" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence121">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway30">
 <bp:pathwayOrder rdf:resource="#PathwayStep159" />
 <bp:pathwayOrder rdf:resource="#PathwayStep158" />
 <bp:pathwayOrder rdf:resource="#PathwayStep157" />
 <bp:pathwayOrder rdf:resource="#PathwayStep145" />
 <bp:pathwayOrder rdf:resource="#PathwayStep144" />
 <bp:pathwayOrder rdf:resource="#PathwayStep143" />
 <bp:pathwayOrder rdf:resource="#PathwayStep160" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction114" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction130" />
 <bp:pathwayComponent rdf:resource="#Pathway31" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence143" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep772">
 <bp:stepProcess rdf:resource="#BiochemicalReaction639" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence126">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep771">
 <bp:stepProcess rdf:resource="#BiochemicalReaction638" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence127">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep770">
 <bp:stepProcess rdf:resource="#BiochemicalReaction637" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence124">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence125">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway35">
 <bp:pathwayOrder rdf:resource="#PathwayStep188" />
 <bp:pathwayOrder rdf:resource="#PathwayStep187" />
 <bp:pathwayOrder rdf:resource="#PathwayStep186" />
 <bp:pathwayOrder rdf:resource="#PathwayStep185" />
 <bp:pathwayOrder rdf:resource="#PathwayStep184" />
 <bp:pathwayOrder rdf:resource="#PathwayStep183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction149" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction152" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction151" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction154" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction153" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence183" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6-mediated induction of TAK1 complex within TLR4 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In human, together with ubiquitin-conjugating E2-type enzymes UBC13 and UEV1A (also known as UBE2V1), TRAF6 catalyses Lys63-linked ubiquitination. It is believed that auto polyubiquitination  and oligomerization of TRAF6 is followed by binding the ubiquitin receptors of TAB2 or TAB3 (TAK1 binding protein 2 and 3), which stimulates phosphorylation and activation of TGF beta-activated kinase 1(TAK1). TAK1 phosphorylates IKK alpha and IKK beta, which in turn phosphorylate NF-kB inhibitors - IkB  and eventually results in IkB degradation and NF-kB translocation to the nucleus. Also TAK1 mediates JNK and p38 MAP kinases activation by phosphorylating MKK4/7 and MKK3/6 respectivly resulting in the activation of many transcription factors.  The role of TRAF6 is somewhat controversial and probably cell type specific. TRAF6 autoubiquitination was found to be dispensable for TRAF6 function to activate TAK1 pathway. These findings are consistent with the new mechanism of TRAF6-mediated NF-kB activation that was suggested by Xia et al. (2009). TRAF6 generates unanchored Lys63-linked polyubiquitin chains that bind to the regulatory subunits of TAK1 (TAB2 or TAB3) and IKK(NEMO), leading to the activation of the kinases.  Xia et al. (2009) demonstrated in vitro that unlike polyubiquitin chains covalently attached to TRAF6 or IRAK, TAB2 and NEMO-associated ubiquitin chains were found to be unanchored and susceptible to N-terminal ubiquitin cleavage. Only K63-linked polyubiquitin chains, but not monomeric ubiquitin, activated TAK1 in a dose-dependent manner. Optimal activation of the IKK complex was achieved using ubiquitin polymers containing both K48 and K63 linkages. Furthermore, the authors proposed that the TAK1 complexes might be brougt in close proximity by binding several TAB2/3 to a single polyubiquitin chain to facilitate TAK1 kinase trans-phosphorylation. Alternativly, the possibility that polyUb binding promotes allosteric activation of TAK1 complex should  be considered (Walsh et al 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway36">
 <bp:pathwayOrder rdf:resource="#PathwayStep192" />
 <bp:pathwayOrder rdf:resource="#PathwayStep191" />
 <bp:pathwayOrder rdf:resource="#PathwayStep190" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction157" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction156" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction155" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence190" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKK complex recruitment mediated by RIP1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Receptor-interacting protein 1 (RIP1) mediates the activation of proinflammatory cytokines via intermediate induction of IKK complex in NFkB pathways [Ea et al. 2006]. Poly(I-C) treatment stimulated the recruitment of RIP1, TRAF6, and TAK1 to the TLR3 receptor complex in human embryonic kidney HEK293 transfected with FLAG-tagged TLR3 [Cusson-Hermance et al. 2005]. RIP1 was shown to be dispensable for TRIF-dependent activation of IRF3, which occurs in a TRIF/TBK1/IKKi-dependent manner [Cusson-Hermance et al. 2005, Sato et al. 2003]</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway37">
 <bp:pathwayOrder rdf:resource="#PathwayStep196" />
 <bp:pathwayOrder rdf:resource="#PathwayStep195" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction159" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction160" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence195" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transfer of LPS from LBP carrier to CD14</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LBP delivers LPS from bacteria (or bacterial membrane fragments) to CD14 on the surfaces of phagocytes, where it is recognised by the MD2:TLR4 complex . Thus, LBP is an opsonin and CD14 is an opsonic receptor for complexes of LPS (or LPS-containing particles such as bacteria) and LBP. CD14 exists as two isoforms. CD14 can be either secreted into the extracellular compartment, or it can be anchored to the plasma membrane via its GPI module.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway38">
 <bp:pathwayOrder rdf:resource="#PathwayStep229" />
 <bp:pathwayOrder rdf:resource="#PathwayStep228" />
 <bp:pathwayOrder rdf:resource="#PathwayStep205" />
 <bp:pathwayOrder rdf:resource="#PathwayStep227" />
 <bp:pathwayOrder rdf:resource="#PathwayStep226" />
 <bp:pathwayOrder rdf:resource="#PathwayStep225" />
 <bp:pathwayOrder rdf:resource="#PathwayStep224" />
 <bp:pathwayOrder rdf:resource="#PathwayStep279" />
 <bp:pathwayOrder rdf:resource="#PathwayStep278" />
 <bp:pathwayOrder rdf:resource="#PathwayStep200" />
 <bp:pathwayOrder rdf:resource="#PathwayStep233" />
 <bp:pathwayOrder rdf:resource="#PathwayStep277" />
 <bp:pathwayOrder rdf:resource="#PathwayStep199" />
 <bp:pathwayOrder rdf:resource="#PathwayStep232" />
 <bp:pathwayOrder rdf:resource="#PathwayStep276" />
 <bp:pathwayOrder rdf:resource="#PathwayStep231" />
 <bp:pathwayOrder rdf:resource="#PathwayStep275" />
 <bp:pathwayOrder rdf:resource="#PathwayStep230" />
 <bp:pathwayOrder rdf:resource="#PathwayStep283" />
 <bp:pathwayOrder rdf:resource="#PathwayStep282" />
 <bp:pathwayOrder rdf:resource="#PathwayStep281" />
 <bp:pathwayOrder rdf:resource="#PathwayStep280" />
 <bp:pathwayComponent rdf:resource="#Pathway39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction190" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction192" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction191" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction185" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction184" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction187" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction231" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction186" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction230" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction233" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction188" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction232" />
 <bp:pathwayComponent rdf:resource="#Pathway40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction226" />
 <bp:pathwayComponent rdf:resource="#Pathway51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction228" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction227" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction229" />
 <bp:pathwayComponent rdf:resource="#Pathway42" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence199" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88:MAL(TIRAP) cascade initiated on plasma membrane</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The first known downstream component of TLR4 and TLR2 signaling is the adaptor MyD88. Another adapter MyD88-adaptor-like (Mal; also known as TIR-domain-containing adaptor protein or TIRAP) has also been described for TLR4 and TLR2 signaling. MyD88 comprises an N-terminal Death Domain (DD) and a C-terminal TIR, whereas Mal lacks the DD. The TIR homotypic interactions bring adapters into contact with the activated TLRs, whereas the DD modules recruit serine/threonine kinases such as interleukin-1-receptor-associated kinase (IRAK). Recruitment of these protein kinases is accompanied by phosphorylation, which in turn results in the interaction of IRAKs with TNF-receptor-associated factor 6 (TRAF6). The oligomerization of TRAF6 activates TAK1, a member of the MAP3-kinase family, and this leads to the activation of the IkB kinases. These kinases, in turn, phosphorylate IkB, leading to its proteolytic degradation and the translocation of NF-kB to the nucleus. Concomitantly, members of the activator protein-1 (AP-1) transcription factor family, Jun and Fos, are activated, and both AP-1 transcription factors and NF-kB are required for cytokine production, which in turn produces downstream inflammatory effects.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway31">
 <bp:pathwayOrder rdf:resource="#PathwayStep148" />
 <bp:pathwayOrder rdf:resource="#PathwayStep147" />
 <bp:pathwayOrder rdf:resource="#PathwayStep146" />
 <bp:pathwayOrder rdf:resource="#PathwayStep156" />
 <bp:pathwayOrder rdf:resource="#PathwayStep155" />
 <bp:pathwayOrder rdf:resource="#PathwayStep154" />
 <bp:pathwayOrder rdf:resource="#PathwayStep153" />
 <bp:pathwayOrder rdf:resource="#PathwayStep152" />
 <bp:pathwayOrder rdf:resource="#PathwayStep151" />
 <bp:pathwayOrder rdf:resource="#PathwayStep150" />
 <bp:pathwayOrder rdf:resource="#PathwayStep149" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction124" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction116" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction126" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction118" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction120" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction123" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction122" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence146" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway32">
 <bp:pathwayOrder rdf:resource="#PathwayStep164" />
 <bp:pathwayOrder rdf:resource="#PathwayStep163" />
 <bp:pathwayOrder rdf:resource="#PathwayStep162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction132" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction133" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence162" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRIF-mediated programmed cell death</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR3 and -4 trigger TRIF-dependent programmed cell death in various human and mouse cells (Kalai M et al. 2002; Han KJ et al. 2004; Kaiser WJ and Offermann MK 2005; Estornes Y et al. 2012; He S et al. 2011). Apoptosis is a prevalent form of programmed cell death and is mediated by the activation of a set of caspases. In addition to apoptosis, TLR3/TLR4 activation induces RIP3-dependent necroptosis. These two programmed cell-death pathways may suppress each other. When the caspase activity is impaired or inhibited, certain cell types switch the apoptotic death program to necroptosis in response to various stimuli (TNF, Fas, viral infection and other stress stimuli) (Kalai M et al. 2002; Weber A et al. 2010; Feoktistova M et al. 2011, Tenev et al 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway33">
 <bp:pathwayOrder rdf:resource="#PathwayStep169" />
 <bp:pathwayOrder rdf:resource="#PathwayStep168" />
 <bp:pathwayOrder rdf:resource="#PathwayStep167" />
 <bp:pathwayOrder rdf:resource="#PathwayStep166" />
 <bp:pathwayOrder rdf:resource="#PathwayStep177" />
 <bp:pathwayOrder rdf:resource="#PathwayStep176" />
 <bp:pathwayOrder rdf:resource="#PathwayStep175" />
 <bp:pathwayOrder rdf:resource="#PathwayStep174" />
 <bp:pathwayOrder rdf:resource="#PathwayStep173" />
 <bp:pathwayOrder rdf:resource="#PathwayStep172" />
 <bp:pathwayOrder rdf:resource="#PathwayStep171" />
 <bp:pathwayOrder rdf:resource="#PathwayStep170" />
 <bp:pathwayOrder rdf:resource="#PathwayStep181" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction141" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction140" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction143" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction134" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction144" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction136" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction138" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction137" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction148" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction139" />
 <bp:pathwayComponent rdf:resource="#Pathway34" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence166" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of IRF3, IRF7 mediated by TBK1, IKK&#949; (IKBKE)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cell stimulation with viral double-stranded (ds) RNA and bacterial lipopolysaccharide (LPS) activate Toll-like receptors 3 (TLR3) and TLR4, respectively, triggering the activation the activation of two IKK-related serine/threonine kinases, TANK-binding kinase 1 (TBK1) and I&#954;B kinase &#949; (IKK&#949;, IKBKE) which directly phosphorylate interferon regulatory factor 3 (IRF3) and IRF7 promoting their dimerization and translocation into the nucleus. Although both kinases show structural and functional similarities, it seems that TBK1 and IKBKE differ in their regulation of downstream signaling events of TLR3/TLR4.  IRF3 activation and interferon &#946; (IFN&#946;) production by poly(I:C), a synthetic analog of dsRNA, are decreased in TBK1-deficient mouse fibroblasts, whereas normal activation was observed in the IKBKE-deficient fibroblasts. However, in double-deficient mouse fibroblasts, the activation of IRF3 is completely abolished, suggesting a partially redundant functions of TBK1 and IKK&#949; (IKBKE) (Hemmi H et al., 2004).  The poly(I:C)-induced phosphorylation of TBK1 and IRF3 was abolished in TRIF (TICAM1)-knockout human keratinocyte HACAT cells (Bakshi S et al., 2017). TICAM1 is utilized as an adaptor protein by TLR3 and TLR4 (Yamamoto M et al., 2003).  TLR3 recruits and activates PI3 kinase (PI3K), which activates the downstream kinase, Akt, leading to full phosphorylation and activation of IRF3 (Sarkar SN et al., 2004). When PI3K is not recruited to TLR3 or its activity is blocked, IRF3 is only partially phosphorylated and fails to bind the promoter of the target gene (Sarkar SN et al., 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway34">
 <bp:pathwayOrder rdf:resource="#PathwayStep179" />
 <bp:pathwayOrder rdf:resource="#PathwayStep178" />
 <bp:pathwayOrder rdf:resource="#PathwayStep180" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction147" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction146" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction145" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence178" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of TBK1, IKK&#949; (IKBKE)-mediated activation of IRF3, IRF7 </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Production of type I IFN genes in response to Toll-like receptor 3 (TLR3) and TLR4 ligands is mediated by TANK-binding kinase 1 (TBK1) or I-kappa-B kinase epsilon (IKK&#949;, IKBKE), which phosphorylate IFN regulatory factor 3 (IRF3) and IRF7. The activity of TBK1 and/or IRF3, IRF7 is regulated by multiple mechanisms including post-translational modifications, protein-protein interactions, and protein degradation (Zhao W et al., 2013; Runde AP et al., 2022).  This Reactome module describes regulation of TBK1, IKK&#949; activity by K63-linked ubiquitination of TBK1 and IKK&#949;, and TBK1 interaction with OPTN.  .</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep729">
 <bp:stepProcess rdf:resource="#BiochemicalReaction603" />
 <bp:stepProcess rdf:resource="#Catalysis293" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep728">
 <bp:stepProcess rdf:resource="#BiochemicalReaction602" />
 <bp:stepProcess rdf:resource="#Catalysis292" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep727">
 <bp:stepProcess rdf:resource="#BiochemicalReaction601" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence579">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep726">
 <bp:stepProcess rdf:resource="#Pathway127" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep725">
 <bp:stepProcess rdf:resource="#Pathway126" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep724">
 <bp:stepProcess rdf:resource="#BiochemicalReaction600" />
 <bp:stepProcess rdf:resource="#Catalysis291" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep723">
 <bp:stepProcess rdf:resource="#BiochemicalReaction599" />
 <bp:stepProcess rdf:resource="#Catalysis290" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep722">
 <bp:stepProcess rdf:resource="#BiochemicalReaction598" />
 <bp:stepProcess rdf:resource="#Catalysis289" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep721">
 <bp:stepProcess rdf:resource="#BiochemicalReaction597" />
 <bp:stepProcess rdf:resource="#Catalysis288" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence573">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep720">
 <bp:stepProcess rdf:resource="#Catalysis287" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction596" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence574">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence571">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence572">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence577">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence578">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence575">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence576">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence570">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep719">
 <bp:stepProcess rdf:resource="#BiochemicalReaction595" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep718">
 <bp:stepProcess rdf:resource="#BiochemicalReaction594" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence108">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep717">
 <bp:stepProcess rdf:resource="#Catalysis286" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction593" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence109">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep716">
 <bp:stepProcess rdf:resource="#BiochemicalReaction592" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence106">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep715">
 <bp:stepProcess rdf:resource="#Catalysis285" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction591" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence107">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep714">
 <bp:stepProcess rdf:resource="#Catalysis284" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction590" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep713">
 <bp:stepProcess rdf:resource="#BiochemicalReaction589" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep712">
 <bp:stepProcess rdf:resource="#BiochemicalReaction588" />
 <bp:stepProcess rdf:resource="#Catalysis283" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep711">
 <bp:stepProcess rdf:resource="#BiochemicalReaction587" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep710">
 <bp:stepProcess rdf:resource="#BiochemicalReaction586" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence584">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence585">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence582">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence583">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence588">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence589">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence586">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence587">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence580">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence581">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence559">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep749">
 <bp:stepProcess rdf:resource="#BiochemicalReaction618" />
 <bp:stepProcess rdf:resource="#Catalysis304" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence557">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep748">
 <bp:stepProcess rdf:resource="#Pathway132" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence558">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep747">
 <bp:stepProcess rdf:resource="#BiochemicalReaction617" />
 <bp:stepProcess rdf:resource="#Catalysis303" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep746">
 <bp:stepProcess rdf:resource="#BiochemicalReaction616" />
 <bp:stepProcess rdf:resource="#Catalysis302" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep745">
 <bp:stepProcess rdf:resource="#Catalysis301" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction615" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep744">
 <bp:stepProcess rdf:resource="#Catalysis300" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction614" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep743">
 <bp:stepProcess rdf:resource="#Pathway131" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence551">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep742">
 <bp:stepProcess rdf:resource="#BiochemicalReaction613" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence552">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep741">
 <bp:stepProcess rdf:resource="#Catalysis299" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction612" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep740">
 <bp:stepProcess rdf:resource="#Catalysis298" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction611" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence550">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence555">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence556">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence553">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence554">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep739">
 <bp:stepProcess rdf:resource="#BiochemicalReaction610" />
 <bp:stepProcess rdf:resource="#Catalysis297" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep738">
 <bp:stepProcess rdf:resource="#BiochemicalReaction609" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence568">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep737">
 <bp:stepProcess rdf:resource="#Pathway130" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence569">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep736">
 <bp:stepProcess rdf:resource="#Pathway129" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep735">
 <bp:stepProcess rdf:resource="#BiochemicalReaction608" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep734">
 <bp:stepProcess rdf:resource="#Catalysis296" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction607" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep733">
 <bp:stepProcess rdf:resource="#Catalysis295" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction606" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep732">
 <bp:stepProcess rdf:resource="#Catalysis294" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction605" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence562">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep731">
 <bp:stepProcess rdf:resource="#BiochemicalReaction604" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence563">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep730">
 <bp:stepProcess rdf:resource="#Pathway128" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence560">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence561">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence566">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence567">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence564">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence565">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence537">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence538">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence535">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence536">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction660">
 <bp:evidence rdf:resource="#Evidence800" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence539">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction662">
 <bp:evidence rdf:resource="#Evidence802" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction661">
 <bp:evidence rdf:resource="#Evidence801" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction653">
 <bp:evidence rdf:resource="#Evidence791" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence530">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction652">
 <bp:evidence rdf:resource="#Evidence790" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction655">
 <bp:evidence rdf:resource="#Evidence794" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction654">
 <bp:evidence rdf:resource="#Evidence793" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis58">
 <bp:controlled rdf:resource="#BiochemicalReaction101" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence533">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction657">
 <bp:evidence rdf:resource="#Evidence797" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis59">
 <bp:controlled rdf:resource="#BiochemicalReaction102" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence534">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction656">
 <bp:evidence rdf:resource="#Evidence796" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence531">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction659">
 <bp:evidence rdf:resource="#Evidence799" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence532">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction658">
 <bp:evidence rdf:resource="#Evidence798" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis54">
 <bp:controlled rdf:resource="#BiochemicalReaction97" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis55">
 <bp:controlled rdf:resource="#BiochemicalReaction98" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis56">
 <bp:controlled rdf:resource="#BiochemicalReaction99" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis57">
 <bp:controlled rdf:resource="#BiochemicalReaction100" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis50">
 <bp:controlled rdf:resource="#BiochemicalReaction92" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis51">
 <bp:controlled rdf:resource="#BiochemicalReaction94" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis52">
 <bp:controlled rdf:resource="#BiochemicalReaction95" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis53">
 <bp:controlled rdf:resource="#BiochemicalReaction96" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis60">
 <bp:controlled rdf:resource="#BiochemicalReaction103" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence548">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence549">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence546">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence547">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction651">
 <bp:evidence rdf:resource="#Evidence789" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction650">
 <bp:evidence rdf:resource="#Evidence788" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence540">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction642">
 <bp:evidence rdf:resource="#Evidence777" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence541">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction641">
 <bp:evidence rdf:resource="#Evidence775" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to p-IRAK2  </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction644">
 <bp:evidence rdf:resource="#Evidence779" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction643">
 <bp:evidence rdf:resource="#Evidence778" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis69">
 <bp:controlled rdf:resource="#BiochemicalReaction122" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence544">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction646">
 <bp:evidence rdf:resource="#Evidence781" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence545">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction645">
 <bp:evidence rdf:resource="#Evidence780" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence542">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction648">
 <bp:evidence rdf:resource="#Evidence784" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR1:TLR2 is recruited to ligand:CD14</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence543">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction647">
 <bp:evidence rdf:resource="#Evidence782" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR6/2 ligand associates with CD14 and CD36 within lipid rafts</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis65">
 <bp:controlled rdf:resource="#BiochemicalReaction109" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis66">
 <bp:controlled rdf:resource="#BiochemicalReaction111" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction649">
 <bp:evidence rdf:resource="#Evidence786" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to the activated TLR receptor:TIRAP:MyD88 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis67">
 <bp:controlled rdf:resource="#BiochemicalReaction117" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis68">
 <bp:controlled rdf:resource="#BiochemicalReaction120" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis61">
 <bp:controlled rdf:resource="#BiochemicalReaction104" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis62">
 <bp:controlled rdf:resource="#BiochemicalReaction105" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis63">
 <bp:controlled rdf:resource="#BiochemicalReaction107" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis64">
 <bp:controlled rdf:resource="#BiochemicalReaction108" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence515">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence516">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence513">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence514">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence519">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence517">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction640">
 <bp:evidence rdf:resource="#Evidence774" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 forms a complex with TIRAP:activated TLR2/4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence518">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction631">
 <bp:evidence rdf:resource="#Evidence765" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction630">
 <bp:evidence rdf:resource="#Evidence764" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction633">
 <bp:evidence rdf:resource="#Evidence767" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction632">
 <bp:evidence rdf:resource="#Evidence766" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis36">
 <bp:controlled rdf:resource="#BiochemicalReaction65" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence511">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction635">
 <bp:evidence rdf:resource="#Evidence769" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of p-IRAK2:TRAF6 from the activated TLR:oligo-Myd88:TIRAP:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis37">
 <bp:controlled rdf:resource="#BiochemicalReaction67" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence512">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction634">
 <bp:evidence rdf:resource="#Evidence768" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR2/4:TIRAP interacts with BTK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis38">
 <bp:controlled rdf:resource="#BiochemicalReaction71" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction637">
 <bp:evidence rdf:resource="#Evidence771" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1:TRAF6 from the activated TLR:oligo-Myd88:TIRAP:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis39">
 <bp:controlled rdf:resource="#BiochemicalReaction73" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence510">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction636">
 <bp:evidence rdf:resource="#Evidence770" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis32">
 <bp:controlled rdf:resource="#BiochemicalReaction60" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction639">
 <bp:evidence rdf:resource="#Evidence773" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis33">
 <bp:controlled rdf:resource="#BiochemicalReaction61" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction638">
 <bp:evidence rdf:resource="#Evidence772" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR:TIRAP:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis34">
 <bp:controlled rdf:resource="#BiochemicalReaction63" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis35">
 <bp:controlled rdf:resource="#BiochemicalReaction64" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis30">
 <bp:controlled rdf:resource="#BiochemicalReaction58" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis31">
 <bp:controlled rdf:resource="#BiochemicalReaction59" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence526">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence527">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence524">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence525">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence528">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence529">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction620">
 <bp:evidence rdf:resource="#Evidence753" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction622">
 <bp:evidence rdf:resource="#Evidence755" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction621">
 <bp:evidence rdf:resource="#Evidence754" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis47">
 <bp:controlled rdf:resource="#BiochemicalReaction87" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence522">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction624">
 <bp:evidence rdf:resource="#Evidence757" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis48">
 <bp:controlled rdf:resource="#BiochemicalReaction90" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence523">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction623">
 <bp:evidence rdf:resource="#Evidence756" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis49">
 <bp:controlled rdf:resource="#BiochemicalReaction91" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence520">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction626">
 <bp:evidence rdf:resource="#Evidence760" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence521">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction625">
 <bp:evidence rdf:resource="#Evidence758" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis43">
 <bp:controlled rdf:resource="#BiochemicalReaction82" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction628">
 <bp:evidence rdf:resource="#Evidence762" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis44">
 <bp:controlled rdf:resource="#BiochemicalReaction83" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction627">
 <bp:evidence rdf:resource="#Evidence761" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis45">
 <bp:controlled rdf:resource="#BiochemicalReaction85" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis46">
 <bp:controlled rdf:resource="#BiochemicalReaction86" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction629">
 <bp:evidence rdf:resource="#Evidence763" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis40">
 <bp:controlled rdf:resource="#BiochemicalReaction76" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis41">
 <bp:controlled rdf:resource="#BiochemicalReaction77" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis42">
 <bp:controlled rdf:resource="#BiochemicalReaction78" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis90">
 <bp:controlled rdf:resource="#BiochemicalReaction190" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis91">
 <bp:controlled rdf:resource="#BiochemicalReaction191" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis92">
 <bp:controlled rdf:resource="#BiochemicalReaction192" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis93">
 <bp:controlled rdf:resource="#BiochemicalReaction194" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction611">
 <bp:evidence rdf:resource="#Evidence741" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction610">
 <bp:evidence rdf:resource="#Evidence740" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction613">
 <bp:evidence rdf:resource="#Evidence743" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction612">
 <bp:evidence rdf:resource="#Evidence742" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction615">
 <bp:evidence rdf:resource="#Evidence746" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction614">
 <bp:evidence rdf:resource="#Evidence745" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis98">
 <bp:controlled rdf:resource="#BiochemicalReaction202" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction617">
 <bp:evidence rdf:resource="#Evidence748" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis99">
 <bp:controlled rdf:resource="#BiochemicalReaction203" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction616">
 <bp:evidence rdf:resource="#Evidence747" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction619">
 <bp:evidence rdf:resource="#Evidence752" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction618">
 <bp:evidence rdf:resource="#Evidence750" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis94">
 <bp:controlled rdf:resource="#BiochemicalReaction195" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis95">
 <bp:controlled rdf:resource="#BiochemicalReaction197" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis96">
 <bp:controlled rdf:resource="#BiochemicalReaction198" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis97">
 <bp:controlled rdf:resource="#BiochemicalReaction199" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence504">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence505">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence502">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence503">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence508">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence509">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence506">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence507">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction600">
 <bp:evidence rdf:resource="#Evidence725" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation in the complex with activated TLR:MyD88:TIRAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence500">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction602">
 <bp:evidence rdf:resource="#Evidence729" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence501">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction601">
 <bp:evidence rdf:resource="#Evidence728" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction604">
 <bp:evidence rdf:resource="#Evidence732" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction603">
 <bp:evidence rdf:resource="#Evidence730" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction606">
 <bp:evidence rdf:resource="#Evidence734" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction605">
 <bp:evidence rdf:resource="#Evidence733" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction608">
 <bp:evidence rdf:resource="#Evidence736" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction607">
 <bp:evidence rdf:resource="#Evidence735" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction609">
 <bp:evidence rdf:resource="#Evidence739" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis70">
 <bp:controlled rdf:resource="#BiochemicalReaction127" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis71">
 <bp:controlled rdf:resource="#BiochemicalReaction129" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep687" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep495" />
 <bp:pathwayOrder rdf:resource="#PathwayStep294" />
 <bp:pathwayOrder rdf:resource="#PathwayStep391" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep876" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayOrder rdf:resource="#PathwayStep600" />
 <bp:pathwayComponent rdf:resource="#Pathway52" />
 <bp:pathwayComponent rdf:resource="#Pathway151" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:pathwayComponent rdf:resource="#Pathway120" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway69" />
 <bp:pathwayComponent rdf:resource="#Pathway105" />
 <bp:pathwayComponent rdf:resource="#Pathway87" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll-like Receptor Cascades</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In human, ten members of the Toll-like receptor (TLR) family (TLR1-TLR10) have been identified (TLR11 has been found in mouse, but not in human). All TLRs have a similar Toll/IL-1 receptor (TIR) domain in their cytoplasmic region and an Ig-like domain in the extracellular region, where each is enriched with a varying number of leucine-rich repeats (LRRs). Each TLR can recognize specific microbial pathogen components. The binding pathogenic component to TLR initializes signaling pathways that lead to induction of Interferon alpha/beta and inflammatory cytokines. There are two main signaling pathways. The first is a MyD88-dependent pathway that is common to all TLRs, except TLR3; the second is a TRIF(TICAM1)-dependent pathway that is peculiar to TLR3 and TLR4. TLR4-mediated signaling pathway via TRIF requires adapter molecule TRAM (TRIF-related adapter molecule or TICAM2). TRAM is thought to bridge between the activated TLR4 complex and TRIF.(Takeda    Akira 2004; Akira 2003; Takeda    Akira 2005; Kawai 2005; Heine    Ulmer 2005). This pathway is organized as trafficking and processing of TLR, various TLR cascades (TLR10,TLR3,TLR5,TLR7/8,TLR9,TLR4,TLR2) and their regulation.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trafficking and processing of endosomal TLR</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mammalian TLR3, TLR7, TLR8, TLR9 are endosomal receptors that sense nucleic acids that have been released from endocytosed/phagocytosed bacteria, viruses or parasites. These TLRs have a ligand-recognition domain that faces the lumen of the endosome (which is topologically equivalent to the outside of the cell), a transmembrane domain, and a signaling domain that faces the cytosol. Under normal conditions, self nucleic acids are not recognized by TLRs due to multiple levels of regulation including receptor compartmentalization, trafficking and proteolytic processing (Barton GM et al 2006, Ewald SE et al 2008). At steady state TLR3, TLR7, TLR8, TLR9 reside primarily in the endoplasmic reticulum (ER), however, their activation by specific ligands only occurs within acidified endolysosomal compartments (Hacker H et al 1998, Funami K et al 2004, Gibbard RJ et al 2006). Several chaperon proteins associate with TLRs in the ER to provide efficient translocation to endolysosome. Upon reaching endolysosomal compartments the ectodomains of TLR7 and TLR9 are proteolytically cleaved by cysteine endoproteases. Both full-length and cleaved C-terminus of TLR9 bind CpG-oligodeoxynucleotides, however it has been proposed that only the processed receptor is functional.  Although similar cleavage of TLR3 has been reported by Ewald et al 2011, other studies demonstrated that the N-terminal region of TLR3 ectodomain was implicated in ligand binding, thus TLR3 may function as a full-length receptor (Liu L et al 2008, Tokisue T et al 2008).  There are no data on TLR8 processing, although the cell biology of TLR8 is probably similar to TLR9 and TLR7 (Gibbard RJ et al 2006, Wei T et al 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 5 (TLR5) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR5 is the receptor for flagellin, the protein that forms bacterial flagella. Unlike most other Pathogen-Associated Molecular Patterns (PAMPs), flagellin does not undergo any posttranslational modifications that would distinguish it from cellular proteins. However, flagellin is extremely conserved at its amino- and carboxyl-termini, which presumably explains why it was selected as a ligand for innate immune recognition. TLR5 is expressed on epithelial cells as well as on macrophages and dendritic cells. Expression of TLR5 on intestinal epithelium is polarized such that TLR5 is expressed only on the basolateral side of the cell, as pathogenic but not commensal microbes cross the epithelial barrier. This ensures that innate immune responses are confined to pathogenic but not commensal microbes (Paul 2004; Hayashi et al. 2001; Gewirtz et al. 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 cascade initiated on plasma membrane</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mammalian myeloid differentiation factor 88 (MyD88) is Toll/interleukin (IL)-1 (TIR)-domain containing adapter  protein which plays crucial role in TLR signaling. All TLRs, with only one exception of TLR3, can initiate downstream  signaling trough MyD88. In the MyD88 - dependent pathway, once the adaptor is bound to TLR  it leads to recruitment of IL1 receptor associated kinase family  IRAK which is followed by activation of tumour necrosis factor receptor-associated factor 6 (TRAF6) . TRAF6 is an ubiquitin E3 ligase which in turn induces TGF-beta activating kinase 1 (TAK1) auto phosphorylation. Once activated TAK1 can ultimately mediate the induction of the transcription factor NF-kB or the mitogen-activated protein kinases  (MAPK), such as JNK, p38 and ERK. This results in the translocation of the activated NF-kB and MAPKs to the nucleus and the initiation of appropriate gene transcription leading to the production of many proinflammatory cytokines and antimicrobial peptides.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis76">
 <bp:controlled rdf:resource="#BiochemicalReaction151" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis77">
 <bp:controlled rdf:resource="#BiochemicalReaction154" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis78">
 <bp:controlled rdf:resource="#BiochemicalReaction157" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis79">
 <bp:controlled rdf:resource="#BiochemicalReaction165" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis72">
 <bp:controlled rdf:resource="#BiochemicalReaction130" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis73">
 <bp:controlled rdf:resource="#BiochemicalReaction133" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis74">
 <bp:controlled rdf:resource="#BiochemicalReaction137" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis75">
 <bp:controlled rdf:resource="#BiochemicalReaction143" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis80">
 <bp:controlled rdf:resource="#BiochemicalReaction166" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis81">
 <bp:controlled rdf:resource="#BiochemicalReaction170" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis82">
 <bp:controlled rdf:resource="#BiochemicalReaction173" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis87">
 <bp:controlled rdf:resource="#BiochemicalReaction185" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis88">
 <bp:controlled rdf:resource="#BiochemicalReaction188" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis89">
 <bp:controlled rdf:resource="#BiochemicalReaction189" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis83">
 <bp:controlled rdf:resource="#BiochemicalReaction175" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis84">
 <bp:controlled rdf:resource="#BiochemicalReaction180" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis85">
 <bp:controlled rdf:resource="#BiochemicalReaction182" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis86">
 <bp:controlled rdf:resource="#BiochemicalReaction183" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction260">
 <bp:evidence rdf:resource="#Evidence318" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction262">
 <bp:evidence rdf:resource="#Evidence322" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction261">
 <bp:evidence rdf:resource="#Evidence320" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction264">
 <bp:evidence rdf:resource="#Evidence324" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction263">
 <bp:evidence rdf:resource="#Evidence323" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction266">
 <bp:evidence rdf:resource="#Evidence326" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction265">
 <bp:evidence rdf:resource="#Evidence325" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction257">
 <bp:evidence rdf:resource="#Evidence315" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction256">
 <bp:evidence rdf:resource="#Evidence313" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction259">
 <bp:evidence rdf:resource="#Evidence317" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis300">
 <bp:controlled rdf:resource="#BiochemicalReaction614" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction258">
 <bp:evidence rdf:resource="#Evidence316" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis301">
 <bp:controlled rdf:resource="#BiochemicalReaction615" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis306">
 <bp:controlled rdf:resource="#BiochemicalReaction620" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis307">
 <bp:controlled rdf:resource="#BiochemicalReaction621" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction251">
 <bp:evidence rdf:resource="#Evidence306" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis308">
 <bp:controlled rdf:resource="#BiochemicalReaction622" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction250">
 <bp:evidence rdf:resource="#Evidence305" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis309">
 <bp:controlled rdf:resource="#BiochemicalReaction623" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction253">
 <bp:evidence rdf:resource="#Evidence310" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis302">
 <bp:controlled rdf:resource="#BiochemicalReaction616" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction252">
 <bp:evidence rdf:resource="#Evidence309" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis303">
 <bp:controlled rdf:resource="#BiochemicalReaction617" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction255">
 <bp:evidence rdf:resource="#Evidence312" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis304">
 <bp:controlled rdf:resource="#BiochemicalReaction618" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction254">
 <bp:evidence rdf:resource="#Evidence311" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis305">
 <bp:controlled rdf:resource="#BiochemicalReaction619" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction246">
 <bp:evidence rdf:resource="#Evidence300" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction245">
 <bp:evidence rdf:resource="#Evidence299" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis310">
 <bp:controlled rdf:resource="#BiochemicalReaction624" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction248">
 <bp:evidence rdf:resource="#Evidence303" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis311">
 <bp:controlled rdf:resource="#BiochemicalReaction625" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction247">
 <bp:evidence rdf:resource="#Evidence302" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis312">
 <bp:controlled rdf:resource="#BiochemicalReaction627" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction249">
 <bp:evidence rdf:resource="#Evidence304" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction240">
 <bp:evidence rdf:resource="#Evidence291" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transfer of LPS onto TLR4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction242">
 <bp:evidence rdf:resource="#Evidence293" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of TRAM (TICAM2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction241">
 <bp:evidence rdf:resource="#Evidence292" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of TLR4:LY96:LPS:CD14</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction244">
 <bp:evidence rdf:resource="#Evidence298" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction243">
 <bp:evidence rdf:resource="#Evidence294" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of LBP with LPS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction235">
 <bp:evidence rdf:resource="#Evidence286" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction234">
 <bp:evidence rdf:resource="#Evidence285" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction237">
 <bp:evidence rdf:resource="#Evidence288" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction236">
 <bp:evidence rdf:resource="#Evidence287" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction239">
 <bp:evidence rdf:resource="#Evidence290" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR4:LY96:LPS:CD14 recruits TRAM (TICAM2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction238">
 <bp:evidence rdf:resource="#Evidence289" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction231">
 <bp:evidence rdf:resource="#Evidence281" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction230">
 <bp:evidence rdf:resource="#Evidence280" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR:TIRAP:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction233">
 <bp:evidence rdf:resource="#Evidence283" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to p-IRAK2  </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction232">
 <bp:evidence rdf:resource="#Evidence282" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 forms a complex with TIRAP:activated TLR2/4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction224">
 <bp:evidence rdf:resource="#Evidence274" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction223">
 <bp:evidence rdf:resource="#Evidence273" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction226">
 <bp:evidence rdf:resource="#Evidence276" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR2/4:TIRAP interacts with BTK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction225">
 <bp:evidence rdf:resource="#Evidence275" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction228">
 <bp:evidence rdf:resource="#Evidence278" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction227">
 <bp:evidence rdf:resource="#Evidence277" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of p-IRAK2:TRAF6 from the activated TLR:oligo-Myd88:TIRAP:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction229">
 <bp:evidence rdf:resource="#Evidence279" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1:TRAF6 from the activated TLR:oligo-Myd88:TIRAP:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis339">
 <bp:controlled rdf:resource="#BiochemicalReaction690" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction220">
 <bp:evidence rdf:resource="#Evidence270" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis335">
 <bp:controlled rdf:resource="#BiochemicalReaction684" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis336">
 <bp:controlled rdf:resource="#BiochemicalReaction685" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction222">
 <bp:evidence rdf:resource="#Evidence272" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis337">
 <bp:controlled rdf:resource="#BiochemicalReaction686" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction221">
 <bp:evidence rdf:resource="#Evidence271" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis338">
 <bp:controlled rdf:resource="#BiochemicalReaction689" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction43" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction213">
 <bp:evidence rdf:resource="#Evidence262" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis342">
 <bp:controlled rdf:resource="#BiochemicalReaction694" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction697">
 <bp:evidence rdf:resource="#Evidence844" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction46" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction212">
 <bp:evidence rdf:resource="#Evidence261" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis343">
 <bp:controlled rdf:resource="#BiochemicalReaction695" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction696">
 <bp:evidence rdf:resource="#Evidence842" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction215">
 <bp:evidence rdf:resource="#Evidence264" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis344">
 <bp:controlled rdf:resource="#BiochemicalReaction696" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction699">
 <bp:evidence rdf:resource="#Evidence847" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction214">
 <bp:evidence rdf:resource="#Evidence263" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis345">
 <bp:controlled rdf:resource="#BiochemicalReaction697" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction698">
 <bp:evidence rdf:resource="#Evidence846" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction38" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction217">
 <bp:evidence rdf:resource="#Evidence266" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction39" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction216">
 <bp:evidence rdf:resource="#Evidence265" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction41" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction219">
 <bp:evidence rdf:resource="#Evidence269" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis340">
 <bp:controlled rdf:resource="#BiochemicalReaction691" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction42" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction218">
 <bp:evidence rdf:resource="#Evidence268" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis341">
 <bp:controlled rdf:resource="#BiochemicalReaction693" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction30" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction31" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction33" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction35" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction691">
 <bp:evidence rdf:resource="#Evidence836" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction690">
 <bp:evidence rdf:resource="#Evidence835" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction693">
 <bp:evidence rdf:resource="#Evidence839" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis346">
 <bp:controlled rdf:resource="#BiochemicalReaction698" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction692">
 <bp:evidence rdf:resource="#Evidence837" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis347">
 <bp:controlled rdf:resource="#BiochemicalReaction699" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction211">
 <bp:evidence rdf:resource="#Evidence260" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction695">
 <bp:evidence rdf:resource="#Evidence841" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis348">
 <bp:controlled rdf:resource="#BiochemicalReaction700" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction210">
 <bp:evidence rdf:resource="#Evidence258" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction694">
 <bp:evidence rdf:resource="#Evidence840" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis349">
 <bp:controlled rdf:resource="#BiochemicalReaction701" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis29">
 <bp:controlled rdf:resource="#BiochemicalReaction57" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction202">
 <bp:evidence rdf:resource="#Evidence248" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction686">
 <bp:evidence rdf:resource="#Evidence829" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis353">
 <bp:controlled rdf:resource="#BiochemicalReaction706" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction201">
 <bp:evidence rdf:resource="#Evidence247" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction685">
 <bp:evidence rdf:resource="#Evidence828" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis354">
 <bp:controlled rdf:resource="#BiochemicalReaction707" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction204">
 <bp:evidence rdf:resource="#Evidence250" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction688">
 <bp:evidence rdf:resource="#Evidence833" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis355">
 <bp:controlled rdf:resource="#BiochemicalReaction708" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction203">
 <bp:evidence rdf:resource="#Evidence249" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction687">
 <bp:evidence rdf:resource="#Evidence830" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis356">
 <bp:controlled rdf:resource="#BiochemicalReaction710" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis25">
 <bp:controlled rdf:resource="#BiochemicalReaction53" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction206">
 <bp:evidence rdf:resource="#Evidence253" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis26">
 <bp:controlled rdf:resource="#BiochemicalReaction54" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction205">
 <bp:evidence rdf:resource="#Evidence251" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction689">
 <bp:evidence rdf:resource="#Evidence834" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis350">
 <bp:controlled rdf:resource="#BiochemicalReaction702" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis27">
 <bp:controlled rdf:resource="#BiochemicalReaction55" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction208">
 <bp:evidence rdf:resource="#Evidence255" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis351">
 <bp:controlled rdf:resource="#BiochemicalReaction703" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis28">
 <bp:controlled rdf:resource="#BiochemicalReaction56" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction207">
 <bp:evidence rdf:resource="#Evidence254" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis352">
 <bp:controlled rdf:resource="#BiochemicalReaction704" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction48" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction50" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction209">
 <bp:evidence rdf:resource="#Evidence256" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction51" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis24">
 <bp:controlled rdf:resource="#BiochemicalReaction52" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction47" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis317">
 <bp:controlled rdf:resource="#BiochemicalReaction645" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis318">
 <bp:controlled rdf:resource="#BiochemicalReaction646" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis319">
 <bp:controlled rdf:resource="#BiochemicalReaction652" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction680">
 <bp:evidence rdf:resource="#Evidence822" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis313">
 <bp:controlled rdf:resource="#BiochemicalReaction628" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction682">
 <bp:evidence rdf:resource="#Evidence824" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis314">
 <bp:controlled rdf:resource="#BiochemicalReaction629" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction681">
 <bp:evidence rdf:resource="#Evidence823" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction200">
 <bp:evidence rdf:resource="#Evidence244" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis315">
 <bp:controlled rdf:resource="#BiochemicalReaction631" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction684">
 <bp:evidence rdf:resource="#Evidence827" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis316">
 <bp:controlled rdf:resource="#BiochemicalReaction644" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction683">
 <bp:evidence rdf:resource="#Evidence826" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis320">
 <bp:controlled rdf:resource="#BiochemicalReaction653" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction675">
 <bp:evidence rdf:resource="#Evidence815" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TIRAP is phosphorylated by BTK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis321">
 <bp:controlled rdf:resource="#BiochemicalReaction657" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction674">
 <bp:evidence rdf:resource="#Evidence814" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 or IRAK2 binds to the activated IRAK4 :activated TLR:MyD88:TIRAP complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis322">
 <bp:controlled rdf:resource="#BiochemicalReaction660" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction677">
 <bp:evidence rdf:resource="#Evidence817" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomer:TIRAP:activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis323">
 <bp:controlled rdf:resource="#BiochemicalReaction662" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction676">
 <bp:evidence rdf:resource="#Evidence816" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation steps</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction679">
 <bp:evidence rdf:resource="#Evidence819" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation in the complex with activated TLR:MyD88:TIRAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction678">
 <bp:evidence rdf:resource="#Evidence818" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to activated TLR:MyD88:TIRAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis328">
 <bp:controlled rdf:resource="#BiochemicalReaction675" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis329">
 <bp:controlled rdf:resource="#BiochemicalReaction676" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis324">
 <bp:controlled rdf:resource="#BiochemicalReaction667" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction671">
 <bp:evidence rdf:resource="#Evidence811" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR2/4 interacts with MAL (TIRAP)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis325">
 <bp:controlled rdf:resource="#BiochemicalReaction669" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction670">
 <bp:evidence rdf:resource="#Evidence810" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis326">
 <bp:controlled rdf:resource="#BiochemicalReaction670" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction673">
 <bp:evidence rdf:resource="#Evidence813" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TIRAP binds PIP2-rich regions in the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction672">
 <bp:evidence rdf:resource="#Evidence812" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to activated TLR:MyD88:Mal</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis327">
 <bp:controlled rdf:resource="#BiochemicalReaction672" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction664">
 <bp:evidence rdf:resource="#Evidence804" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis331">
 <bp:controlled rdf:resource="#BiochemicalReaction678" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction663">
 <bp:evidence rdf:resource="#Evidence803" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis332">
 <bp:controlled rdf:resource="#BiochemicalReaction679" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction666">
 <bp:evidence rdf:resource="#Evidence806" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis333">
 <bp:controlled rdf:resource="#BiochemicalReaction681" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction665">
 <bp:evidence rdf:resource="#Evidence805" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis334">
 <bp:controlled rdf:resource="#BiochemicalReaction682" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction668">
 <bp:evidence rdf:resource="#Evidence808" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction667">
 <bp:evidence rdf:resource="#Evidence807" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction669">
 <bp:evidence rdf:resource="#Evidence809" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis330">
 <bp:controlled rdf:resource="#BiochemicalReaction677" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#Catalysis14" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
 <bp:stepProcess rdf:resource="#Catalysis15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
 <bp:stepProcess rdf:resource="#Catalysis13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep489">
 <bp:stepProcess rdf:resource="#Pathway86" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep488">
 <bp:stepProcess rdf:resource="#BiochemicalReaction404" />
 <bp:stepProcess rdf:resource="#Catalysis194" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep487">
 <bp:stepProcess rdf:resource="#BiochemicalReaction403" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep486">
 <bp:stepProcess rdf:resource="#BiochemicalReaction402" />
 <bp:stepProcess rdf:resource="#Catalysis193" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep485">
 <bp:stepProcess rdf:resource="#BiochemicalReaction401" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep484">
 <bp:stepProcess rdf:resource="#BiochemicalReaction400" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep483">
 <bp:stepProcess rdf:resource="#Pathway85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep482">
 <bp:stepProcess rdf:resource="#BiochemicalReaction399" />
 <bp:stepProcess rdf:resource="#Catalysis192" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep481">
 <bp:stepProcess rdf:resource="#Catalysis191" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction398" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep480">
 <bp:stepProcess rdf:resource="#BiochemicalReaction397" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#Catalysis19" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
 <bp:stepProcess rdf:resource="#Catalysis20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#Catalysis21" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#Catalysis16" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#Catalysis17" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#Catalysis18" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep479">
 <bp:stepProcess rdf:resource="#BiochemicalReaction396" />
 <bp:stepProcess rdf:resource="#Catalysis190" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep478">
 <bp:stepProcess rdf:resource="#BiochemicalReaction395" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep477">
 <bp:stepProcess rdf:resource="#BiochemicalReaction394" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep476">
 <bp:stepProcess rdf:resource="#BiochemicalReaction393" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep475">
 <bp:stepProcess rdf:resource="#BiochemicalReaction392" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep474">
 <bp:stepProcess rdf:resource="#Catalysis189" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction391" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep473">
 <bp:stepProcess rdf:resource="#BiochemicalReaction390" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep472">
 <bp:stepProcess rdf:resource="#BiochemicalReaction389" />
 <bp:stepProcess rdf:resource="#Catalysis188" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep471">
 <bp:stepProcess rdf:resource="#BiochemicalReaction388" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep470">
 <bp:stepProcess rdf:resource="#BiochemicalReaction387" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#Catalysis8" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#Catalysis7" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis357">
 <bp:controlled rdf:resource="#BiochemicalReaction723" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis358">
 <bp:controlled rdf:resource="#BiochemicalReaction724" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis359">
 <bp:controlled rdf:resource="#BiochemicalReaction725" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#Catalysis12" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction190">
 <bp:evidence rdf:resource="#Evidence231" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomer:TIRAP:activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#Catalysis10" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction192">
 <bp:evidence rdf:resource="#Evidence233" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation in the complex with activated TLR:MyD88:TIRAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction191">
 <bp:evidence rdf:resource="#Evidence232" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to activated TLR:MyD88:TIRAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction194">
 <bp:evidence rdf:resource="#Evidence237" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction193">
 <bp:evidence rdf:resource="#Evidence236" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction196">
 <bp:evidence rdf:resource="#Evidence240" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#Catalysis9" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction195">
 <bp:evidence rdf:resource="#Evidence238" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction198">
 <bp:evidence rdf:resource="#Evidence242" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction197">
 <bp:evidence rdf:resource="#Evidence241" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction199">
 <bp:evidence rdf:resource="#Evidence243" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep499">
 <bp:stepProcess rdf:resource="#BiochemicalReaction412" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep498">
 <bp:stepProcess rdf:resource="#BiochemicalReaction411" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep497">
 <bp:stepProcess rdf:resource="#Pathway88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep496">
 <bp:stepProcess rdf:resource="#BiochemicalReaction410" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep495">
 <bp:stepProcess rdf:resource="#Pathway87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep494">
 <bp:stepProcess rdf:resource="#BiochemicalReaction409" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep493">
 <bp:stepProcess rdf:resource="#BiochemicalReaction408" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep492">
 <bp:stepProcess rdf:resource="#BiochemicalReaction407" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep491">
 <bp:stepProcess rdf:resource="#Catalysis196" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction406" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep490">
 <bp:stepProcess rdf:resource="#Catalysis195" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction405" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
 <bp:stepProcess rdf:resource="#Catalysis1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction181">
 <bp:evidence rdf:resource="#Evidence222" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction180">
 <bp:evidence rdf:resource="#Evidence221" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction183">
 <bp:evidence rdf:resource="#Evidence224" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction182">
 <bp:evidence rdf:resource="#Evidence223" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction185">
 <bp:evidence rdf:resource="#Evidence226" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to activated TLR:MyD88:Mal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction184">
 <bp:evidence rdf:resource="#Evidence225" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR2/4 interacts with MAL (TIRAP)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction187">
 <bp:evidence rdf:resource="#Evidence228" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 or IRAK2 binds to the activated IRAK4 :activated TLR:MyD88:TIRAP complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep449">
 <bp:stepProcess rdf:resource="#Catalysis178" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction369" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction186">
 <bp:evidence rdf:resource="#Evidence227" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TIRAP binds PIP2-rich regions in the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep448">
 <bp:stepProcess rdf:resource="#Catalysis177" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction368" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction189">
 <bp:evidence rdf:resource="#Evidence230" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation steps</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep447">
 <bp:stepProcess rdf:resource="#BiochemicalReaction367" />
 <bp:stepProcess rdf:resource="#Catalysis176" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction188">
 <bp:evidence rdf:resource="#Evidence229" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TIRAP is phosphorylated by BTK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep446">
 <bp:stepProcess rdf:resource="#Pathway81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep445">
 <bp:stepProcess rdf:resource="#BiochemicalReaction366" />
 <bp:stepProcess rdf:resource="#Catalysis175" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction179">
 <bp:evidence rdf:resource="#Evidence220" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep444">
 <bp:stepProcess rdf:resource="#Pathway80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep443">
 <bp:stepProcess rdf:resource="#Catalysis174" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction365" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep442">
 <bp:stepProcess rdf:resource="#Catalysis173" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction364" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep441">
 <bp:stepProcess rdf:resource="#Catalysis172" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction363" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep440">
 <bp:stepProcess rdf:resource="#Catalysis171" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction362" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction170">
 <bp:evidence rdf:resource="#Evidence211" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
 <bp:stepProcess rdf:resource="#Catalysis4" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction172">
 <bp:evidence rdf:resource="#Evidence213" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction171">
 <bp:evidence rdf:resource="#Evidence212" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction174">
 <bp:evidence rdf:resource="#Evidence215" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction173">
 <bp:evidence rdf:resource="#Evidence214" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep439">
 <bp:stepProcess rdf:resource="#Pathway79" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction176">
 <bp:evidence rdf:resource="#Evidence217" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep438">
 <bp:stepProcess rdf:resource="#BiochemicalReaction361" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction175">
 <bp:evidence rdf:resource="#Evidence216" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep437">
 <bp:stepProcess rdf:resource="#Catalysis170" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction360" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction178">
 <bp:evidence rdf:resource="#Evidence219" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep436">
 <bp:stepProcess rdf:resource="#Catalysis169" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction359" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction177">
 <bp:evidence rdf:resource="#Evidence218" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep435">
 <bp:stepProcess rdf:resource="#BiochemicalReaction358" />
 <bp:stepProcess rdf:resource="#Catalysis168" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction169">
 <bp:evidence rdf:resource="#Evidence210" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep434">
 <bp:stepProcess rdf:resource="#BiochemicalReaction357" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction168">
 <bp:evidence rdf:resource="#Evidence208" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep433">
 <bp:stepProcess rdf:resource="#Pathway78" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep432">
 <bp:stepProcess rdf:resource="#Pathway77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep431">
 <bp:stepProcess rdf:resource="#BiochemicalReaction356" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep430">
 <bp:stepProcess rdf:resource="#BiochemicalReaction355" />
 <bp:stepProcess rdf:resource="#Catalysis167" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR9 processing at neutral pH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction161">
 <bp:evidence rdf:resource="#Evidence198" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CD14:LPS binds CR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endosomal TLRs pass through the Golgi</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction160">
 <bp:evidence rdf:resource="#Evidence197" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GPI-bound CD14 binds LPS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction163">
 <bp:evidence rdf:resource="#Evidence202" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction162">
 <bp:evidence rdf:resource="#Evidence200" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to the activated TLR receptor:TIRAP:MyD88 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction165">
 <bp:evidence rdf:resource="#Evidence204" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction164">
 <bp:evidence rdf:resource="#Evidence203" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction167">
 <bp:evidence rdf:resource="#Evidence207" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep469">
 <bp:stepProcess rdf:resource="#Catalysis187" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction386" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction166">
 <bp:evidence rdf:resource="#Evidence205" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep468">
 <bp:stepProcess rdf:resource="#BiochemicalReaction385" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction158">
 <bp:evidence rdf:resource="#Evidence194" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAM:TLR4:LY96:LPS:CD14 recruits TRIF (TICAM1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep467">
 <bp:stepProcess rdf:resource="#Pathway84" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction157">
 <bp:evidence rdf:resource="#Evidence193" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">K63-linked ubiquitination of RIP1 bound to the activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep466">
 <bp:stepProcess rdf:resource="#BiochemicalReaction384" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep465">
 <bp:stepProcess rdf:resource="#BiochemicalReaction383" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction159">
 <bp:evidence rdf:resource="#Evidence196" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Secreted CD14 binds LPS</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep464">
 <bp:stepProcess rdf:resource="#Pathway83" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep463">
 <bp:stepProcess rdf:resource="#BiochemicalReaction382" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep462">
 <bp:stepProcess rdf:resource="#BiochemicalReaction381" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep461">
 <bp:stepProcess rdf:resource="#BiochemicalReaction380" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep460">
 <bp:stepProcess rdf:resource="#BiochemicalReaction379" />
 <bp:stepProcess rdf:resource="#Catalysis186" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction150">
 <bp:evidence rdf:resource="#Evidence185" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR4:TICAM1:K63pUb-TRAF6 recruits TAK1complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction152">
 <bp:evidence rdf:resource="#Evidence187" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR4:TICAM1 recruits TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction151">
 <bp:evidence rdf:resource="#Evidence186" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of TAK1 complex bound to activated TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction154">
 <bp:evidence rdf:resource="#Evidence189" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains upon TLR stimulation </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction153">
 <bp:evidence rdf:resource="#Evidence188" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of TRAF6 bound to the activated TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep459">
 <bp:stepProcess rdf:resource="#BiochemicalReaction378" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction156">
 <bp:evidence rdf:resource="#Evidence192" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRIF:activated TLR3/TLR4 complex recruits RIP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep458">
 <bp:stepProcess rdf:resource="#BiochemicalReaction377" />
 <bp:stepProcess rdf:resource="#Catalysis185" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction155">
 <bp:evidence rdf:resource="#Evidence191" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKG subunit of IKK complex binds polyubiquinated RIP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep457">
 <bp:stepProcess rdf:resource="#Catalysis184" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction376" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction147">
 <bp:evidence rdf:resource="#Evidence181" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 is ubiquitinated within TBK1:K63polyUb-TANK:K63polyUb-TRAF3:TRIF:activated TLR4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep456">
 <bp:stepProcess rdf:resource="#Catalysis183" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction375" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction146">
 <bp:evidence rdf:resource="#Evidence180" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKK&#949; (IKBKE) is ubiquitinated within the activated TLR4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep455">
 <bp:stepProcess rdf:resource="#BiochemicalReaction374" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction149">
 <bp:evidence rdf:resource="#Evidence184" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated TAK1 leaves activated TLR receptor complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep454">
 <bp:stepProcess rdf:resource="#Pathway82" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction148">
 <bp:evidence rdf:resource="#Evidence182" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRF3/IRF7 recruitment to p-TBK1/p-IKK epsilon bound to the activated TLR4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep453">
 <bp:stepProcess rdf:resource="#Catalysis182" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction373" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep452">
 <bp:stepProcess rdf:resource="#Catalysis181" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction372" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep451">
 <bp:stepProcess rdf:resource="#Catalysis180" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction371" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep450">
 <bp:stepProcess rdf:resource="#Catalysis179" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction370" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep409">
 <bp:stepProcess rdf:resource="#Pathway72" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep408">
 <bp:stepProcess rdf:resource="#BiochemicalReaction338" />
 <bp:stepProcess rdf:resource="#Catalysis159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep407">
 <bp:stepProcess rdf:resource="#BiochemicalReaction337" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep406">
 <bp:stepProcess rdf:resource="#BiochemicalReaction336" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep405">
 <bp:stepProcess rdf:resource="#BiochemicalReaction335" />
 <bp:stepProcess rdf:resource="#Catalysis158" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep889">
 <bp:stepProcess rdf:resource="#BiochemicalReaction739" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep404">
 <bp:stepProcess rdf:resource="#BiochemicalReaction334" />
 <bp:stepProcess rdf:resource="#Catalysis157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep888">
 <bp:stepProcess rdf:resource="#BiochemicalReaction738" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep403">
 <bp:stepProcess rdf:resource="#Pathway71" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep887">
 <bp:stepProcess rdf:resource="#BiochemicalReaction737" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep402">
 <bp:stepProcess rdf:resource="#BiochemicalReaction333" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep886">
 <bp:stepProcess rdf:resource="#BiochemicalReaction736" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep401">
 <bp:stepProcess rdf:resource="#BiochemicalReaction332" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence496">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep885">
 <bp:stepProcess rdf:resource="#BiochemicalReaction735" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep400">
 <bp:stepProcess rdf:resource="#BiochemicalReaction331" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence497">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep884">
 <bp:stepProcess rdf:resource="#BiochemicalReaction734" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence494">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep883">
 <bp:stepProcess rdf:resource="#BiochemicalReaction733" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence495">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep882">
 <bp:stepProcess rdf:resource="#BiochemicalReaction732" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep881">
 <bp:stepProcess rdf:resource="#BiochemicalReaction731" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep880">
 <bp:stepProcess rdf:resource="#BiochemicalReaction730" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence498">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence499">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence492">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence493">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence490">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence491">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep879">
 <bp:stepProcess rdf:resource="#BiochemicalReaction729" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep878">
 <bp:stepProcess rdf:resource="#BiochemicalReaction728" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep877">
 <bp:stepProcess rdf:resource="#BiochemicalReaction727" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep876">
 <bp:stepProcess rdf:resource="#Pathway151" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep875">
 <bp:stepProcess rdf:resource="#BiochemicalReaction726" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep874">
 <bp:stepProcess rdf:resource="#BiochemicalReaction725" />
 <bp:stepProcess rdf:resource="#Catalysis359" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep873">
 <bp:stepProcess rdf:resource="#BiochemicalReaction724" />
 <bp:stepProcess rdf:resource="#Catalysis358" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Flagellin binds to TLR5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep872">
 <bp:stepProcess rdf:resource="#BiochemicalReaction723" />
 <bp:stepProcess rdf:resource="#Catalysis357" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Full-length TLR3/7/8/9 binds to UNC93B1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep871">
 <bp:stepProcess rdf:resource="#BiochemicalReaction722" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR processing at low pH</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep870">
 <bp:stepProcess rdf:resource="#BiochemicalReaction721" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR folding by chaperones GP96 and CNPY3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UNC93B1 delivers endosomal full-length TLRs to endolysosome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Folded full-length TLR7/8/9 dissociates from the GP96:CNPY3 complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep429">
 <bp:stepProcess rdf:resource="#Catalysis166" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction354" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep428">
 <bp:stepProcess rdf:resource="#Catalysis165" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction353" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep427">
 <bp:stepProcess rdf:resource="#BiochemicalReaction352" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep426">
 <bp:stepProcess rdf:resource="#Pathway76" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep425">
 <bp:stepProcess rdf:resource="#Catalysis164" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction351" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep424">
 <bp:stepProcess rdf:resource="#Catalysis163" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction350" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep423">
 <bp:stepProcess rdf:resource="#BiochemicalReaction349" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence474">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep422">
 <bp:stepProcess rdf:resource="#Pathway75" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence475">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep421">
 <bp:stepProcess rdf:resource="#Pathway74" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence472">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep420">
 <bp:stepProcess rdf:resource="#Pathway73" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence473">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence478">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence479">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence476">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence477">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence470">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence471">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep419">
 <bp:stepProcess rdf:resource="#Catalysis162" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction348" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep418">
 <bp:stepProcess rdf:resource="#BiochemicalReaction347" />
 <bp:stepProcess rdf:resource="#Catalysis161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep417">
 <bp:stepProcess rdf:resource="#BiochemicalReaction346" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep416">
 <bp:stepProcess rdf:resource="#BiochemicalReaction345" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep415">
 <bp:stepProcess rdf:resource="#BiochemicalReaction344" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep414">
 <bp:stepProcess rdf:resource="#Catalysis160" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction343" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep413">
 <bp:stepProcess rdf:resource="#BiochemicalReaction342" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep412">
 <bp:stepProcess rdf:resource="#BiochemicalReaction341" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence485">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep411">
 <bp:stepProcess rdf:resource="#BiochemicalReaction340" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence486">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep410">
 <bp:stepProcess rdf:resource="#BiochemicalReaction339" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence483">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence484">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence489">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence487">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence488">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence481">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence482">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence480">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep849">
 <bp:stepProcess rdf:resource="#Catalysis350" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction702" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep848">
 <bp:stepProcess rdf:resource="#BiochemicalReaction701" />
 <bp:stepProcess rdf:resource="#Catalysis349" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence458">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep847">
 <bp:stepProcess rdf:resource="#BiochemicalReaction700" />
 <bp:stepProcess rdf:resource="#Catalysis348" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence459">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep846">
 <bp:stepProcess rdf:resource="#BiochemicalReaction699" />
 <bp:stepProcess rdf:resource="#Catalysis347" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep845">
 <bp:stepProcess rdf:resource="#BiochemicalReaction698" />
 <bp:stepProcess rdf:resource="#Catalysis346" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep844">
 <bp:stepProcess rdf:resource="#Pathway148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep843">
 <bp:stepProcess rdf:resource="#BiochemicalReaction697" />
 <bp:stepProcess rdf:resource="#Catalysis345" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep842">
 <bp:stepProcess rdf:resource="#Pathway147" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence452">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep841">
 <bp:stepProcess rdf:resource="#BiochemicalReaction696" />
 <bp:stepProcess rdf:resource="#Catalysis344" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence453">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep840">
 <bp:stepProcess rdf:resource="#Catalysis343" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction695" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence450">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence451">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence456">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence457">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence454">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence455">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep839">
 <bp:stepProcess rdf:resource="#Catalysis342" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction694" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep838">
 <bp:stepProcess rdf:resource="#Catalysis341" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction693" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep837">
 <bp:stepProcess rdf:resource="#Pathway146" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence469">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep836">
 <bp:stepProcess rdf:resource="#BiochemicalReaction692" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep835">
 <bp:stepProcess rdf:resource="#Catalysis340" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction691" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep834">
 <bp:stepProcess rdf:resource="#Catalysis339" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction690" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep833">
 <bp:stepProcess rdf:resource="#BiochemicalReaction689" />
 <bp:stepProcess rdf:resource="#Catalysis338" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep832">
 <bp:stepProcess rdf:resource="#BiochemicalReaction688" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep831">
 <bp:stepProcess rdf:resource="#Pathway145" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence463">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep830">
 <bp:stepProcess rdf:resource="#Pathway144" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence464">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence461">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence462">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence467">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence468">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence465">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence466">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence460">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence438">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence439">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence436">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep869">
 <bp:stepProcess rdf:resource="#Pathway150" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence437">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep868">
 <bp:stepProcess rdf:resource="#BiochemicalReaction720" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep867">
 <bp:stepProcess rdf:resource="#BiochemicalReaction719" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep866">
 <bp:stepProcess rdf:resource="#BiochemicalReaction718" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep865">
 <bp:stepProcess rdf:resource="#BiochemicalReaction717" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep864">
 <bp:stepProcess rdf:resource="#BiochemicalReaction716" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence430">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep863">
 <bp:stepProcess rdf:resource="#BiochemicalReaction715" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence431">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep862">
 <bp:stepProcess rdf:resource="#BiochemicalReaction714" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep861">
 <bp:stepProcess rdf:resource="#BiochemicalReaction713" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep860">
 <bp:stepProcess rdf:resource="#BiochemicalReaction712" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence434">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence435">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence432">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence433">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence449">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep859">
 <bp:stepProcess rdf:resource="#BiochemicalReaction711" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence447">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep858">
 <bp:stepProcess rdf:resource="#BiochemicalReaction710" />
 <bp:stepProcess rdf:resource="#Catalysis356" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence448">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep857">
 <bp:stepProcess rdf:resource="#BiochemicalReaction709" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep856">
 <bp:stepProcess rdf:resource="#Catalysis355" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction708" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep855">
 <bp:stepProcess rdf:resource="#Catalysis354" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction707" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep854">
 <bp:stepProcess rdf:resource="#Catalysis353" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction706" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep853">
 <bp:stepProcess rdf:resource="#BiochemicalReaction705" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence441">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep852">
 <bp:stepProcess rdf:resource="#Pathway149" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence442">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep851">
 <bp:stepProcess rdf:resource="#Catalysis352" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction704" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep850">
 <bp:stepProcess rdf:resource="#BiochemicalReaction703" />
 <bp:stepProcess rdf:resource="#Catalysis351" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence440">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence445">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence446">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence443">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence444">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence416">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence417">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence414">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence415">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence418">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction541">
 <bp:evidence rdf:resource="#Evidence656" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence419">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction540">
 <bp:evidence rdf:resource="#Evidence655" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction532">
 <bp:evidence rdf:resource="#Evidence644" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction531">
 <bp:evidence rdf:resource="#Evidence643" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction534">
 <bp:evidence rdf:resource="#Evidence648" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence890">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction533">
 <bp:evidence rdf:resource="#Evidence647" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence412">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction536">
 <bp:evidence rdf:resource="#Evidence650" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence413">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction535">
 <bp:evidence rdf:resource="#Evidence649" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence410">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction538">
 <bp:evidence rdf:resource="#Evidence653" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence411">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction537">
 <bp:evidence rdf:resource="#Evidence651" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction539">
 <bp:evidence rdf:resource="#Evidence654" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence427">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence428">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence425">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence426">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence429">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction530">
 <bp:evidence rdf:resource="#Evidence642" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction521">
 <bp:evidence rdf:resource="#Evidence630" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to MyD88:activated TLR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence420">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction520">
 <bp:evidence rdf:resource="#Evidence629" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction523">
 <bp:evidence rdf:resource="#Evidence632" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to MyD88:activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction522">
 <bp:evidence rdf:resource="#Evidence631" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1:TRAF6 or IRAK2:TRAF6-oligomer from the activated TLR5 or 10:oligo-Myd88:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence423">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction525">
 <bp:evidence rdf:resource="#Evidence636" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence424">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction524">
 <bp:evidence rdf:resource="#Evidence633" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to MyD88 bound to the activated TLR5 or 10 receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence421">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction527">
 <bp:evidence rdf:resource="#Evidence638" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence422">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction526">
 <bp:evidence rdf:resource="#Evidence637" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction529">
 <bp:evidence rdf:resource="#Evidence641" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction528">
 <bp:evidence rdf:resource="#Evidence640" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence878">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence879">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence876">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence877">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction510">
 <bp:evidence rdf:resource="#Evidence619" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence870">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence871">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction512">
 <bp:evidence rdf:resource="#Evidence621" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction511">
 <bp:evidence rdf:resource="#Evidence620" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction514">
 <bp:evidence rdf:resource="#Evidence623" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence874">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction513">
 <bp:evidence rdf:resource="#Evidence622" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence875">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction516">
 <bp:evidence rdf:resource="#Evidence625" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence872">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction515">
 <bp:evidence rdf:resource="#Evidence624" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence873">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction518">
 <bp:evidence rdf:resource="#Evidence627" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction517">
 <bp:evidence rdf:resource="#Evidence626" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction519">
 <bp:evidence rdf:resource="#Evidence628" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence405">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence889">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence406">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence403">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence887">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence404">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence888">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence409">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence407">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence408">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence881">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence882">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction501">
 <bp:evidence rdf:resource="#Evidence608" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1/or IRAK2 binds to the activated IRAK4 :oligo MyD88:activated TLR5 or 10 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction500">
 <bp:evidence rdf:resource="#Evidence607" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence880">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence401">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction503">
 <bp:evidence rdf:resource="#Evidence611" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence885">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence402">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction502">
 <bp:evidence rdf:resource="#Evidence609" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation within the complex p-IRAK4:oligo MyD88:activated TLR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence886">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction505">
 <bp:evidence rdf:resource="#Evidence614" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence883">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence400">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction504">
 <bp:evidence rdf:resource="#Evidence612" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence884">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction507">
 <bp:evidence rdf:resource="#Evidence616" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction506">
 <bp:evidence rdf:resource="#Evidence615" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction509">
 <bp:evidence rdf:resource="#Evidence618" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction508">
 <bp:evidence rdf:resource="#Evidence617" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence856">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence857">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence854">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence855">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence858">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence859">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence852">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence853">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence850">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence851">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence867">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence868">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence865">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence866">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence869">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence860">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence863">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence864">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence861">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence862">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence834">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence835">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence832">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence833">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence838">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence839">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence836">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence837">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence830">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence831">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence845">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence846">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence843">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence844">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence849">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence847">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence848">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence841">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence842">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence840">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence818">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence819">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence812">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence813">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction141">
 <bp:evidence rdf:resource="#Evidence174" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TANK is ubiquitinated within TANK:K63polyUb-TRAF3:TRIF:activated TLR4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence810">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction140">
 <bp:evidence rdf:resource="#Evidence173" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of TBK1 to K63polyUb-TANK:K63polyUb-TRAF3:TRIF:activated TLR4 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence811">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction143">
 <bp:evidence rdf:resource="#Evidence176" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto-ubiquitination of TRAF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence816">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction142">
 <bp:evidence rdf:resource="#Evidence175" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 is phosphorylated within the activated TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence817">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction145">
 <bp:evidence rdf:resource="#Evidence179" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OPTN binds TBK1 within the activated TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence814">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction144">
 <bp:evidence rdf:resource="#Evidence177" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF3 binds TICAM1:activated TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence815">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction136">
 <bp:evidence rdf:resource="#Evidence169" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKK&#949; (IKBKE) is phosphorylated within the activated TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction135">
 <bp:evidence rdf:resource="#Evidence168" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TANK binds K63-poly-Ub-TRAF3:TICAM1:activated TLR4 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction138">
 <bp:evidence rdf:resource="#Evidence171" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of phosphorylated IRF3/IRF7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction137">
 <bp:evidence rdf:resource="#Evidence170" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRF-3/IRF7 and their release from the activated TLR complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction139">
 <bp:evidence rdf:resource="#Evidence172" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of IKK&#949; (IKBKE) to K63polyUb-TANK:K63polyUb-TRAF3:TRIF:activated TLR4 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence829">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence823">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence824">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction130">
 <bp:evidence rdf:resource="#Evidence161" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence821">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence822">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction132">
 <bp:evidence rdf:resource="#Evidence164" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RIP3 binds TRIF to mediate necroptosis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence827">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction131">
 <bp:evidence rdf:resource="#Evidence163" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR4-induced ripoptosome assembly</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence828">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction134">
 <bp:evidence rdf:resource="#Evidence167" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerized phospho-IRF3/IRF7 is transported to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence825">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction133">
 <bp:evidence rdf:resource="#Evidence165" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Caspase-8 processing within TLR4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence826">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction125">
 <bp:evidence rdf:resource="#Evidence156" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction124">
 <bp:evidence rdf:resource="#Evidence155" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction127">
 <bp:evidence rdf:resource="#Evidence158" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction126">
 <bp:evidence rdf:resource="#Evidence157" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction129">
 <bp:evidence rdf:resource="#Evidence160" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep199">
 <bp:stepProcess rdf:resource="#BiochemicalReaction162" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction128">
 <bp:evidence rdf:resource="#Evidence159" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep198">
 <bp:stepProcess rdf:resource="#Pathway38" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence820">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep197">
 <bp:stepProcess rdf:resource="#BiochemicalReaction161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep196">
 <bp:stepProcess rdf:resource="#BiochemicalReaction160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep195">
 <bp:stepProcess rdf:resource="#BiochemicalReaction159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep194">
 <bp:stepProcess rdf:resource="#Pathway37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep193">
 <bp:stepProcess rdf:resource="#BiochemicalReaction158" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep192">
 <bp:stepProcess rdf:resource="#BiochemicalReaction157" />
 <bp:stepProcess rdf:resource="#Catalysis78" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep191">
 <bp:stepProcess rdf:resource="#BiochemicalReaction156" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep190">
 <bp:stepProcess rdf:resource="#BiochemicalReaction155" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction121">
 <bp:evidence rdf:resource="#Evidence152" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction120">
 <bp:evidence rdf:resource="#Evidence151" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction123">
 <bp:evidence rdf:resource="#Evidence154" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction122">
 <bp:evidence rdf:resource="#Evidence153" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction114">
 <bp:evidence rdf:resource="#Evidence144" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction598">
 <bp:evidence rdf:resource="#Evidence723" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomer:TIRAP:activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction113">
 <bp:evidence rdf:resource="#Evidence142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction597">
 <bp:evidence rdf:resource="#Evidence722" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation steps</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction116">
 <bp:evidence rdf:resource="#Evidence147" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction115">
 <bp:evidence rdf:resource="#Evidence145" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction599">
 <bp:evidence rdf:resource="#Evidence724" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to activated TLR:MyD88:TIRAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction118">
 <bp:evidence rdf:resource="#Evidence149" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction117">
 <bp:evidence rdf:resource="#Evidence148" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction119">
 <bp:evidence rdf:resource="#Evidence150" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence809">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence807">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence808">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction590">
 <bp:evidence rdf:resource="#Evidence715" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence801">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence802">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction592">
 <bp:evidence rdf:resource="#Evidence717" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TLR2/4 interacts with MAL (TIRAP)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction591">
 <bp:evidence rdf:resource="#Evidence716" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence800">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction110">
 <bp:evidence rdf:resource="#Evidence139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction594">
 <bp:evidence rdf:resource="#Evidence719" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TIRAP binds PIP2-rich regions in the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence805">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction593">
 <bp:evidence rdf:resource="#Evidence718" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to activated TLR:MyD88:Mal</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence806">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction112">
 <bp:evidence rdf:resource="#Evidence141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction596">
 <bp:evidence rdf:resource="#Evidence721" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TIRAP is phosphorylated by BTK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence803">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction111">
 <bp:evidence rdf:resource="#Evidence140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction595">
 <bp:evidence rdf:resource="#Evidence720" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 or IRAK2 binds to the activated IRAK4 :activated TLR:MyD88:TIRAP complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence804">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction103">
 <bp:evidence rdf:resource="#Evidence131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction587">
 <bp:evidence rdf:resource="#Evidence712" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction102">
 <bp:evidence rdf:resource="#Evidence130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction586">
 <bp:evidence rdf:resource="#Evidence711" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction105">
 <bp:evidence rdf:resource="#Evidence133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction589">
 <bp:evidence rdf:resource="#Evidence714" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction104">
 <bp:evidence rdf:resource="#Evidence132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction588">
 <bp:evidence rdf:resource="#Evidence713" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction107">
 <bp:evidence rdf:resource="#Evidence136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction106">
 <bp:evidence rdf:resource="#Evidence135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction109">
 <bp:evidence rdf:resource="#Evidence138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction108">
 <bp:evidence rdf:resource="#Evidence137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction581">
 <bp:evidence rdf:resource="#Evidence706" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction580">
 <bp:evidence rdf:resource="#Evidence705" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction583">
 <bp:evidence rdf:resource="#Evidence708" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction582">
 <bp:evidence rdf:resource="#Evidence707" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction101">
 <bp:evidence rdf:resource="#Evidence129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction585">
 <bp:evidence rdf:resource="#Evidence710" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction100">
 <bp:evidence rdf:resource="#Evidence128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction584">
 <bp:evidence rdf:resource="#Evidence709" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction576">
 <bp:evidence rdf:resource="#Evidence700" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep169">
 <bp:stepProcess rdf:resource="#BiochemicalReaction137" />
 <bp:stepProcess rdf:resource="#Catalysis74" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction575">
 <bp:evidence rdf:resource="#Evidence699" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep168">
 <bp:stepProcess rdf:resource="#BiochemicalReaction136" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction578">
 <bp:evidence rdf:resource="#Evidence703" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep167">
 <bp:stepProcess rdf:resource="#BiochemicalReaction135" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction577">
 <bp:evidence rdf:resource="#Evidence702" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep166">
 <bp:stepProcess rdf:resource="#BiochemicalReaction134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep165">
 <bp:stepProcess rdf:resource="#Pathway33" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction579">
 <bp:evidence rdf:resource="#Evidence704" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep164">
 <bp:stepProcess rdf:resource="#Catalysis73" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction133" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep163">
 <bp:stepProcess rdf:resource="#BiochemicalReaction132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep162">
 <bp:stepProcess rdf:resource="#BiochemicalReaction131" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep161">
 <bp:stepProcess rdf:resource="#Pathway32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep160">
 <bp:stepProcess rdf:resource="#BiochemicalReaction130" />
 <bp:stepProcess rdf:resource="#Catalysis72" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction570">
 <bp:evidence rdf:resource="#Evidence692" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to the activated TLR receptor:TIRAP:MyD88 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction572">
 <bp:evidence rdf:resource="#Evidence695" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction571">
 <bp:evidence rdf:resource="#Evidence694" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction574">
 <bp:evidence rdf:resource="#Evidence697" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction573">
 <bp:evidence rdf:resource="#Evidence696" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep159">
 <bp:stepProcess rdf:resource="#Catalysis71" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction129" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction565">
 <bp:evidence rdf:resource="#Evidence684" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep158">
 <bp:stepProcess rdf:resource="#BiochemicalReaction128" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction564">
 <bp:evidence rdf:resource="#Evidence683" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep157">
 <bp:stepProcess rdf:resource="#BiochemicalReaction127" />
 <bp:stepProcess rdf:resource="#Catalysis70" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction567">
 <bp:evidence rdf:resource="#Evidence686" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1 or p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep156">
 <bp:stepProcess rdf:resource="#BiochemicalReaction126" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction566">
 <bp:evidence rdf:resource="#Evidence685" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep155">
 <bp:stepProcess rdf:resource="#BiochemicalReaction125" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction569">
 <bp:evidence rdf:resource="#Evidence690" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR6:TLR2 is recruited to ligand:CD14:CD36</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep154">
 <bp:stepProcess rdf:resource="#BiochemicalReaction124" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction568">
 <bp:evidence rdf:resource="#Evidence687" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand binds to TLR10</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep153">
 <bp:stepProcess rdf:resource="#BiochemicalReaction123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep152">
 <bp:stepProcess rdf:resource="#Catalysis69" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep151">
 <bp:stepProcess rdf:resource="#BiochemicalReaction121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep150">
 <bp:stepProcess rdf:resource="#Catalysis68" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction120" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction561">
 <bp:evidence rdf:resource="#Evidence679" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomerl:activated TLR5 or 10 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction560">
 <bp:evidence rdf:resource="#Evidence678" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction563">
 <bp:evidence rdf:resource="#Evidence682" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction562">
 <bp:evidence rdf:resource="#Evidence681" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction554">
 <bp:evidence rdf:resource="#Evidence672" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction553">
 <bp:evidence rdf:resource="#Evidence671" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction556">
 <bp:evidence rdf:resource="#Evidence674" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep189">
 <bp:stepProcess rdf:resource="#Pathway36" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction555">
 <bp:evidence rdf:resource="#Evidence673" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep188">
 <bp:stepProcess rdf:resource="#Catalysis77" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction154" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction558">
 <bp:evidence rdf:resource="#Evidence676" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 forms a complex with the activated TLR receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep187">
 <bp:stepProcess rdf:resource="#BiochemicalReaction153" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction557">
 <bp:evidence rdf:resource="#Evidence675" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep186">
 <bp:stepProcess rdf:resource="#BiochemicalReaction152" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep185">
 <bp:stepProcess rdf:resource="#Catalysis76" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction151" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction559">
 <bp:evidence rdf:resource="#Evidence677" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation within the complex activated TLR:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep184">
 <bp:stepProcess rdf:resource="#BiochemicalReaction150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep183">
 <bp:stepProcess rdf:resource="#BiochemicalReaction149" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep182">
 <bp:stepProcess rdf:resource="#Pathway35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep181">
 <bp:stepProcess rdf:resource="#BiochemicalReaction148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep180">
 <bp:stepProcess rdf:resource="#BiochemicalReaction147" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction550">
 <bp:evidence rdf:resource="#Evidence668" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction552">
 <bp:evidence rdf:resource="#Evidence670" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction551">
 <bp:evidence rdf:resource="#Evidence669" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction543">
 <bp:evidence rdf:resource="#Evidence660" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction542">
 <bp:evidence rdf:resource="#Evidence658" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep179">
 <bp:stepProcess rdf:resource="#BiochemicalReaction146" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction545">
 <bp:evidence rdf:resource="#Evidence662" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep178">
 <bp:stepProcess rdf:resource="#BiochemicalReaction145" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction544">
 <bp:evidence rdf:resource="#Evidence661" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep177">
 <bp:stepProcess rdf:resource="#Pathway34" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction547">
 <bp:evidence rdf:resource="#Evidence664" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep176">
 <bp:stepProcess rdf:resource="#BiochemicalReaction144" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction546">
 <bp:evidence rdf:resource="#Evidence663" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep175">
 <bp:stepProcess rdf:resource="#BiochemicalReaction143" />
 <bp:stepProcess rdf:resource="#Catalysis75" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction549">
 <bp:evidence rdf:resource="#Evidence666" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep174">
 <bp:stepProcess rdf:resource="#BiochemicalReaction142" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction548">
 <bp:evidence rdf:resource="#Evidence665" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep173">
 <bp:stepProcess rdf:resource="#BiochemicalReaction141" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep172">
 <bp:stepProcess rdf:resource="#BiochemicalReaction140" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep171">
 <bp:stepProcess rdf:resource="#BiochemicalReaction139" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep170">
 <bp:stepProcess rdf:resource="#BiochemicalReaction138" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway100">
 <bp:pathwayOrder rdf:resource="#PathwayStep566" />
 <bp:pathwayOrder rdf:resource="#PathwayStep565" />
 <bp:pathwayOrder rdf:resource="#PathwayStep564" />
 <bp:pathwayOrder rdf:resource="#PathwayStep563" />
 <bp:pathwayOrder rdf:resource="#PathwayStep562" />
 <bp:pathwayOrder rdf:resource="#PathwayStep561" />
 <bp:pathwayOrder rdf:resource="#PathwayStep560" />
 <bp:pathwayOrder rdf:resource="#PathwayStep567" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction466" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction468" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction467" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction462" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction461" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction464" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction463" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence560" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway101">
 <bp:pathwayOrder rdf:resource="#PathwayStep587" />
 <bp:pathwayOrder rdf:resource="#PathwayStep586" />
 <bp:pathwayOrder rdf:resource="#PathwayStep585" />
 <bp:pathwayOrder rdf:resource="#PathwayStep584" />
 <bp:pathwayOrder rdf:resource="#PathwayStep572" />
 <bp:pathwayOrder rdf:resource="#PathwayStep571" />
 <bp:pathwayOrder rdf:resource="#PathwayStep570" />
 <bp:pathwayComponent rdf:resource="#Pathway102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction471" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction470" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction484" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction483" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction486" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction485" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence570" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway102">
 <bp:pathwayOrder rdf:resource="#PathwayStep577" />
 <bp:pathwayOrder rdf:resource="#PathwayStep576" />
 <bp:pathwayOrder rdf:resource="#PathwayStep575" />
 <bp:pathwayOrder rdf:resource="#PathwayStep574" />
 <bp:pathwayOrder rdf:resource="#PathwayStep573" />
 <bp:pathwayOrder rdf:resource="#PathwayStep583" />
 <bp:pathwayOrder rdf:resource="#PathwayStep582" />
 <bp:pathwayOrder rdf:resource="#PathwayStep581" />
 <bp:pathwayOrder rdf:resource="#PathwayStep580" />
 <bp:pathwayOrder rdf:resource="#PathwayStep579" />
 <bp:pathwayOrder rdf:resource="#PathwayStep578" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction477" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction476" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction479" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction478" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction480" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction482" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction481" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction473" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction472" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction475" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction474" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence573" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway103">
 <bp:pathwayOrder rdf:resource="#PathwayStep593" />
 <bp:pathwayOrder rdf:resource="#PathwayStep592" />
 <bp:pathwayOrder rdf:resource="#PathwayStep591" />
 <bp:pathwayOrder rdf:resource="#PathwayStep590" />
 <bp:pathwayOrder rdf:resource="#PathwayStep589" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction488" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction487" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction489" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction491" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction490" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence589" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway104">
 <bp:pathwayOrder rdf:resource="#PathwayStep598" />
 <bp:pathwayOrder rdf:resource="#PathwayStep597" />
 <bp:pathwayOrder rdf:resource="#PathwayStep596" />
 <bp:pathwayOrder rdf:resource="#PathwayStep595" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction493" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction492" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction495" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction494" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence595" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway105">
 <bp:pathwayOrder rdf:resource="#PathwayStep686" />
 <bp:pathwayOrder rdf:resource="#PathwayStep601" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction568" />
 <bp:pathwayComponent rdf:resource="#Pathway106" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence601" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 10 (TLR10) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Little is known about TLR10 ligands. It has been established that the receptor homodimerizes upon binding and signals in an MyD88-dependent manner (Hasan U et al 2005; Nyman T et al 2008). It may also heterodimerize with TLRs 1 and 2. It is expressed in a restricted fashion as a highly N-glycosylated protein detectable in B cells and dendritic cells.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep129">
 <bp:stepProcess rdf:resource="#BiochemicalReaction102" />
 <bp:stepProcess rdf:resource="#Catalysis59" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway106">
 <bp:pathwayOrder rdf:resource="#PathwayStep609" />
 <bp:pathwayOrder rdf:resource="#PathwayStep608" />
 <bp:pathwayOrder rdf:resource="#PathwayStep607" />
 <bp:pathwayOrder rdf:resource="#PathwayStep629" />
 <bp:pathwayOrder rdf:resource="#PathwayStep628" />
 <bp:pathwayOrder rdf:resource="#PathwayStep602" />
 <bp:pathwayOrder rdf:resource="#PathwayStep679" />
 <bp:pathwayOrder rdf:resource="#PathwayStep678" />
 <bp:pathwayOrder rdf:resource="#PathwayStep633" />
 <bp:pathwayOrder rdf:resource="#PathwayStep677" />
 <bp:pathwayOrder rdf:resource="#PathwayStep632" />
 <bp:pathwayOrder rdf:resource="#PathwayStep676" />
 <bp:pathwayOrder rdf:resource="#PathwayStep631" />
 <bp:pathwayOrder rdf:resource="#PathwayStep675" />
 <bp:pathwayOrder rdf:resource="#PathwayStep630" />
 <bp:pathwayOrder rdf:resource="#PathwayStep685" />
 <bp:pathwayComponent rdf:resource="#Pathway110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction561" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction560" />
 <bp:pathwayComponent rdf:resource="#Pathway107" />
 <bp:pathwayComponent rdf:resource="#Pathway108" />
 <bp:pathwayComponent rdf:resource="#Pathway119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction521" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction520" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction501" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction567" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction522" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction558" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction502" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction524" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction559" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence602" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 cascade initiated on plasma membrane</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mammalian myeloid differentiation factor 88 (MyD88) is Toll/interleukin (IL)-1 (TIR)-domain containing adapter  protein which plays crucial role in TLR signaling. All TLRs, with only one exception of TLR3, can initiate downstream  signaling trough MyD88. In the MyD88 - dependent pathway, once the adaptor is bound to TLR  it leads to recruitment of IL1 receptor associated kinase family  IRAK which is followed by activation of tumour necrosis factor receptor-associated factor 6 (TRAF6) . TRAF6 is an ubiquitin E3 ligase which in turn induces TGF-beta activating kinase 1 (TAK1) auto phosphorylation. Once activated TAK1 can ultimately mediate the induction of the transcription factor NF-kB or the mitogen-activated protein kinases  (MAPK), such as JNK, p38 and ERK. This results in the translocation of the activated NF-kB and MAPKs to the nucleus and the initiation of appropriate gene transcription leading to the production of many proinflammatory cytokines and antimicrobial peptides.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep128">
 <bp:stepProcess rdf:resource="#Catalysis58" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction101" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway107">
 <bp:pathwayOrder rdf:resource="#PathwayStep606" />
 <bp:pathwayOrder rdf:resource="#PathwayStep605" />
 <bp:pathwayOrder rdf:resource="#PathwayStep604" />
 <bp:pathwayOrder rdf:resource="#PathwayStep603" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction499" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction498" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction500" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction497" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence603" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep127">
 <bp:stepProcess rdf:resource="#Catalysis57" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction100" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway108">
 <bp:pathwayOrder rdf:resource="#PathwayStep610" />
 <bp:pathwayOrder rdf:resource="#PathwayStep627" />
 <bp:pathwayOrder rdf:resource="#PathwayStep626" />
 <bp:pathwayOrder rdf:resource="#PathwayStep625" />
 <bp:pathwayOrder rdf:resource="#PathwayStep624" />
 <bp:pathwayOrder rdf:resource="#PathwayStep612" />
 <bp:pathwayOrder rdf:resource="#PathwayStep611" />
 <bp:pathwayComponent rdf:resource="#Pathway109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction503" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction504" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction518" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction517" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction519" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence610" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep126">
 <bp:stepProcess rdf:resource="#Catalysis56" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction99" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep125">
 <bp:stepProcess rdf:resource="#Pathway28" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep124">
 <bp:stepProcess rdf:resource="#Catalysis55" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction98" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep123">
 <bp:stepProcess rdf:resource="#Pathway27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep122">
 <bp:stepProcess rdf:resource="#Catalysis54" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction97" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep121">
 <bp:stepProcess rdf:resource="#BiochemicalReaction96" />
 <bp:stepProcess rdf:resource="#Catalysis53" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep120">
 <bp:stepProcess rdf:resource="#BiochemicalReaction95" />
 <bp:stepProcess rdf:resource="#Catalysis52" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway110">
 <bp:pathwayOrder rdf:resource="#PathwayStep638" />
 <bp:pathwayOrder rdf:resource="#PathwayStep634" />
 <bp:pathwayOrder rdf:resource="#PathwayStep644" />
 <bp:pathwayOrder rdf:resource="#PathwayStep666" />
 <bp:pathwayComponent rdf:resource="#Pathway111" />
 <bp:pathwayComponent rdf:resource="#Pathway112" />
 <bp:pathwayComponent rdf:resource="#Pathway113" />
 <bp:pathwayComponent rdf:resource="#Pathway118" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence634" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway111">
 <bp:pathwayOrder rdf:resource="#PathwayStep637" />
 <bp:pathwayOrder rdf:resource="#PathwayStep636" />
 <bp:pathwayOrder rdf:resource="#PathwayStep635" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction527" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction526" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence635" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway112">
 <bp:pathwayOrder rdf:resource="#PathwayStep643" />
 <bp:pathwayOrder rdf:resource="#PathwayStep642" />
 <bp:pathwayOrder rdf:resource="#PathwayStep641" />
 <bp:pathwayOrder rdf:resource="#PathwayStep640" />
 <bp:pathwayOrder rdf:resource="#PathwayStep639" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction532" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction531" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction529" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction528" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction530" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence639" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway113">
 <bp:pathwayOrder rdf:resource="#PathwayStep651" />
 <bp:pathwayOrder rdf:resource="#PathwayStep645" />
 <bp:pathwayOrder rdf:resource="#PathwayStep656" />
 <bp:pathwayComponent rdf:resource="#Pathway114" />
 <bp:pathwayComponent rdf:resource="#Pathway115" />
 <bp:pathwayComponent rdf:resource="#Pathway116" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence645" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway114">
 <bp:pathwayOrder rdf:resource="#PathwayStep650" />
 <bp:pathwayOrder rdf:resource="#PathwayStep649" />
 <bp:pathwayOrder rdf:resource="#PathwayStep648" />
 <bp:pathwayOrder rdf:resource="#PathwayStep647" />
 <bp:pathwayOrder rdf:resource="#PathwayStep646" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction534" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction533" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction536" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction535" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction537" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence646" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway115">
 <bp:pathwayOrder rdf:resource="#PathwayStep654" />
 <bp:pathwayOrder rdf:resource="#PathwayStep653" />
 <bp:pathwayOrder rdf:resource="#PathwayStep652" />
 <bp:pathwayOrder rdf:resource="#PathwayStep655" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction538" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction539" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction541" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction540" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence652" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep119">
 <bp:stepProcess rdf:resource="#BiochemicalReaction94" />
 <bp:stepProcess rdf:resource="#Catalysis51" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway116">
 <bp:pathwayOrder rdf:resource="#PathwayStep665" />
 <bp:pathwayOrder rdf:resource="#PathwayStep664" />
 <bp:pathwayOrder rdf:resource="#PathwayStep663" />
 <bp:pathwayOrder rdf:resource="#PathwayStep662" />
 <bp:pathwayOrder rdf:resource="#PathwayStep661" />
 <bp:pathwayOrder rdf:resource="#PathwayStep658" />
 <bp:pathwayOrder rdf:resource="#PathwayStep657" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction542" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction545" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction547" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction546" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction549" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction548" />
 <bp:pathwayComponent rdf:resource="#Pathway117" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence657" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep118">
 <bp:stepProcess rdf:resource="#Pathway26" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway117">
 <bp:pathwayOrder rdf:resource="#PathwayStep660" />
 <bp:pathwayOrder rdf:resource="#PathwayStep659" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction543" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction544" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence659" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep117">
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway118">
 <bp:pathwayOrder rdf:resource="#PathwayStep674" />
 <bp:pathwayOrder rdf:resource="#PathwayStep673" />
 <bp:pathwayOrder rdf:resource="#PathwayStep672" />
 <bp:pathwayOrder rdf:resource="#PathwayStep671" />
 <bp:pathwayOrder rdf:resource="#PathwayStep670" />
 <bp:pathwayOrder rdf:resource="#PathwayStep669" />
 <bp:pathwayOrder rdf:resource="#PathwayStep668" />
 <bp:pathwayOrder rdf:resource="#PathwayStep667" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction554" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction553" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction556" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction555" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction557" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction550" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction551" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence667" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep116">
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
 <bp:stepProcess rdf:resource="#Catalysis50" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway119">
 <bp:pathwayOrder rdf:resource="#PathwayStep684" />
 <bp:pathwayOrder rdf:resource="#PathwayStep683" />
 <bp:pathwayOrder rdf:resource="#PathwayStep682" />
 <bp:pathwayOrder rdf:resource="#PathwayStep681" />
 <bp:pathwayOrder rdf:resource="#PathwayStep680" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction565" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction564" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction566" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction563" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction562" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence680" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep115">
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
 <bp:stepProcess rdf:resource="#Catalysis49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep599">
 <bp:stepProcess rdf:resource="#BiochemicalReaction496" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway109">
 <bp:pathwayOrder rdf:resource="#PathwayStep621" />
 <bp:pathwayOrder rdf:resource="#PathwayStep620" />
 <bp:pathwayOrder rdf:resource="#PathwayStep619" />
 <bp:pathwayOrder rdf:resource="#PathwayStep618" />
 <bp:pathwayOrder rdf:resource="#PathwayStep617" />
 <bp:pathwayOrder rdf:resource="#PathwayStep616" />
 <bp:pathwayOrder rdf:resource="#PathwayStep615" />
 <bp:pathwayOrder rdf:resource="#PathwayStep614" />
 <bp:pathwayOrder rdf:resource="#PathwayStep613" />
 <bp:pathwayOrder rdf:resource="#PathwayStep623" />
 <bp:pathwayOrder rdf:resource="#PathwayStep622" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction510" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction512" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction511" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction514" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction513" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction505" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction515" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction507" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction506" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction509" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction508" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence613" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep114">
 <bp:stepProcess rdf:resource="#Catalysis48" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep598">
 <bp:stepProcess rdf:resource="#BiochemicalReaction495" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep597">
 <bp:stepProcess rdf:resource="#BiochemicalReaction494" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep112">
 <bp:stepProcess rdf:resource="#Pathway25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep596">
 <bp:stepProcess rdf:resource="#BiochemicalReaction493" />
 <bp:stepProcess rdf:resource="#Catalysis237" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep111">
 <bp:stepProcess rdf:resource="#Pathway24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep595">
 <bp:stepProcess rdf:resource="#BiochemicalReaction492" />
 <bp:stepProcess rdf:resource="#Catalysis236" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep110">
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep594">
 <bp:stepProcess rdf:resource="#Pathway104" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep593">
 <bp:stepProcess rdf:resource="#Catalysis235" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction491" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep592">
 <bp:stepProcess rdf:resource="#BiochemicalReaction490" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep591">
 <bp:stepProcess rdf:resource="#Catalysis234" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction489" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep590">
 <bp:stepProcess rdf:resource="#BiochemicalReaction488" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep149">
 <bp:stepProcess rdf:resource="#BiochemicalReaction119" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep148">
 <bp:stepProcess rdf:resource="#BiochemicalReaction118" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep147">
 <bp:stepProcess rdf:resource="#BiochemicalReaction117" />
 <bp:stepProcess rdf:resource="#Catalysis67" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep146">
 <bp:stepProcess rdf:resource="#BiochemicalReaction116" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep145">
 <bp:stepProcess rdf:resource="#Pathway31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep144">
 <bp:stepProcess rdf:resource="#BiochemicalReaction115" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep143">
 <bp:stepProcess rdf:resource="#BiochemicalReaction114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep142">
 <bp:stepProcess rdf:resource="#Pathway30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep141">
 <bp:stepProcess rdf:resource="#BiochemicalReaction113" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep140">
 <bp:stepProcess rdf:resource="#BiochemicalReaction112" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep139">
 <bp:stepProcess rdf:resource="#Catalysis66" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep138">
 <bp:stepProcess rdf:resource="#BiochemicalReaction110" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep137">
 <bp:stepProcess rdf:resource="#BiochemicalReaction109" />
 <bp:stepProcess rdf:resource="#Catalysis65" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep136">
 <bp:stepProcess rdf:resource="#BiochemicalReaction108" />
 <bp:stepProcess rdf:resource="#Catalysis64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep135">
 <bp:stepProcess rdf:resource="#BiochemicalReaction107" />
 <bp:stepProcess rdf:resource="#Catalysis63" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep134">
 <bp:stepProcess rdf:resource="#BiochemicalReaction106" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep133">
 <bp:stepProcess rdf:resource="#Pathway29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep132">
 <bp:stepProcess rdf:resource="#BiochemicalReaction105" />
 <bp:stepProcess rdf:resource="#Catalysis62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep131">
 <bp:stepProcess rdf:resource="#BiochemicalReaction104" />
 <bp:stepProcess rdf:resource="#Catalysis61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep130">
 <bp:stepProcess rdf:resource="#BiochemicalReaction103" />
 <bp:stepProcess rdf:resource="#Catalysis60" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep569">
 <bp:stepProcess rdf:resource="#Pathway101" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep568">
 <bp:stepProcess rdf:resource="#BiochemicalReaction469" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep567">
 <bp:stepProcess rdf:resource="#BiochemicalReaction468" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep566">
 <bp:stepProcess rdf:resource="#BiochemicalReaction467" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep565">
 <bp:stepProcess rdf:resource="#BiochemicalReaction466" />
 <bp:stepProcess rdf:resource="#Catalysis227" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep564">
 <bp:stepProcess rdf:resource="#BiochemicalReaction465" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep563">
 <bp:stepProcess rdf:resource="#Catalysis226" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction464" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep562">
 <bp:stepProcess rdf:resource="#Catalysis225" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction463" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep561">
 <bp:stepProcess rdf:resource="#Catalysis224" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction462" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep560">
 <bp:stepProcess rdf:resource="#BiochemicalReaction461" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep559">
 <bp:stepProcess rdf:resource="#Pathway100" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep558">
 <bp:stepProcess rdf:resource="#Catalysis223" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction460" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep557">
 <bp:stepProcess rdf:resource="#Catalysis222" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction459" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep556">
 <bp:stepProcess rdf:resource="#Catalysis221" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction458" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep555">
 <bp:stepProcess rdf:resource="#BiochemicalReaction457" />
 <bp:stepProcess rdf:resource="#Catalysis220" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep554">
 <bp:stepProcess rdf:resource="#BiochemicalReaction456" />
 <bp:stepProcess rdf:resource="#Catalysis219" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep553">
 <bp:stepProcess rdf:resource="#BiochemicalReaction455" />
 <bp:stepProcess rdf:resource="#Catalysis218" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep552">
 <bp:stepProcess rdf:resource="#BiochemicalReaction454" />
 <bp:stepProcess rdf:resource="#Catalysis217" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep551">
 <bp:stepProcess rdf:resource="#Pathway99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep550">
 <bp:stepProcess rdf:resource="#BiochemicalReaction453" />
 <bp:stepProcess rdf:resource="#Catalysis216" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep109">
 <bp:stepProcess rdf:resource="#Catalysis47" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep108">
 <bp:stepProcess rdf:resource="#Catalysis46" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep107">
 <bp:stepProcess rdf:resource="#Catalysis45" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep106">
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep105">
 <bp:stepProcess rdf:resource="#Pathway23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep589">
 <bp:stepProcess rdf:resource="#BiochemicalReaction487" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
 <bp:stepProcess rdf:resource="#Catalysis44" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence397">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep588">
 <bp:stepProcess rdf:resource="#Pathway103" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
 <bp:stepProcess rdf:resource="#Catalysis43" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence398">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep587">
 <bp:stepProcess rdf:resource="#Catalysis233" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction486" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence395">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep586">
 <bp:stepProcess rdf:resource="#Catalysis232" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction485" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#Pathway22" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence396">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep585">
 <bp:stepProcess rdf:resource="#BiochemicalReaction484" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#Pathway21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep584">
 <bp:stepProcess rdf:resource="#Catalysis231" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction483" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep583">
 <bp:stepProcess rdf:resource="#BiochemicalReaction482" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence399">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep582">
 <bp:stepProcess rdf:resource="#BiochemicalReaction481" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep581">
 <bp:stepProcess rdf:resource="#BiochemicalReaction480" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep580">
 <bp:stepProcess rdf:resource="#BiochemicalReaction479" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence390">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence393">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence394">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence391">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence392">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep579">
 <bp:stepProcess rdf:resource="#BiochemicalReaction478" />
 <bp:stepProcess rdf:resource="#Catalysis230" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep578">
 <bp:stepProcess rdf:resource="#BiochemicalReaction477" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep577">
 <bp:stepProcess rdf:resource="#BiochemicalReaction476" />
 <bp:stepProcess rdf:resource="#Catalysis229" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep576">
 <bp:stepProcess rdf:resource="#BiochemicalReaction475" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep575">
 <bp:stepProcess rdf:resource="#BiochemicalReaction474" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep574">
 <bp:stepProcess rdf:resource="#BiochemicalReaction473" />
 <bp:stepProcess rdf:resource="#Catalysis228" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep573">
 <bp:stepProcess rdf:resource="#BiochemicalReaction472" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep572">
 <bp:stepProcess rdf:resource="#Pathway102" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep571">
 <bp:stepProcess rdf:resource="#BiochemicalReaction471" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep570">
 <bp:stepProcess rdf:resource="#BiochemicalReaction470" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep529">
 <bp:stepProcess rdf:resource="#BiochemicalReaction437" />
 <bp:stepProcess rdf:resource="#Catalysis204" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep528">
 <bp:stepProcess rdf:resource="#BiochemicalReaction436" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep527">
 <bp:stepProcess rdf:resource="#Pathway93" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep526">
 <bp:stepProcess rdf:resource="#Pathway92" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep525">
 <bp:stepProcess rdf:resource="#Pathway91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep524">
 <bp:stepProcess rdf:resource="#BiochemicalReaction435" />
 <bp:stepProcess rdf:resource="#Catalysis203" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep523">
 <bp:stepProcess rdf:resource="#BiochemicalReaction434" />
 <bp:stepProcess rdf:resource="#Catalysis202" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence375">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep522">
 <bp:stepProcess rdf:resource="#BiochemicalReaction433" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence376">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep521">
 <bp:stepProcess rdf:resource="#BiochemicalReaction432" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence373">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep520">
 <bp:stepProcess rdf:resource="#BiochemicalReaction431" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence374">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence379">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence377">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence378">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence371">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence372">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence370">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep519">
 <bp:stepProcess rdf:resource="#Catalysis201" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction430" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep518">
 <bp:stepProcess rdf:resource="#BiochemicalReaction429" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep517">
 <bp:stepProcess rdf:resource="#BiochemicalReaction428" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep516">
 <bp:stepProcess rdf:resource="#BiochemicalReaction427" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep515">
 <bp:stepProcess rdf:resource="#BiochemicalReaction426" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep514">
 <bp:stepProcess rdf:resource="#Pathway90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep513">
 <bp:stepProcess rdf:resource="#Catalysis200" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction425" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep512">
 <bp:stepProcess rdf:resource="#BiochemicalReaction424" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence386">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep511">
 <bp:stepProcess rdf:resource="#BiochemicalReaction423" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence387">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep510">
 <bp:stepProcess rdf:resource="#BiochemicalReaction422" />
 <bp:stepProcess rdf:resource="#Catalysis199" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence384">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence385">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence388">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence389">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence382">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence383">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence380">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence381">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence359">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep549">
 <bp:stepProcess rdf:resource="#Pathway98" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep548">
 <bp:stepProcess rdf:resource="#Catalysis215" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction452" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep547">
 <bp:stepProcess rdf:resource="#BiochemicalReaction451" />
 <bp:stepProcess rdf:resource="#Catalysis214" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep546">
 <bp:stepProcess rdf:resource="#Catalysis213" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction450" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep545">
 <bp:stepProcess rdf:resource="#Catalysis212" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction449" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence353">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep544">
 <bp:stepProcess rdf:resource="#Pathway97" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence354">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep543">
 <bp:stepProcess rdf:resource="#BiochemicalReaction448" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence351">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep542">
 <bp:stepProcess rdf:resource="#Catalysis211" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction447" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence352">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep541">
 <bp:stepProcess rdf:resource="#Catalysis210" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction446" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence357">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep540">
 <bp:stepProcess rdf:resource="#BiochemicalReaction445" />
 <bp:stepProcess rdf:resource="#Catalysis209" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence358">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence355">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence356">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence350">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep539">
 <bp:stepProcess rdf:resource="#BiochemicalReaction444" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep538">
 <bp:stepProcess rdf:resource="#Pathway96" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep537">
 <bp:stepProcess rdf:resource="#Pathway95" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep536">
 <bp:stepProcess rdf:resource="#BiochemicalReaction443" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep535">
 <bp:stepProcess rdf:resource="#Catalysis208" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction442" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep534">
 <bp:stepProcess rdf:resource="#Catalysis207" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction441" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence364">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep533">
 <bp:stepProcess rdf:resource="#BiochemicalReaction440" />
 <bp:stepProcess rdf:resource="#Catalysis206" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence365">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep532">
 <bp:stepProcess rdf:resource="#BiochemicalReaction439" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence362">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep531">
 <bp:stepProcess rdf:resource="#Pathway94" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence363">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep530">
 <bp:stepProcess rdf:resource="#BiochemicalReaction438" />
 <bp:stepProcess rdf:resource="#Catalysis205" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence368">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence369">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence366">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence367">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence360">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence361">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway140">
 <bp:pathwayOrder rdf:resource="#PathwayStep797" />
 <bp:pathwayOrder rdf:resource="#PathwayStep796" />
 <bp:pathwayOrder rdf:resource="#PathwayStep795" />
 <bp:pathwayOrder rdf:resource="#PathwayStep805" />
 <bp:pathwayOrder rdf:resource="#PathwayStep804" />
 <bp:pathwayOrder rdf:resource="#PathwayStep803" />
 <bp:pathwayOrder rdf:resource="#PathwayStep802" />
 <bp:pathwayOrder rdf:resource="#PathwayStep801" />
 <bp:pathwayOrder rdf:resource="#PathwayStep800" />
 <bp:pathwayOrder rdf:resource="#PathwayStep799" />
 <bp:pathwayOrder rdf:resource="#PathwayStep798" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction664" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction663" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction666" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction665" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction657" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction656" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction659" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction658" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction660" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction662" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction661" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence795" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway141">
 <bp:pathwayOrder rdf:resource="#PathwayStep830" />
 <bp:pathwayOrder rdf:resource="#PathwayStep852" />
 <bp:pathwayOrder rdf:resource="#PathwayStep824" />
 <bp:pathwayOrder rdf:resource="#PathwayStep820" />
 <bp:pathwayComponent rdf:resource="#Pathway142" />
 <bp:pathwayComponent rdf:resource="#Pathway143" />
 <bp:pathwayComponent rdf:resource="#Pathway144" />
 <bp:pathwayComponent rdf:resource="#Pathway149" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence820" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway142">
 <bp:pathwayOrder rdf:resource="#PathwayStep823" />
 <bp:pathwayOrder rdf:resource="#PathwayStep822" />
 <bp:pathwayOrder rdf:resource="#PathwayStep821" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction680" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction682" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction681" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence821" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway143">
 <bp:pathwayOrder rdf:resource="#PathwayStep829" />
 <bp:pathwayOrder rdf:resource="#PathwayStep828" />
 <bp:pathwayOrder rdf:resource="#PathwayStep827" />
 <bp:pathwayOrder rdf:resource="#PathwayStep826" />
 <bp:pathwayOrder rdf:resource="#PathwayStep825" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction686" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction685" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction687" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction684" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction683" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence825" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway144">
 <bp:pathwayOrder rdf:resource="#PathwayStep837" />
 <bp:pathwayOrder rdf:resource="#PathwayStep831" />
 <bp:pathwayOrder rdf:resource="#PathwayStep842" />
 <bp:pathwayComponent rdf:resource="#Pathway145" />
 <bp:pathwayComponent rdf:resource="#Pathway146" />
 <bp:pathwayComponent rdf:resource="#Pathway147" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence831" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence339">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway145">
 <bp:pathwayOrder rdf:resource="#PathwayStep836" />
 <bp:pathwayOrder rdf:resource="#PathwayStep835" />
 <bp:pathwayOrder rdf:resource="#PathwayStep834" />
 <bp:pathwayOrder rdf:resource="#PathwayStep833" />
 <bp:pathwayOrder rdf:resource="#PathwayStep832" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction688" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction689" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction691" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction690" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction692" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence832" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway146">
 <bp:pathwayOrder rdf:resource="#PathwayStep841" />
 <bp:pathwayOrder rdf:resource="#PathwayStep840" />
 <bp:pathwayOrder rdf:resource="#PathwayStep839" />
 <bp:pathwayOrder rdf:resource="#PathwayStep838" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction696" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction693" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction695" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction694" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence838" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence337">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway147">
 <bp:pathwayOrder rdf:resource="#PathwayStep851" />
 <bp:pathwayOrder rdf:resource="#PathwayStep850" />
 <bp:pathwayOrder rdf:resource="#PathwayStep849" />
 <bp:pathwayOrder rdf:resource="#PathwayStep848" />
 <bp:pathwayOrder rdf:resource="#PathwayStep847" />
 <bp:pathwayOrder rdf:resource="#PathwayStep844" />
 <bp:pathwayOrder rdf:resource="#PathwayStep843" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction697" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction701" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction700" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction703" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction702" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction704" />
 <bp:pathwayComponent rdf:resource="#Pathway148" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence843" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence338">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway148">
 <bp:pathwayOrder rdf:resource="#PathwayStep846" />
 <bp:pathwayOrder rdf:resource="#PathwayStep845" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction699" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction698" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence845" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway149">
 <bp:pathwayOrder rdf:resource="#PathwayStep860" />
 <bp:pathwayOrder rdf:resource="#PathwayStep859" />
 <bp:pathwayOrder rdf:resource="#PathwayStep858" />
 <bp:pathwayOrder rdf:resource="#PathwayStep857" />
 <bp:pathwayOrder rdf:resource="#PathwayStep856" />
 <bp:pathwayOrder rdf:resource="#PathwayStep855" />
 <bp:pathwayOrder rdf:resource="#PathwayStep854" />
 <bp:pathwayOrder rdf:resource="#PathwayStep853" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction710" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction712" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction711" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction705" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction707" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction706" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction709" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction708" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence853" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence331">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence332">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence330">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence335">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence336">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence333">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence334">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway150">
 <bp:pathwayOrder rdf:resource="#PathwayStep874" />
 <bp:pathwayOrder rdf:resource="#PathwayStep873" />
 <bp:pathwayOrder rdf:resource="#PathwayStep872" />
 <bp:pathwayOrder rdf:resource="#PathwayStep871" />
 <bp:pathwayOrder rdf:resource="#PathwayStep870" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction721" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction723" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction722" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction725" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction724" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence870" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway151">
 <bp:pathwayOrder rdf:resource="#PathwayStep879" />
 <bp:pathwayOrder rdf:resource="#PathwayStep878" />
 <bp:pathwayOrder rdf:resource="#PathwayStep889" />
 <bp:pathwayOrder rdf:resource="#PathwayStep877" />
 <bp:pathwayOrder rdf:resource="#PathwayStep888" />
 <bp:pathwayOrder rdf:resource="#PathwayStep887" />
 <bp:pathwayOrder rdf:resource="#PathwayStep886" />
 <bp:pathwayOrder rdf:resource="#PathwayStep885" />
 <bp:pathwayOrder rdf:resource="#PathwayStep884" />
 <bp:pathwayOrder rdf:resource="#PathwayStep883" />
 <bp:pathwayOrder rdf:resource="#PathwayStep882" />
 <bp:pathwayOrder rdf:resource="#PathwayStep881" />
 <bp:pathwayOrder rdf:resource="#PathwayStep880" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction730" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction732" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction731" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction734" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction733" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction736" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction735" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction727" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction738" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction737" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction729" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction728" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction739" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence877" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of TLR by endogenous ligand</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diverse molecules of host-cell origin may serve as endogenous ligands of Toll-like receptors (TLRs) (Erridge C 2010; Piccinini AM    Midwood KS 2010). These molecules are known as damage-associated molecular patterns (DAMPs). DAMPs are immunologically silent in healthy tissues but become active upon tissue damage during both infectious and sterile insult. DAMPs are released from necrotic cells or secreted from activated cells in response to tissue damage to mediate tissue repair by promoting inflammatory responses. However, DAMPs have also been implicated in the pathogenesis of many inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), cancer, and atherosclerosis. The mechanism underlying the switch from DAMPs that initiate controlled tissue repair, to those that mediate chronic, uncontrolled inflammation is still unclear. Recent evidence suggests that an abnormal increase in protein citrullination is involved in disease pathophysiology (Anzilotti C et al. 2010; Sanchez-Pernaute O et al. 2013; Sokolove J et al. 2011; Sharma P et al. 2012). Citrullination is a post-translational modification event mediated by peptidyl-arginine deaminase enzymes which catalyze the deimination of proteins by converting arginine residues into citrullines in the presence of calcium ions.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence348">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence349">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence342">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence343">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence340">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence341">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence346">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence347">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence344">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence345">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway120">
 <bp:pathwayOrder rdf:resource="#PathwayStep782" />
 <bp:pathwayOrder rdf:resource="#PathwayStep688" />
 <bp:pathwayComponent rdf:resource="#Pathway121" />
 <bp:pathwayComponent rdf:resource="#Pathway136" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence688" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor 2 (TLR2) Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR2 is involved in recognition of peptidoglycan from gram-positive bacteria, bacterial lipoproteins, mycoplasma lipoprotein and mycobacterial products. It is quite possible that recognition of at least some other TLR2 ligands may be assisted by additional accessory proteins, particularly in association with TLR1 or TLR6. TLR2 is expressed constitutively on macrophages, dendritic cells, and B cells, and can be induced in some other cell types, including epithelial cells. TLR1 and TLR6, on the other hand, are expressed almost ubiquitously (Muzio et al. 2000). TLR2 may be a sensor and inductor of specific defense processes, including oxidative stress and cellular necrosis initially spurred by microbial compounds.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway121">
 <bp:pathwayOrder rdf:resource="#PathwayStep781" />
 <bp:pathwayOrder rdf:resource="#PathwayStep690" />
 <bp:pathwayOrder rdf:resource="#PathwayStep689" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction569" />
 <bp:pathwayComponent rdf:resource="#Pathway122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction647" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence689" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor TLR6:TLR2 Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR2 and TLR4 recognize different bacterial cell wall components. While TLR4 is trained onto Gram-negative lipopolysaccharide components, TLR2 - in combination with TLR6 - plays a major role in recognizing peptidoglycan wall products from Gram-positive bacteria, as well as Mycobacterial diacylated lipopeptides. In particular, TLR6 appears to participate in discriminating the subtle differences between dipalmitoyl and tripalmitoyl cysteinyl residues (Okusawa et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep509">
 <bp:stepProcess rdf:resource="#BiochemicalReaction421" />
 <bp:stepProcess rdf:resource="#Catalysis198" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway122">
 <bp:pathwayOrder rdf:resource="#PathwayStep719" />
 <bp:pathwayOrder rdf:resource="#PathwayStep718" />
 <bp:pathwayOrder rdf:resource="#PathwayStep717" />
 <bp:pathwayOrder rdf:resource="#PathwayStep716" />
 <bp:pathwayOrder rdf:resource="#PathwayStep725" />
 <bp:pathwayOrder rdf:resource="#PathwayStep769" />
 <bp:pathwayOrder rdf:resource="#PathwayStep724" />
 <bp:pathwayOrder rdf:resource="#PathwayStep768" />
 <bp:pathwayOrder rdf:resource="#PathwayStep723" />
 <bp:pathwayOrder rdf:resource="#PathwayStep767" />
 <bp:pathwayOrder rdf:resource="#PathwayStep722" />
 <bp:pathwayOrder rdf:resource="#PathwayStep721" />
 <bp:pathwayOrder rdf:resource="#PathwayStep720" />
 <bp:pathwayOrder rdf:resource="#PathwayStep775" />
 <bp:pathwayOrder rdf:resource="#PathwayStep697" />
 <bp:pathwayOrder rdf:resource="#PathwayStep774" />
 <bp:pathwayOrder rdf:resource="#PathwayStep773" />
 <bp:pathwayOrder rdf:resource="#PathwayStep772" />
 <bp:pathwayOrder rdf:resource="#PathwayStep771" />
 <bp:pathwayOrder rdf:resource="#PathwayStep770" />
 <bp:pathwayOrder rdf:resource="#PathwayStep692" />
 <bp:pathwayOrder rdf:resource="#PathwayStep691" />
 <bp:pathwayComponent rdf:resource="#Pathway123" />
 <bp:pathwayComponent rdf:resource="#Pathway124" />
 <bp:pathwayComponent rdf:resource="#Pathway135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction570" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction592" />
 <bp:pathwayComponent rdf:resource="#Pathway126" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction594" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction593" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction596" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction640" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction595" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction598" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction597" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction641" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction600" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction599" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction635" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction634" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction637" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction636" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction639" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction638" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence691" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88:MAL(TIRAP) cascade initiated on plasma membrane</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The first known downstream component of TLR4 and TLR2 signaling is the adaptor MyD88. Another adapter MyD88-adaptor-like (Mal; also known as TIR-domain-containing adaptor protein or TIRAP) has also been described for TLR4 and TLR2 signaling. MyD88 comprises an N-terminal Death Domain (DD) and a C-terminal TIR, whereas Mal lacks the DD. The TIR homotypic interactions bring adapters into contact with the activated TLRs, whereas the DD modules recruit serine/threonine kinases such as interleukin-1-receptor-associated kinase (IRAK). Recruitment of these protein kinases is accompanied by phosphorylation, which in turn results in the interaction of IRAKs with TNF-receptor-associated factor 6 (TRAF6). The oligomerization of TRAF6 activates TAK1, a member of the MAP3-kinase family, and this leads to the activation of the IkB kinases. These kinases, in turn, phosphorylate IkB, leading to its proteolytic degradation and the translocation of NF-kB to the nucleus. Concomitantly, members of the activator protein-1 (AP-1) transcription factor family, Jun and Fos, are activated, and both AP-1 transcription factors and NF-kB are required for cytokine production, which in turn produces downstream inflammatory effects.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence317">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep508">
 <bp:stepProcess rdf:resource="#Pathway89" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway123">
 <bp:pathwayOrder rdf:resource="#PathwayStep696" />
 <bp:pathwayOrder rdf:resource="#PathwayStep695" />
 <bp:pathwayOrder rdf:resource="#PathwayStep694" />
 <bp:pathwayOrder rdf:resource="#PathwayStep693" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction572" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction571" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction574" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction573" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence693" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence318">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep507">
 <bp:stepProcess rdf:resource="#BiochemicalReaction420" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway124">
 <bp:pathwayOrder rdf:resource="#PathwayStep698" />
 <bp:pathwayOrder rdf:resource="#PathwayStep715" />
 <bp:pathwayOrder rdf:resource="#PathwayStep714" />
 <bp:pathwayOrder rdf:resource="#PathwayStep713" />
 <bp:pathwayOrder rdf:resource="#PathwayStep712" />
 <bp:pathwayOrder rdf:resource="#PathwayStep700" />
 <bp:pathwayOrder rdf:resource="#PathwayStep699" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction576" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction575" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction589" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction588" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction590" />
 <bp:pathwayComponent rdf:resource="#Pathway125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction591" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence698" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence315">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep506">
 <bp:stepProcess rdf:resource="#BiochemicalReaction419" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway125">
 <bp:pathwayOrder rdf:resource="#PathwayStep709" />
 <bp:pathwayOrder rdf:resource="#PathwayStep708" />
 <bp:pathwayOrder rdf:resource="#PathwayStep707" />
 <bp:pathwayOrder rdf:resource="#PathwayStep706" />
 <bp:pathwayOrder rdf:resource="#PathwayStep705" />
 <bp:pathwayOrder rdf:resource="#PathwayStep704" />
 <bp:pathwayOrder rdf:resource="#PathwayStep703" />
 <bp:pathwayOrder rdf:resource="#PathwayStep702" />
 <bp:pathwayOrder rdf:resource="#PathwayStep701" />
 <bp:pathwayOrder rdf:resource="#PathwayStep711" />
 <bp:pathwayOrder rdf:resource="#PathwayStep710" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction587" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction586" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction578" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction577" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction579" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction581" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction580" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction583" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction582" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction585" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction584" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence701" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence799">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence316">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep505">
 <bp:stepProcess rdf:resource="#BiochemicalReaction418" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway126">
 <bp:pathwayOrder rdf:resource="#PathwayStep730" />
 <bp:pathwayOrder rdf:resource="#PathwayStep726" />
 <bp:pathwayOrder rdf:resource="#PathwayStep736" />
 <bp:pathwayOrder rdf:resource="#PathwayStep758" />
 <bp:pathwayComponent rdf:resource="#Pathway134" />
 <bp:pathwayComponent rdf:resource="#Pathway127" />
 <bp:pathwayComponent rdf:resource="#Pathway128" />
 <bp:pathwayComponent rdf:resource="#Pathway129" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence726" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP kinase activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).  There are three major groups of MAP kinases  the extracellular signal-regulated protein kinases ERK1/2,  the p38 MAP kinase  and the c-Jun NH-terminal kinases JNK.  ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the  tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK. The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep504">
 <bp:stepProcess rdf:resource="#BiochemicalReaction417" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway127">
 <bp:pathwayOrder rdf:resource="#PathwayStep729" />
 <bp:pathwayOrder rdf:resource="#PathwayStep728" />
 <bp:pathwayOrder rdf:resource="#PathwayStep727" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction602" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction601" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction603" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence727" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-Jun NH2 terminal kinases (JNKs) are an evolutionarily conserved family of serine/threonine protein kinases, that belong to mitogen activated protein kinase family (MAPKs - also known as stress-activated protein kinases, SAPKs). The JNK pathway is activated by heat shock, or inflammatory cytokines, or UV radiation.  The JNKs are encoded by at least three genes: JNK1/SAPK-gamma, JNK2/SAPK-alpha and JNK3/ SAPK-beta. The first two are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain and to a lesser extent in heart and testes. As a result of alternative gene splicing all cells express distinct active forms of JNK from 46 to 55 kDa in size. Sequence alignment of these different products shows homologies of &gt;80%. In spite of this similarity, the multiple JNK isoforms differ in their ability to bind and phosphorylate different target proteins, thus leading to the distinctive cellular processes: induction of apoptosis, or enhancment of cell survival, or proliferation. Activation of JNKs is mediated by activated TAK1 which phosphorylates two dual specificity enzymes MKK4 (MAPK kinase 4) and MKK7(MAPK kinase 7).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep503">
 <bp:stepProcess rdf:resource="#BiochemicalReaction416" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway128">
 <bp:pathwayOrder rdf:resource="#PathwayStep731" />
 <bp:pathwayOrder rdf:resource="#PathwayStep735" />
 <bp:pathwayOrder rdf:resource="#PathwayStep734" />
 <bp:pathwayOrder rdf:resource="#PathwayStep733" />
 <bp:pathwayOrder rdf:resource="#PathwayStep732" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction604" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction606" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction605" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction608" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction607" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence731" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated TAK1 mediates p38 MAPK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38 mitogen-activated protein kinase (MAPK) belongs to a highly conserved family of serine/threonine protein kinases.  The p38 MAPK-dependent signaling cascade is activated by pro-inflammatory or stressful stimuli such as ultraviolet radiation, oxidative injury, heat shock, cytokines, and other pro-inflammatory stimuli. p38 MAPK exists as four isoforms (alpha, beta, gamma, and delta). Of these, p38alpha and p38beta are ubiquitously expressed while p38gamma and p38delta are differentially expressed depending on tissue type. Each isoform is activated by upstream kinases including MAP kinase kinases (MKK) 3, 4, and 6, which in turn are phosphorylated by activated  TAK1 at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops. Once p38 MAPK is phosphorylated it activates numerous downstream substrates, including MAPK-activated protein kinase-2  and 3 (MAPKAPK-2 or 3) and mitogen and stress-activated kinase-1/2 (MSK1/2). MAPKAPK-2/3 and MSK1/2 function to phosphorylate heat shock protein 27 (HSP27) and cAMP-response element binding protein transcriptional factor, respectively. Other transcription factors, including activating transcription factor 2, Elk, CHOP/GADD153, and myocyte enhancer factor 2, are known to be regulated by these kinases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence319">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep502">
 <bp:stepProcess rdf:resource="#BiochemicalReaction415" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway129">
 <bp:pathwayOrder rdf:resource="#PathwayStep737" />
 <bp:pathwayOrder rdf:resource="#PathwayStep748" />
 <bp:pathwayOrder rdf:resource="#PathwayStep743" />
 <bp:pathwayComponent rdf:resource="#Pathway130" />
 <bp:pathwayComponent rdf:resource="#Pathway131" />
 <bp:pathwayComponent rdf:resource="#Pathway132" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence737" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK targets/ Nuclear events mediated by MAP kinases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.   The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and  also AP-1 components c-Jun and c-Fos.  Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.  Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).  JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK.  Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep501">
 <bp:stepProcess rdf:resource="#BiochemicalReaction414" />
 <bp:stepProcess rdf:resource="#Catalysis197" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep500">
 <bp:stepProcess rdf:resource="#BiochemicalReaction413" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence793">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence310">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence794">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence791">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence792">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence313">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence797">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence314">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence798">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence311">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence795">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence312">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence796">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence790">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway130">
 <bp:pathwayOrder rdf:resource="#PathwayStep742" />
 <bp:pathwayOrder rdf:resource="#PathwayStep741" />
 <bp:pathwayOrder rdf:resource="#PathwayStep740" />
 <bp:pathwayOrder rdf:resource="#PathwayStep739" />
 <bp:pathwayOrder rdf:resource="#PathwayStep738" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction611" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction610" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction613" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction612" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction609" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence738" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the AP-1 family of transcription factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activator protein-1 (AP-1) is a collective term referring to a group of transcription factors that bind to promoters of target genes in a sequence-specific manner. AP-1 family consists of hetero- and homodimers of bZIP (basic region leucine zipper) proteins, mainly of Jun-Jun, Jun-Fos or Jun-ATF.  AP-1 members are involved in the regulation of a number of cellular processes including cell growth, proliferation, survival, apoptosis, differentiation, cell migration. The ability of a single transcription factor to determine a cell fate critically depends on the relative abundance of AP-1 subunits, the composition of AP-1 dimers, the quality of stimulus, the cell type, the co-factor assembly.   AP-1 activity is regulated on multiple levels; transcriptional, translational and post-translational control mechanisms contribute to the balanced production of AP-1 proteins and their functions. Briefly, regulation occurs through:  effects on jun, fos, atf gene transcription and mRNA turnover.  AP-1 protein members turnover.  post-translational modifications of AP-1 proteins that modulate their transactivation potential (effect of protein kinases or phosphatases). interactions with other transcription factors that can either induce or interfere with AP-1 activity. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway131">
 <bp:pathwayOrder rdf:resource="#PathwayStep747" />
 <bp:pathwayOrder rdf:resource="#PathwayStep746" />
 <bp:pathwayOrder rdf:resource="#PathwayStep745" />
 <bp:pathwayOrder rdf:resource="#PathwayStep744" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction615" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction614" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction617" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction616" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence744" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB phosphorylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nerve growth factor (NGF) activates multiple signalling pathways that mediate the phosphorylation of CREB at the critical regulatory site, serine 133. CREB phosphorylation at serine 133 is a crucial event in neurotrophin signalling, being mediated by ERK/RSK, ERK/MSK1 and p38/MAPKAPK2 pathways. Several kinases, such as MSK1, RSK1/2/3 (MAPKAPK1A/B/C), and MAPKAPK2, are able to directly phosphorylate CREB at S133. MSK1 is also able to activate ATF (Cyclic-AMP-dependent transcription factor). However, the NGF-induced CREB phosphorylation appears to correlate better with activation of MSK1 rather than RSK1/2/3, or MAPKAPK2. In retrograde signalling, activation of CREB occurs within 20 minutes after neurotrophin stimulation of distal axons.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway132">
 <bp:pathwayOrder rdf:resource="#PathwayStep753" />
 <bp:pathwayOrder rdf:resource="#PathwayStep750" />
 <bp:pathwayOrder rdf:resource="#PathwayStep749" />
 <bp:pathwayOrder rdf:resource="#PathwayStep757" />
 <bp:pathwayOrder rdf:resource="#PathwayStep756" />
 <bp:pathwayOrder rdf:resource="#PathwayStep755" />
 <bp:pathwayOrder rdf:resource="#PathwayStep754" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction622" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction621" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction624" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction623" />
 <bp:pathwayComponent rdf:resource="#Pathway133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction625" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction618" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence749" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK targets</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK/MAPK kinases have a number of targets within the nucleus, usually transcription factors or other kinases. The best known targets, ELK1, ETS1, ATF2, MITF, MAPKAPK2, MSK1, RSK1/2/3 and MEF2 are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway133">
 <bp:pathwayOrder rdf:resource="#PathwayStep752" />
 <bp:pathwayOrder rdf:resource="#PathwayStep751" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction620" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction619" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence751" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP Kinases are inactivated by a family of protein named MAP Kinase Phosphatases (MKPs). They act through dephosphorylation of threonine and/or tyrosine residues within the signature sequence -pTXpY- located in the activation loop of MAP kinases (pT=phosphothreonine and pY=phosphotyrosine). MKPs are divided into three major categories depending on their preference for dephosphorylating; tyrosine, serine/threonine and both the tyrosine and threonine (dual specificity phoshatases or DUSPs). The tyrosine-specific MKPs include PTP-SL, STEP  and HePTP, serine/threonine-specific MKPs are PP2A and PP2C, and many DUSPs acting on MAPKs are known. Activated MAP kinases trigger activation of transcription of MKP genes. Therefore, MKPs provide a negative feedback regulatory mechanism on MAPK signaling, by inactivating MAPKs via dephosphorylation, in the cytoplasm and the nucleus. Some MKPs are more specific for ERKs, others for JNK or p38MAPK.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence328">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway134">
 <bp:pathwayOrder rdf:resource="#PathwayStep764" />
 <bp:pathwayOrder rdf:resource="#PathwayStep763" />
 <bp:pathwayOrder rdf:resource="#PathwayStep762" />
 <bp:pathwayOrder rdf:resource="#PathwayStep761" />
 <bp:pathwayOrder rdf:resource="#PathwayStep760" />
 <bp:pathwayOrder rdf:resource="#PathwayStep759" />
 <bp:pathwayOrder rdf:resource="#PathwayStep766" />
 <bp:pathwayOrder rdf:resource="#PathwayStep765" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction631" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction630" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction633" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction632" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction626" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction628" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction627" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction629" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence759" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence329">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway135">
 <bp:pathwayOrder rdf:resource="#PathwayStep780" />
 <bp:pathwayOrder rdf:resource="#PathwayStep779" />
 <bp:pathwayOrder rdf:resource="#PathwayStep778" />
 <bp:pathwayOrder rdf:resource="#PathwayStep777" />
 <bp:pathwayOrder rdf:resource="#PathwayStep776" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction642" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction644" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction643" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction646" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction645" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence776" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 mediated activation of TAK1 complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although IRAK-1 was originally thought to be a key mediator of TRAF6 activation in the IL1R/TLR signaling (Dong W et al. 2006), recent studies showed that IRAK-2, but not IRAK-1, led to TRAF6 polyubiquitination (Keating SE et al 2007). IRAK-2 loss-of-function mutants, with mutated TRAF6-binding motifs, could no longer activate NF-kB and could no longer stimulate TRAF-6 ubiquitination (Keating SE et al 2007). Furthermore, the proxyvirus protein A52 - an inhibitor of all IL-1R/TLR pathways to NF-kB activation, was found to interact with both IRAK-2 and TRAF6, but not IRAK-1. Further work showed that A52 inhibits IRAK-2 functions, whereas association with TRAF6 results in A52-induced MAPK activation. The strong inhibition effect of A52 was also observed on the TLR3-NFkB axis and this observation led to the discovery that IRAK-2 is recruited to TLR3 to activate NF-kB (Keating SE et al 2007). Thus, A52 possibly inhibits MyD88-independent TLR3 pathways to NF-kB  via targeting IRAK-2 as it does for other IL-1R/TLR pathways, although it remains unclear how IRAK-2 is involved in TLR3 signaling. IRAK-2 was shown to have two TRAF6 binding motifs that are responsible for initiating TRAF6 signaling transduction (Ye H et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence326">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway136">
 <bp:pathwayOrder rdf:resource="#PathwayStep784" />
 <bp:pathwayOrder rdf:resource="#PathwayStep783" />
 <bp:pathwayOrder rdf:resource="#PathwayStep875" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction648" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction726" />
 <bp:pathwayComponent rdf:resource="#Pathway137" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence783" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll Like Receptor TLR1:TLR2 Cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR1 is expressed by monocytes. TLR1 and TLR2 cotranslationally form heterodimeric complexes on the cell surface and in the cytosol. The TLR2:TLR1 complex recognizes Neisserial PorB and Mycobacterial triacylated lipoproteins and peptides, amongst others, triggering up-regulation of nuclear factor-kappaB production and apoptotic cascades. Such cooperation between TLR1 and TLR2 on the cell surface of normal human peripheral blood mononuclear cells, for instance, leads to the activation of pro-inflammatory cytokine secretion (Sandor et al. 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence327">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway137">
 <bp:pathwayOrder rdf:resource="#PathwayStep819" />
 <bp:pathwayOrder rdf:resource="#PathwayStep818" />
 <bp:pathwayOrder rdf:resource="#PathwayStep817" />
 <bp:pathwayOrder rdf:resource="#PathwayStep816" />
 <bp:pathwayOrder rdf:resource="#PathwayStep815" />
 <bp:pathwayOrder rdf:resource="#PathwayStep814" />
 <bp:pathwayOrder rdf:resource="#PathwayStep869" />
 <bp:pathwayOrder rdf:resource="#PathwayStep813" />
 <bp:pathwayOrder rdf:resource="#PathwayStep868" />
 <bp:pathwayOrder rdf:resource="#PathwayStep812" />
 <bp:pathwayOrder rdf:resource="#PathwayStep867" />
 <bp:pathwayOrder rdf:resource="#PathwayStep811" />
 <bp:pathwayOrder rdf:resource="#PathwayStep866" />
 <bp:pathwayOrder rdf:resource="#PathwayStep810" />
 <bp:pathwayOrder rdf:resource="#PathwayStep865" />
 <bp:pathwayOrder rdf:resource="#PathwayStep864" />
 <bp:pathwayOrder rdf:resource="#PathwayStep786" />
 <bp:pathwayOrder rdf:resource="#PathwayStep863" />
 <bp:pathwayOrder rdf:resource="#PathwayStep785" />
 <bp:pathwayOrder rdf:resource="#PathwayStep862" />
 <bp:pathwayOrder rdf:resource="#PathwayStep861" />
 <bp:pathwayOrder rdf:resource="#PathwayStep791" />
 <bp:pathwayComponent rdf:resource="#Pathway150" />
 <bp:pathwayComponent rdf:resource="#Pathway141" />
 <bp:pathwayComponent rdf:resource="#Pathway138" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction671" />
 <bp:pathwayComponent rdf:resource="#Pathway139" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction673" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction672" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction675" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction674" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction677" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction676" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction720" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction679" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction678" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction714" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction713" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction716" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction649" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction715" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction718" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction717" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction719" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence785" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88:MAL(TIRAP) cascade initiated on plasma membrane</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The first known downstream component of TLR4 and TLR2 signaling is the adaptor MyD88. Another adapter MyD88-adaptor-like (Mal; also known as TIR-domain-containing adaptor protein or TIRAP) has also been described for TLR4 and TLR2 signaling. MyD88 comprises an N-terminal Death Domain (DD) and a C-terminal TIR, whereas Mal lacks the DD. The TIR homotypic interactions bring adapters into contact with the activated TLRs, whereas the DD modules recruit serine/threonine kinases such as interleukin-1-receptor-associated kinase (IRAK). Recruitment of these protein kinases is accompanied by phosphorylation, which in turn results in the interaction of IRAKs with TNF-receptor-associated factor 6 (TRAF6). The oligomerization of TRAF6 activates TAK1, a member of the MAP3-kinase family, and this leads to the activation of the IkB kinases. These kinases, in turn, phosphorylate IkB, leading to its proteolytic degradation and the translocation of NF-kB to the nucleus. Concomitantly, members of the activator protein-1 (AP-1) transcription factor family, Jun and Fos, are activated, and both AP-1 transcription factors and NF-kB are required for cytokine production, which in turn produces downstream inflammatory effects.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway138">
 <bp:pathwayOrder rdf:resource="#PathwayStep790" />
 <bp:pathwayOrder rdf:resource="#PathwayStep789" />
 <bp:pathwayOrder rdf:resource="#PathwayStep788" />
 <bp:pathwayOrder rdf:resource="#PathwayStep787" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction653" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction652" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction651" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction650" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence787" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 recruits IKK complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of IRAK1 kinase activity in the activation of NF-kappa-B by IL-1/TLR  is still uncertain. It has been shown that a kinase-dead IRAK1 mutants can still activate NF-kappa-B. Furthermore, stimulation of IRAK1-deficient I1A 293 cells with LMP1 (latent membrane protein 1- a known viral activator of NF-kappa-B) leads to TRAF6 polyubiquitination and IKKbeta activation [Song et al 2006]. On the other hand, IRAK1 enhances p65 Ser536 phosphorylation [Song et al 2006] and p65 binding to the promoter of NF-kappa-B dependent target genes [Liu G et al 2008].  IRAK1 has also been shown to be itself Lys63-polyubiquitinated (probably by Pellino proteins, which have E3 ligase activity). Mutation of the ubiquitination sites on IRAK1 prevented interaction with the NEMO subunit of IKK complex and subsequent IL-1/TLR-induced NF-kappa-B activation [Conze et al 2008]. These data suggest that kinase activity of IRAK1 is not essential for its ability to activate NF-kappa-B, while its Lys63-polyubuquitination allows IRAK1 to bind NEMO thus facilitating association of TRAF6 and TAK1 complex with IKK complex followed by induction of NF-kappa-B.   Upon IL-1/TLR stimulation IRAK1 protein can undergo covalent modifications including phosphorylation [Kollewe et al 2004], ubiquitination [Conze DB et al 2008] and sumoylation [Huang et al 2004]. Depending upon the nature of its modification, IRAK1 may perform distinct functions including activation of IRF5/7 [Uematsu et al 2005, Schoenemeyer et al 2005], NF-kappa-B [Song et al 2006], and Stat1/3 [Huang et al 2004, Nguyen et al 2003].</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway139">
 <bp:pathwayOrder rdf:resource="#PathwayStep794" />
 <bp:pathwayOrder rdf:resource="#PathwayStep793" />
 <bp:pathwayOrder rdf:resource="#PathwayStep809" />
 <bp:pathwayOrder rdf:resource="#PathwayStep792" />
 <bp:pathwayOrder rdf:resource="#PathwayStep808" />
 <bp:pathwayOrder rdf:resource="#PathwayStep807" />
 <bp:pathwayOrder rdf:resource="#PathwayStep806" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction655" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction654" />
 <bp:pathwayComponent rdf:resource="#Pathway140" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction668" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction667" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction669" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction670" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence792" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence320">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence321">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence324">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence325">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence322">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence323">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence779">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence777">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence778">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction420">
 <bp:evidence rdf:resource="#Evidence508" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Engulfed CpG DNA binds to endosomal full-length TLR9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction411">
 <bp:evidence rdf:resource="#Evidence499" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TASL is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence771">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction410">
 <bp:evidence rdf:resource="#Evidence497" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rab5-mediated recruitment of class III PI3K to TLR9</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence772">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction413">
 <bp:evidence rdf:resource="#Evidence501" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TASL recruits IRF5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction412">
 <bp:evidence rdf:resource="#Evidence500" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of p-S446-IRF5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence770">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction415">
 <bp:evidence rdf:resource="#Evidence503" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC15A4 binds TASL</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence775">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction414">
 <bp:evidence rdf:resource="#Evidence502" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated IKBKB phosphorylates IRF5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence776">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction417">
 <bp:evidence rdf:resource="#Evidence505" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Engulfed CpG DNA binds to endosomal N-ter TLR9 dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence773">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction416">
 <bp:evidence rdf:resource="#Evidence504" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-S446-IRF5 dimer translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence774">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction419">
 <bp:evidence rdf:resource="#Evidence507" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR9 dimer binds HCQ</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction418">
 <bp:evidence rdf:resource="#Evidence506" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Engulfed CpG DNA binds to endosomal C-ter TLR9</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence306">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence307">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence304">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence788">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence305">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence789">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence308">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence309">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction400">
 <bp:evidence rdf:resource="#Evidence485" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization initiated from endosomal compartments</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence782">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence783">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction402">
 <bp:evidence rdf:resource="#Evidence487" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2 at endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence780">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction401">
 <bp:evidence rdf:resource="#Evidence486" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex upon TLR7/8 or 9 stimulation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence781">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence302">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction404">
 <bp:evidence rdf:resource="#Evidence489" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains upon TLR stimulation </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence786">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence303">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction403">
 <bp:evidence rdf:resource="#Evidence488" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3  upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence787">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence300">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction406">
 <bp:evidence rdf:resource="#Evidence492" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1 upon TLR7/8 or 9 activation&lt;br&gt;</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence784">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence301">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction405">
 <bp:evidence rdf:resource="#Evidence491" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino upon TLR7/8 or 9 activation </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence785">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction408">
 <bp:evidence rdf:resource="#Evidence494" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1 upon stimulation of TLR7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction407">
 <bp:evidence rdf:resource="#Evidence493" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6 upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction409">
 <bp:evidence rdf:resource="#Evidence495" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep709">
 <bp:stepProcess rdf:resource="#BiochemicalReaction585" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep708">
 <bp:stepProcess rdf:resource="#BiochemicalReaction584" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep707">
 <bp:stepProcess rdf:resource="#Catalysis282" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction583" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep706">
 <bp:stepProcess rdf:resource="#BiochemicalReaction582" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence757">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep705">
 <bp:stepProcess rdf:resource="#BiochemicalReaction581" />
 <bp:stepProcess rdf:resource="#Catalysis281" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence758">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep704">
 <bp:stepProcess rdf:resource="#BiochemicalReaction580" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence755">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep703">
 <bp:stepProcess rdf:resource="#BiochemicalReaction579" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence756">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep702">
 <bp:stepProcess rdf:resource="#BiochemicalReaction578" />
 <bp:stepProcess rdf:resource="#Catalysis280" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep701">
 <bp:stepProcess rdf:resource="#BiochemicalReaction577" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep700">
 <bp:stepProcess rdf:resource="#Pathway125" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence759">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence750">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence753">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence754">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence751">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence752">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence768">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence769">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence766">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence767">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence760">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence761">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence764">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence765">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence762">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence763">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence735">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence736">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence733">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence734">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence739">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence737">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence738">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence731">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence732">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence730">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence746">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence747">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence744">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence745">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence748">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence749">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence742">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence743">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence740">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence741">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence719">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence713">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence714">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence711">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence712">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence717">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence718">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence715">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence716">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence710">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence724">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence725">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence722">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence723">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence728">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence729">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence726">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence727">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence720">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence721">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction499">
 <bp:evidence rdf:resource="#Evidence606" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction498">
 <bp:evidence rdf:resource="#Evidence605" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence708">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence709">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction491">
 <bp:evidence rdf:resource="#Evidence594" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains upon TLR stimulation </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence702">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction490">
 <bp:evidence rdf:resource="#Evidence593" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3  upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence703">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction493">
 <bp:evidence rdf:resource="#Evidence597" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1 upon TLR7/8 or 9 activation&lt;br&gt;</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence700">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction492">
 <bp:evidence rdf:resource="#Evidence596" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino upon TLR7/8 or 9 activation </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence701">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction495">
 <bp:evidence rdf:resource="#Evidence599" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1 upon stimulation of TLR7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence706">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction494">
 <bp:evidence rdf:resource="#Evidence598" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6 upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence707">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction497">
 <bp:evidence rdf:resource="#Evidence604" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino binds hp-IRAK1:TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence704">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction496">
 <bp:evidence rdf:resource="#Evidence600" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence705">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction488">
 <bp:evidence rdf:resource="#Evidence591" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex upon TLR7/8 or 9 stimulation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction487">
 <bp:evidence rdf:resource="#Evidence590" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization initiated from endosomal compartments</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction489">
 <bp:evidence rdf:resource="#Evidence592" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2 at endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction480">
 <bp:evidence rdf:resource="#Evidence582" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction482">
 <bp:evidence rdf:resource="#Evidence584" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction481">
 <bp:evidence rdf:resource="#Evidence583" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction484">
 <bp:evidence rdf:resource="#Evidence586" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction483">
 <bp:evidence rdf:resource="#Evidence585" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction486">
 <bp:evidence rdf:resource="#Evidence588" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction485">
 <bp:evidence rdf:resource="#Evidence587" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction477">
 <bp:evidence rdf:resource="#Evidence579" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction476">
 <bp:evidence rdf:resource="#Evidence578" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction479">
 <bp:evidence rdf:resource="#Evidence581" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction478">
 <bp:evidence rdf:resource="#Evidence580" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction471">
 <bp:evidence rdf:resource="#Evidence572" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction470">
 <bp:evidence rdf:resource="#Evidence571" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction473">
 <bp:evidence rdf:resource="#Evidence575" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction472">
 <bp:evidence rdf:resource="#Evidence574" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction475">
 <bp:evidence rdf:resource="#Evidence577" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction474">
 <bp:evidence rdf:resource="#Evidence576" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction466">
 <bp:evidence rdf:resource="#Evidence566" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction465">
 <bp:evidence rdf:resource="#Evidence565" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction468">
 <bp:evidence rdf:resource="#Evidence568" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction467">
 <bp:evidence rdf:resource="#Evidence567" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction469">
 <bp:evidence rdf:resource="#Evidence569" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1/or IRAK2:TRAF6-oligomer from the p-IRAK4 :oligo-Myd88:activated TLR7/8 or 9 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction460">
 <bp:evidence rdf:resource="#Evidence559" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction462">
 <bp:evidence rdf:resource="#Evidence562" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction461">
 <bp:evidence rdf:resource="#Evidence561" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction464">
 <bp:evidence rdf:resource="#Evidence564" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction463">
 <bp:evidence rdf:resource="#Evidence563" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis100">
 <bp:controlled rdf:resource="#BiochemicalReaction204" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction455">
 <bp:evidence rdf:resource="#Evidence554" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis101">
 <bp:controlled rdf:resource="#BiochemicalReaction206" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction454">
 <bp:evidence rdf:resource="#Evidence553" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis102">
 <bp:controlled rdf:resource="#BiochemicalReaction207" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep289">
 <bp:stepProcess rdf:resource="#BiochemicalReaction239" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction457">
 <bp:evidence rdf:resource="#Evidence556" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis103">
 <bp:controlled rdf:resource="#BiochemicalReaction208" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep288">
 <bp:stepProcess rdf:resource="#BiochemicalReaction238" />
 <bp:stepProcess rdf:resource="#Catalysis119" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction456">
 <bp:evidence rdf:resource="#Evidence555" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep287">
 <bp:stepProcess rdf:resource="#BiochemicalReaction237" />
 <bp:stepProcess rdf:resource="#Catalysis118" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction459">
 <bp:evidence rdf:resource="#Evidence558" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep286">
 <bp:stepProcess rdf:resource="#BiochemicalReaction236" />
 <bp:stepProcess rdf:resource="#Catalysis117" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction458">
 <bp:evidence rdf:resource="#Evidence557" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep285">
 <bp:stepProcess rdf:resource="#BiochemicalReaction235" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep284">
 <bp:stepProcess rdf:resource="#BiochemicalReaction234" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep283">
 <bp:stepProcess rdf:resource="#Pathway51" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep282">
 <bp:stepProcess rdf:resource="#BiochemicalReaction233" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep281">
 <bp:stepProcess rdf:resource="#BiochemicalReaction232" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep280">
 <bp:stepProcess rdf:resource="#BiochemicalReaction231" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis108">
 <bp:controlled rdf:resource="#BiochemicalReaction213" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis109">
 <bp:controlled rdf:resource="#BiochemicalReaction214" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis104">
 <bp:controlled rdf:resource="#BiochemicalReaction209" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction451">
 <bp:evidence rdf:resource="#Evidence548" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis105">
 <bp:controlled rdf:resource="#BiochemicalReaction210" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction450">
 <bp:evidence rdf:resource="#Evidence547" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis106">
 <bp:controlled rdf:resource="#BiochemicalReaction211" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction453">
 <bp:evidence rdf:resource="#Evidence551" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis107">
 <bp:controlled rdf:resource="#BiochemicalReaction212" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction452">
 <bp:evidence rdf:resource="#Evidence549" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis111">
 <bp:controlled rdf:resource="#BiochemicalReaction216" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction444">
 <bp:evidence rdf:resource="#Evidence540" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis112">
 <bp:controlled rdf:resource="#BiochemicalReaction217" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep279">
 <bp:stepProcess rdf:resource="#BiochemicalReaction230" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction443">
 <bp:evidence rdf:resource="#Evidence537" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis113">
 <bp:controlled rdf:resource="#BiochemicalReaction219" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep278">
 <bp:stepProcess rdf:resource="#BiochemicalReaction229" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction446">
 <bp:evidence rdf:resource="#Evidence542" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis114">
 <bp:controlled rdf:resource="#BiochemicalReaction220" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep277">
 <bp:stepProcess rdf:resource="#BiochemicalReaction228" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction445">
 <bp:evidence rdf:resource="#Evidence541" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep276">
 <bp:stepProcess rdf:resource="#BiochemicalReaction227" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction448">
 <bp:evidence rdf:resource="#Evidence544" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep275">
 <bp:stepProcess rdf:resource="#BiochemicalReaction226" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction447">
 <bp:evidence rdf:resource="#Evidence543" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep274">
 <bp:stepProcess rdf:resource="#BiochemicalReaction225" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis110">
 <bp:controlled rdf:resource="#BiochemicalReaction215" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep273">
 <bp:stepProcess rdf:resource="#BiochemicalReaction224" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction449">
 <bp:evidence rdf:resource="#Evidence546" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep272">
 <bp:stepProcess rdf:resource="#BiochemicalReaction223" />
 <bp:stepProcess rdf:resource="#Catalysis116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep271">
 <bp:stepProcess rdf:resource="#BiochemicalReaction222" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep270">
 <bp:stepProcess rdf:resource="#Catalysis115" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction221" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction440">
 <bp:evidence rdf:resource="#Evidence534" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction442">
 <bp:evidence rdf:resource="#Evidence536" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction441">
 <bp:evidence rdf:resource="#Evidence535" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction433">
 <bp:evidence rdf:resource="#Evidence523" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to the activated TLR7/8 or 9 receptor:MyD88 complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction432">
 <bp:evidence rdf:resource="#Evidence522" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1/or p-IRAK2:p-IRAK4:MyD88:activated TLR7/8 or 9  </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction435">
 <bp:evidence rdf:resource="#Evidence525" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation in the complex with MyD88:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction434">
 <bp:evidence rdf:resource="#Evidence524" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation steps within the complex pIRAK4:MyD88:activated TLR7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction437">
 <bp:evidence rdf:resource="#Evidence530" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction436">
 <bp:evidence rdf:resource="#Evidence529" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction439">
 <bp:evidence rdf:resource="#Evidence533" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction438">
 <bp:evidence rdf:resource="#Evidence531" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction431">
 <bp:evidence rdf:resource="#Evidence521" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 interacts with the activated TLR receptor 7, 8 or 9 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction430">
 <bp:evidence rdf:resource="#Evidence520" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 ubiquitinqtes IRF7 within the activated TLR7/8 or 9 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction422">
 <bp:evidence rdf:resource="#Evidence511" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to MyD88:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction421">
 <bp:evidence rdf:resource="#Evidence510" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to MyD88: activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction424">
 <bp:evidence rdf:resource="#Evidence513" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1/or IRAK2 binds to the activated IRAK4 :MyD88:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep299">
 <bp:stepProcess rdf:resource="#BiochemicalReaction246" />
 <bp:stepProcess rdf:resource="#Catalysis121" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction423">
 <bp:evidence rdf:resource="#Evidence512" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR 7/8 or 9 : MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep298">
 <bp:stepProcess rdf:resource="#BiochemicalReaction245" />
 <bp:stepProcess rdf:resource="#Catalysis120" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction426">
 <bp:evidence rdf:resource="#Evidence516" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation and release of IRF7 upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep297">
 <bp:stepProcess rdf:resource="#BiochemicalReaction244" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction425">
 <bp:evidence rdf:resource="#Evidence514" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomer:activated TLR 7/8 or 9</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep296">
 <bp:stepProcess rdf:resource="#Pathway54" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction428">
 <bp:evidence rdf:resource="#Evidence518" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of p-IRF7:p-IRF7 to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep295">
 <bp:stepProcess rdf:resource="#Pathway53" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction427">
 <bp:evidence rdf:resource="#Evidence517" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 interacts with IRF7 upon TLR7/8 or 9 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep294">
 <bp:stepProcess rdf:resource="#Pathway52" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep293">
 <bp:stepProcess rdf:resource="#BiochemicalReaction243" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction429">
 <bp:evidence rdf:resource="#Evidence519" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of p-IRF7</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep292">
 <bp:stepProcess rdf:resource="#BiochemicalReaction242" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep291">
 <bp:stepProcess rdf:resource="#BiochemicalReaction241" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep290">
 <bp:stepProcess rdf:resource="#BiochemicalReaction240" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis137">
 <bp:controlled rdf:resource="#BiochemicalReaction266" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis138">
 <bp:controlled rdf:resource="#BiochemicalReaction267" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep249">
 <bp:stepProcess rdf:resource="#Catalysis100" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction204" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis139">
 <bp:controlled rdf:resource="#BiochemicalReaction268" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep248">
 <bp:stepProcess rdf:resource="#BiochemicalReaction203" />
 <bp:stepProcess rdf:resource="#Catalysis99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep247">
 <bp:stepProcess rdf:resource="#BiochemicalReaction202" />
 <bp:stepProcess rdf:resource="#Catalysis98" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis144">
 <bp:controlled rdf:resource="#BiochemicalReaction281" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep246">
 <bp:stepProcess rdf:resource="#BiochemicalReaction201" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis145">
 <bp:controlled rdf:resource="#BiochemicalReaction284" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep245">
 <bp:stepProcess rdf:resource="#Pathway46" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis146">
 <bp:controlled rdf:resource="#BiochemicalReaction286" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep244">
 <bp:stepProcess rdf:resource="#Pathway45" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis147">
 <bp:controlled rdf:resource="#BiochemicalReaction291" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep243">
 <bp:stepProcess rdf:resource="#BiochemicalReaction200" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis140">
 <bp:controlled rdf:resource="#BiochemicalReaction270" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep242">
 <bp:stepProcess rdf:resource="#BiochemicalReaction199" />
 <bp:stepProcess rdf:resource="#Catalysis97" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis141">
 <bp:controlled rdf:resource="#BiochemicalReaction271" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep241">
 <bp:stepProcess rdf:resource="#BiochemicalReaction198" />
 <bp:stepProcess rdf:resource="#Catalysis96" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis142">
 <bp:controlled rdf:resource="#BiochemicalReaction272" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep240">
 <bp:stepProcess rdf:resource="#BiochemicalReaction197" />
 <bp:stepProcess rdf:resource="#Catalysis95" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis143">
 <bp:controlled rdf:resource="#BiochemicalReaction274" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis148">
 <bp:controlled rdf:resource="#BiochemicalReaction293" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep239">
 <bp:stepProcess rdf:resource="#BiochemicalReaction196" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis149">
 <bp:controlled rdf:resource="#BiochemicalReaction294" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep238">
 <bp:stepProcess rdf:resource="#Pathway44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep237">
 <bp:stepProcess rdf:resource="#BiochemicalReaction195" />
 <bp:stepProcess rdf:resource="#Catalysis94" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep236">
 <bp:stepProcess rdf:resource="#Catalysis93" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction194" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis155">
 <bp:controlled rdf:resource="#BiochemicalReaction320" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep235">
 <bp:stepProcess rdf:resource="#BiochemicalReaction193" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis156">
 <bp:controlled rdf:resource="#BiochemicalReaction327" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep234">
 <bp:stepProcess rdf:resource="#Pathway43" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis157">
 <bp:controlled rdf:resource="#BiochemicalReaction334" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep233">
 <bp:stepProcess rdf:resource="#Pathway42" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis158">
 <bp:controlled rdf:resource="#BiochemicalReaction335" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep232">
 <bp:stepProcess rdf:resource="#Catalysis92" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction192" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis151">
 <bp:controlled rdf:resource="#BiochemicalReaction299" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep231">
 <bp:stepProcess rdf:resource="#Catalysis91" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction191" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis152">
 <bp:controlled rdf:resource="#BiochemicalReaction311" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep230">
 <bp:stepProcess rdf:resource="#Catalysis90" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction190" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis153">
 <bp:controlled rdf:resource="#BiochemicalReaction314" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis154">
 <bp:controlled rdf:resource="#BiochemicalReaction315" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis150">
 <bp:controlled rdf:resource="#BiochemicalReaction296" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1/or IRAK2 binds to the activated IRAK4 :oligo MyD88:activated TLR5 or 10 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis119">
 <bp:controlled rdf:resource="#BiochemicalReaction238" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 phosphorylates Pellino</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multiple IRAK1 autophosphorylation within the complex p-IRAK4:oligo MyD88:activated TLR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis115">
 <bp:controlled rdf:resource="#BiochemicalReaction221" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis116">
 <bp:controlled rdf:resource="#BiochemicalReaction223" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates hp-IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis117">
 <bp:controlled rdf:resource="#BiochemicalReaction236" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO subunit of IKK complex binds to activated IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis118">
 <bp:controlled rdf:resource="#BiochemicalReaction237" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep269">
 <bp:stepProcess rdf:resource="#Catalysis114" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction220" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis122">
 <bp:controlled rdf:resource="#BiochemicalReaction248" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep268">
 <bp:stepProcess rdf:resource="#Catalysis113" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction219" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis123">
 <bp:controlled rdf:resource="#BiochemicalReaction249" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep267">
 <bp:stepProcess rdf:resource="#BiochemicalReaction218" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis124">
 <bp:controlled rdf:resource="#BiochemicalReaction250" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep266">
 <bp:stepProcess rdf:resource="#Pathway50" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis125">
 <bp:controlled rdf:resource="#BiochemicalReaction253" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep265">
 <bp:stepProcess rdf:resource="#Catalysis112" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction217" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep264">
 <bp:stepProcess rdf:resource="#Catalysis111" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction216" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep263">
 <bp:stepProcess rdf:resource="#BiochemicalReaction215" />
 <bp:stepProcess rdf:resource="#Catalysis110" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis120">
 <bp:controlled rdf:resource="#BiochemicalReaction245" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep262">
 <bp:stepProcess rdf:resource="#BiochemicalReaction214" />
 <bp:stepProcess rdf:resource="#Catalysis109" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis121">
 <bp:controlled rdf:resource="#BiochemicalReaction246" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep261">
 <bp:stepProcess rdf:resource="#BiochemicalReaction213" />
 <bp:stepProcess rdf:resource="#Catalysis108" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep260">
 <bp:stepProcess rdf:resource="#BiochemicalReaction212" />
 <bp:stepProcess rdf:resource="#Catalysis107" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis126">
 <bp:controlled rdf:resource="#BiochemicalReaction254" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis127">
 <bp:controlled rdf:resource="#BiochemicalReaction255" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis128">
 <bp:controlled rdf:resource="#BiochemicalReaction257" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep259">
 <bp:stepProcess rdf:resource="#BiochemicalReaction211" />
 <bp:stepProcess rdf:resource="#Catalysis106" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis129">
 <bp:controlled rdf:resource="#BiochemicalReaction258" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep258">
 <bp:stepProcess rdf:resource="#Pathway49" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis133">
 <bp:controlled rdf:resource="#BiochemicalReaction262" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep257">
 <bp:stepProcess rdf:resource="#Catalysis105" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction210" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis134">
 <bp:controlled rdf:resource="#BiochemicalReaction263" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep256">
 <bp:stepProcess rdf:resource="#Pathway48" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis135">
 <bp:controlled rdf:resource="#BiochemicalReaction264" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep255">
 <bp:stepProcess rdf:resource="#BiochemicalReaction209" />
 <bp:stepProcess rdf:resource="#Catalysis104" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis136">
 <bp:controlled rdf:resource="#BiochemicalReaction265" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep254">
 <bp:stepProcess rdf:resource="#Catalysis103" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction208" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep253">
 <bp:stepProcess rdf:resource="#Catalysis102" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction207" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis130">
 <bp:controlled rdf:resource="#BiochemicalReaction259" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep252">
 <bp:stepProcess rdf:resource="#Catalysis101" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction206" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis131">
 <bp:controlled rdf:resource="#BiochemicalReaction260" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep251">
 <bp:stepProcess rdf:resource="#Pathway47" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis132">
 <bp:controlled rdf:resource="#BiochemicalReaction261" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep250">
 <bp:stepProcess rdf:resource="#BiochemicalReaction205" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep209">
 <bp:stepProcess rdf:resource="#BiochemicalReaction169" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep208">
 <bp:stepProcess rdf:resource="#Pathway41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep207">
 <bp:stepProcess rdf:resource="#BiochemicalReaction168" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep206">
 <bp:stepProcess rdf:resource="#BiochemicalReaction167" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep205">
 <bp:stepProcess rdf:resource="#Pathway40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep689">
 <bp:stepProcess rdf:resource="#BiochemicalReaction569" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep204">
 <bp:stepProcess rdf:resource="#Catalysis80" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction166" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep688">
 <bp:stepProcess rdf:resource="#Pathway121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep203">
 <bp:stepProcess rdf:resource="#Catalysis79" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction165" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence298">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis188">
 <bp:controlled rdf:resource="#BiochemicalReaction389" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep687">
 <bp:stepProcess rdf:resource="#Pathway120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep202">
 <bp:stepProcess rdf:resource="#BiochemicalReaction164" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence299">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis189">
 <bp:controlled rdf:resource="#BiochemicalReaction391" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep686">
 <bp:stepProcess rdf:resource="#BiochemicalReaction568" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep201">
 <bp:stepProcess rdf:resource="#BiochemicalReaction163" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence296">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep685">
 <bp:stepProcess rdf:resource="#BiochemicalReaction567" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep200">
 <bp:stepProcess rdf:resource="#Pathway39" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence297">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep684">
 <bp:stepProcess rdf:resource="#Catalysis277" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction566" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis184">
 <bp:controlled rdf:resource="#BiochemicalReaction376" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep683">
 <bp:stepProcess rdf:resource="#BiochemicalReaction565" />
 <bp:stepProcess rdf:resource="#Catalysis276" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis185">
 <bp:controlled rdf:resource="#BiochemicalReaction377" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep682">
 <bp:stepProcess rdf:resource="#BiochemicalReaction564" />
 <bp:stepProcess rdf:resource="#Catalysis275" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis186">
 <bp:controlled rdf:resource="#BiochemicalReaction379" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep681">
 <bp:stepProcess rdf:resource="#BiochemicalReaction563" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis187">
 <bp:controlled rdf:resource="#BiochemicalReaction386" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep680">
 <bp:stepProcess rdf:resource="#BiochemicalReaction562" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence290">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis180">
 <bp:controlled rdf:resource="#BiochemicalReaction371" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence291">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis181">
 <bp:controlled rdf:resource="#BiochemicalReaction372" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis182">
 <bp:controlled rdf:resource="#BiochemicalReaction373" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis183">
 <bp:controlled rdf:resource="#BiochemicalReaction375" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence294">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence295">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence292">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence293">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep679">
 <bp:stepProcess rdf:resource="#Pathway119" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep678">
 <bp:stepProcess rdf:resource="#Catalysis274" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction561" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep677">
 <bp:stepProcess rdf:resource="#BiochemicalReaction560" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis199">
 <bp:controlled rdf:resource="#BiochemicalReaction422" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep676">
 <bp:stepProcess rdf:resource="#Catalysis273" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction559" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep675">
 <bp:stepProcess rdf:resource="#BiochemicalReaction558" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep674">
 <bp:stepProcess rdf:resource="#BiochemicalReaction557" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep673">
 <bp:stepProcess rdf:resource="#BiochemicalReaction556" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis195">
 <bp:controlled rdf:resource="#BiochemicalReaction405" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep672">
 <bp:stepProcess rdf:resource="#BiochemicalReaction555" />
 <bp:stepProcess rdf:resource="#Catalysis272" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis196">
 <bp:controlled rdf:resource="#BiochemicalReaction406" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep671">
 <bp:stepProcess rdf:resource="#BiochemicalReaction554" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis197">
 <bp:controlled rdf:resource="#BiochemicalReaction414" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep670">
 <bp:stepProcess rdf:resource="#BiochemicalReaction553" />
 <bp:stepProcess rdf:resource="#Catalysis271" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis198">
 <bp:controlled rdf:resource="#BiochemicalReaction421" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis191">
 <bp:controlled rdf:resource="#BiochemicalReaction398" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis192">
 <bp:controlled rdf:resource="#BiochemicalReaction399" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis193">
 <bp:controlled rdf:resource="#BiochemicalReaction402" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis194">
 <bp:controlled rdf:resource="#BiochemicalReaction404" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis190">
 <bp:controlled rdf:resource="#BiochemicalReaction396" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep229">
 <bp:stepProcess rdf:resource="#Catalysis89" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction189" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis159">
 <bp:controlled rdf:resource="#BiochemicalReaction338" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep228">
 <bp:stepProcess rdf:resource="#Catalysis88" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction188" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep227">
 <bp:stepProcess rdf:resource="#BiochemicalReaction187" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep226">
 <bp:stepProcess rdf:resource="#BiochemicalReaction186" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep225">
 <bp:stepProcess rdf:resource="#Catalysis87" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction185" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence276">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis166">
 <bp:controlled rdf:resource="#BiochemicalReaction354" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep224">
 <bp:stepProcess rdf:resource="#BiochemicalReaction184" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence277">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis167">
 <bp:controlled rdf:resource="#BiochemicalReaction355" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction399">
 <bp:evidence rdf:resource="#Evidence483" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep223">
 <bp:stepProcess rdf:resource="#BiochemicalReaction183" />
 <bp:stepProcess rdf:resource="#Catalysis86" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence274">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis168">
 <bp:controlled rdf:resource="#BiochemicalReaction358" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep222">
 <bp:stepProcess rdf:resource="#BiochemicalReaction182" />
 <bp:stepProcess rdf:resource="#Catalysis85" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence275">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis169">
 <bp:controlled rdf:resource="#BiochemicalReaction359" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep221">
 <bp:stepProcess rdf:resource="#BiochemicalReaction181" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis162">
 <bp:controlled rdf:resource="#BiochemicalReaction348" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep220">
 <bp:stepProcess rdf:resource="#BiochemicalReaction180" />
 <bp:stepProcess rdf:resource="#Catalysis84" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis163">
 <bp:controlled rdf:resource="#BiochemicalReaction350" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence278">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis164">
 <bp:controlled rdf:resource="#BiochemicalReaction351" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence279">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis165">
 <bp:controlled rdf:resource="#BiochemicalReaction353" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis160">
 <bp:controlled rdf:resource="#BiochemicalReaction343" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis161">
 <bp:controlled rdf:resource="#BiochemicalReaction347" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence272">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence273">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence270">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence271">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction390">
 <bp:evidence rdf:resource="#Evidence474" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction392">
 <bp:evidence rdf:resource="#Evidence476" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction391">
 <bp:evidence rdf:resource="#Evidence475" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction394">
 <bp:evidence rdf:resource="#Evidence478" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep219">
 <bp:stepProcess rdf:resource="#BiochemicalReaction179" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction393">
 <bp:evidence rdf:resource="#Evidence477" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep218">
 <bp:stepProcess rdf:resource="#BiochemicalReaction178" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction396">
 <bp:evidence rdf:resource="#Evidence480" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep217">
 <bp:stepProcess rdf:resource="#BiochemicalReaction177" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction395">
 <bp:evidence rdf:resource="#Evidence479" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep216">
 <bp:stepProcess rdf:resource="#BiochemicalReaction176" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction398">
 <bp:evidence rdf:resource="#Evidence482" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep215">
 <bp:stepProcess rdf:resource="#Catalysis83" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction175" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction397">
 <bp:evidence rdf:resource="#Evidence481" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep699">
 <bp:stepProcess rdf:resource="#BiochemicalReaction576" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep214">
 <bp:stepProcess rdf:resource="#BiochemicalReaction174" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence287">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis177">
 <bp:controlled rdf:resource="#BiochemicalReaction368" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction389">
 <bp:evidence rdf:resource="#Evidence473" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep698">
 <bp:stepProcess rdf:resource="#BiochemicalReaction575" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep213">
 <bp:stepProcess rdf:resource="#Catalysis82" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction173" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence288">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis178">
 <bp:controlled rdf:resource="#BiochemicalReaction369" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction388">
 <bp:evidence rdf:resource="#Evidence472" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep697">
 <bp:stepProcess rdf:resource="#Pathway124" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep212">
 <bp:stepProcess rdf:resource="#BiochemicalReaction172" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence285">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis179">
 <bp:controlled rdf:resource="#BiochemicalReaction370" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep696">
 <bp:stepProcess rdf:resource="#Catalysis279" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction574" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep211">
 <bp:stepProcess rdf:resource="#BiochemicalReaction171" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence286">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep695">
 <bp:stepProcess rdf:resource="#Catalysis278" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction573" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep210">
 <bp:stepProcess rdf:resource="#Catalysis81" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction170" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis173">
 <bp:controlled rdf:resource="#BiochemicalReaction364" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep694">
 <bp:stepProcess rdf:resource="#BiochemicalReaction572" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis174">
 <bp:controlled rdf:resource="#BiochemicalReaction365" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep693">
 <bp:stepProcess rdf:resource="#BiochemicalReaction571" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence289">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis175">
 <bp:controlled rdf:resource="#BiochemicalReaction366" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep692">
 <bp:stepProcess rdf:resource="#Pathway123" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis176">
 <bp:controlled rdf:resource="#BiochemicalReaction367" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep691">
 <bp:stepProcess rdf:resource="#BiochemicalReaction570" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep690">
 <bp:stepProcess rdf:resource="#Pathway122" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence280">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis170">
 <bp:controlled rdf:resource="#BiochemicalReaction360" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis171">
 <bp:controlled rdf:resource="#BiochemicalReaction362" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis172">
 <bp:controlled rdf:resource="#BiochemicalReaction363" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence283">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence284">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence281">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence282">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds to hp- IRAK1 or p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto ubiquitination of oligo-TRAF6 bound to p-IRAK2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep649">
 <bp:stepProcess rdf:resource="#Catalysis256" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction536" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep648">
 <bp:stepProcess rdf:resource="#Catalysis255" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction535" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 induces TRAF6 oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep647">
 <bp:stepProcess rdf:resource="#Catalysis254" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction534" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6:p-IRAK2 interacts with TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep646">
 <bp:stepProcess rdf:resource="#BiochemicalReaction533" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Auto phosphorylation of TAK1 bound to p-IRAK2:pUb oligo-TRAF6: free K63 pUb:TAB1:TAB2/TAB3 </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep645">
 <bp:stepProcess rdf:resource="#Pathway114" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TRAF6 synthesizes unanchored polyubiquitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep644">
 <bp:stepProcess rdf:resource="#Pathway113" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 autophosphorylation within the complex activated TLR:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence254">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep643">
 <bp:stepProcess rdf:resource="#BiochemicalReaction532" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 forms a complex with the activated TLR receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence255">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep642">
 <bp:stepProcess rdf:resource="#BiochemicalReaction531" />
 <bp:stepProcess rdf:resource="#Catalysis253" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of IRAK2 bound to the activated IRAK4:MyD88 oligomerl:activated TLR5 or 10 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence252">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep641">
 <bp:stepProcess rdf:resource="#Catalysis252" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction530" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binds MEKK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence253">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep640">
 <bp:stepProcess rdf:resource="#Catalysis251" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction529" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence258">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence259">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence256">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence257">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence250">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence251">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep639">
 <bp:stepProcess rdf:resource="#BiochemicalReaction528" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep638">
 <bp:stepProcess rdf:resource="#Pathway112" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep637">
 <bp:stepProcess rdf:resource="#Catalysis250" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction527" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep636">
 <bp:stepProcess rdf:resource="#BiochemicalReaction526" />
 <bp:stepProcess rdf:resource="#Catalysis249" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep635">
 <bp:stepProcess rdf:resource="#BiochemicalReaction525" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep634">
 <bp:stepProcess rdf:resource="#Pathway111" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep633">
 <bp:stepProcess rdf:resource="#Pathway110" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence265">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep632">
 <bp:stepProcess rdf:resource="#BiochemicalReaction524" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence266">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep631">
 <bp:stepProcess rdf:resource="#BiochemicalReaction523" />
 <bp:stepProcess rdf:resource="#Catalysis248" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence263">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep630">
 <bp:stepProcess rdf:resource="#BiochemicalReaction522" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence264">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence269">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence267">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence268">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence261">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence262">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence260">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence238">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence239">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction97">
 <bp:evidence rdf:resource="#Evidence123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep669">
 <bp:stepProcess rdf:resource="#Catalysis270" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction552" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction96">
 <bp:evidence rdf:resource="#Evidence122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep668">
 <bp:stepProcess rdf:resource="#Catalysis269" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction551" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction99">
 <bp:evidence rdf:resource="#Evidence127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep667">
 <bp:stepProcess rdf:resource="#BiochemicalReaction550" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction98">
 <bp:evidence rdf:resource="#Evidence125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep666">
 <bp:stepProcess rdf:resource="#Pathway118" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence232">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep665">
 <bp:stepProcess rdf:resource="#Catalysis268" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction549" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence233">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep664">
 <bp:stepProcess rdf:resource="#Catalysis267" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction548" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction95">
 <bp:evidence rdf:resource="#Evidence121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence230">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep663">
 <bp:stepProcess rdf:resource="#Catalysis266" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction547" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction94">
 <bp:evidence rdf:resource="#Evidence120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence231">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep662">
 <bp:stepProcess rdf:resource="#Catalysis265" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction546" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence236">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep661">
 <bp:stepProcess rdf:resource="#BiochemicalReaction545" />
 <bp:stepProcess rdf:resource="#Catalysis264" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence237">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep660">
 <bp:stepProcess rdf:resource="#BiochemicalReaction544" />
 <bp:stepProcess rdf:resource="#Catalysis263" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence234">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence235">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence249">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep659">
 <bp:stepProcess rdf:resource="#BiochemicalReaction543" />
 <bp:stepProcess rdf:resource="#Catalysis262" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep658">
 <bp:stepProcess rdf:resource="#Pathway117" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep657">
 <bp:stepProcess rdf:resource="#BiochemicalReaction542" />
 <bp:stepProcess rdf:resource="#Catalysis261" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep656">
 <bp:stepProcess rdf:resource="#Pathway116" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep655">
 <bp:stepProcess rdf:resource="#Catalysis260" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction541" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence243">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep654">
 <bp:stepProcess rdf:resource="#Catalysis259" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction540" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence244">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep653">
 <bp:stepProcess rdf:resource="#BiochemicalReaction539" />
 <bp:stepProcess rdf:resource="#Catalysis258" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence241">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep652">
 <bp:stepProcess rdf:resource="#Catalysis257" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction538" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence242">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep651">
 <bp:stepProcess rdf:resource="#Pathway115" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence247">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep650">
 <bp:stepProcess rdf:resource="#BiochemicalReaction537" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence248">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARM binds TICAM1:TRAM:TLR4:LY96:LPS:CD14</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence245">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence246">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence240">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of human JNKs by activated MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 phosphorylates MKK4/MKK7</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep609">
 <bp:stepProcess rdf:resource="#Pathway108" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep608">
 <bp:stepProcess rdf:resource="#BiochemicalReaction502" />
 <bp:stepProcess rdf:resource="#Catalysis240" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction6" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second phosphorylation of IRAK1 by IRAK4 bound to MyD88:activated TLR complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence218">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep607">
 <bp:stepProcess rdf:resource="#BiochemicalReaction501" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of hp-IRAK1:TRAF6 or IRAK2:TRAF6-oligomer from the activated TLR5 or 10:oligo-Myd88:p-IRAK4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence219">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep606">
 <bp:stepProcess rdf:resource="#BiochemicalReaction500" />
 <bp:stepProcess rdf:resource="#Catalysis239" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction12" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human JNKs migrate to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence216">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep605">
 <bp:stepProcess rdf:resource="#BiochemicalReaction499" />
 <bp:stepProcess rdf:resource="#Catalysis238" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction11" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 binds to MyD88 bound to the activated TLR5 or 10 receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence217">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep604">
 <bp:stepProcess rdf:resource="#BiochemicalReaction498" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep603">
 <bp:stepProcess rdf:resource="#BiochemicalReaction497" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep602">
 <bp:stepProcess rdf:resource="#Pathway107" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First phosphorylation of IRAK1 by IRAK4 bound to MyD88:activated TLR</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep601">
 <bp:stepProcess rdf:resource="#Pathway106" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 oligomerization within the complex of activated TLR:MyD88</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep600">
 <bp:stepProcess rdf:resource="#Pathway105" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence210">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence694">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence211">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence695">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence692">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence693">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence214">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence698">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence215">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence699">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence212">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence696">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence213">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence697">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence690">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence691">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence229">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence227">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence228">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence221">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction28" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence222">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence220">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction18" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence225">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction14" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence226">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction23" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence223">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction21" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence224">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK5 activates the transcription factor MEF2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep629">
 <bp:stepProcess rdf:resource="#BiochemicalReaction521" />
 <bp:stepProcess rdf:resource="#Catalysis247" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by protein phosphatase 2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep628">
 <bp:stepProcess rdf:resource="#BiochemicalReaction520" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2 activates ELK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep627">
 <bp:stepProcess rdf:resource="#Catalysis246" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction519" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence678">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERK1/2/5 activate RSK1/2/3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep626">
 <bp:stepProcess rdf:resource="#Catalysis245" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction518" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence679">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK1/2/3 phosphorylates CREB at Serine 119</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep625">
 <bp:stepProcess rdf:resource="#BiochemicalReaction517" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates ATF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep624">
 <bp:stepProcess rdf:resource="#Catalysis244" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction516" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs are inactivated by dual-specific phosphatases (DUSPs)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep623">
 <bp:stepProcess rdf:resource="#BiochemicalReaction515" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p38MAPK phosphorylates MSK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep622">
 <bp:stepProcess rdf:resource="#BiochemicalReaction514" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep621">
 <bp:stepProcess rdf:resource="#BiochemicalReaction513" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence672">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep620">
 <bp:stepProcess rdf:resource="#BiochemicalReaction512" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence673">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSK1 activates CREB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence670">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKAPK2 phosphorylates CREB at Serine 133</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence671">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence676">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence677">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence674">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence675">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. cFOS/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep619">
 <bp:stepProcess rdf:resource="#Catalysis243" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction511" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNKs phosphorylate c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence207">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep618">
 <bp:stepProcess rdf:resource="#BiochemicalReaction510" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Activated Protein 1 (AP-1) complex. ATF2/c-JUN heterodimer. </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence208">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep617">
 <bp:stepProcess rdf:resource="#Catalysis242" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction509" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">c-FOS activation by phospho ERK1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence205">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep616">
 <bp:stepProcess rdf:resource="#BiochemicalReaction508" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence689">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MAPKs phosphorylate ATF-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence206">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep615">
 <bp:stepProcess rdf:resource="#BiochemicalReaction507" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated human MKK3/MKK6 phosphorylates p38 MAPK complexed with MAPKAPK2 or MAPKAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep614">
 <bp:stepProcess rdf:resource="#Catalysis241" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction506" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">activated human TAK1 phosphorylates MKK3/MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep613">
 <bp:stepProcess rdf:resource="#BiochemicalReaction505" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear export of human p38 MAPK mediated by its substrate MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence209">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep612">
 <bp:stepProcess rdf:resource="#Pathway109" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active p38 MAPK phosphorylates MAPKAPK2 or 3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep611">
 <bp:stepProcess rdf:resource="#BiochemicalReaction504" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep610">
 <bp:stepProcess rdf:resource="#BiochemicalReaction503" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence683">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence200">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence684">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated MKK3/MKK6 migrates to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence681">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence682">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence203">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence687">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence204">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence688">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence201">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence685">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence202">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence686">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence680">
</bp:Evidence>
</rdf:RDF>